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Abstract
Attempts for the in vitro differentiation of reconstituting human HSCs from ESCs have been 
unsuccessful as key factors of HSC specification remain unclear. Enforced HOXB4 
expression can enhance haemopoietic differentiation of mouse and human ESCs and 
generate reconstituting HSCs from mouse ESCs. We have previously shown that HOXB4 
can enhance haemopoietic differentiation of mouse ESCs in a paracrine manner. Microarray 
analysis identified a number of secreted factors upregulated by HOXB4 potentially 
mediating this paracrine effect. The aim of this study was to assess whether these factors 
alone and/or in combination can enhance the in vitro haemopoietic differentiation of mouse 
and human ESCs. We first developed a defined, serum and feeder-free protocol to test the 
effects of these secreted factors on haemopoietic differentiation.  This defined protocol 
allowed us to compare the haemopoietic potential of mouse ESCs with the recently derived 
epiblast stem cells (EpiSCs), thought to be comparable to hESCs. Haemopoietic colony 
forming assay and flow cytometry analysis showed that serum-free conditions generated 8-
10 fold more CD144+CD41+ and c-Kit+CD41+ haemopoietic progenitor cells (HPCs) 
compared to serum conditions from both ESCs and EpiSCs, with ESCs giving the most 
significant increase. We then validated the panel of HOXB4 target genes by QRT-PCR and 
selected those increased in expression by at least 2.5-fold when HOXB4 was activated. We 
used this defined, serum-free protocol to assess the effects of our panel of secreted factors, 
FGF17, RSPO3 and APLN, on the haemopoietic differentiation of mouse ESCs. We 
demonstrated that FGF17 can mediate HOXB4 haemopoietic activity by enhancing the 
generation of c-Kit+ HPCs. On the other hand increasing concentrations of RSPO3 inhibited 
haemopoietic development by reducing the numbers of CD41+ and CD41+CD45+ HPCs, 
while, APLN did not have any effects on the haemopoietic activity of the cells. We finally 
used the secreted factors in human ESC and iPSC differentiation cultures. We observed 
differences in the activity of the tested factors not only between species but also between 
human cell lines. These results suggest that HOXB4 haemopoietic activity is partly mediated 
by paracrine signalling but more complex cell interactions are probably required for it to 
fully exert its effects. More importantly, HOXB4 regulatory pathways differ between mouse 
and human cells stressing the need for careful translation of data between the two species 
and more detailed analysis of key human haemopoietic factors for the successful generation 
of reconstituting HSCs. 
Lay Summary
Haemopoietic stem cells (HSCs), can replicate themselves and mature into all the blood cells 
found in our body. Currently, HSC transplantation is the only available treatment for blood 
disorders including certain types of cancer, such as leukaemia, myeloma, and lymphoma. 
Unfortunately, the only source of HSCs is the donation of bone marrow and blood, which 
provides a very limited supply. Therefore, scientists have turned to the use of pluripotent 
stem cells (PSCs) as an alternative source. PSCs can be obtained from very early stage 
embryos or from the genetic modification of adult somatic cells. They have the ability to 
replicate themselves indefinitely in culture, and when placed under the appropriate 
conditions, they can give rise to specialised cells. Although cells with similar properties to 
HSCs have been produced by PSCs in culture by replicating the conditions found inside our 
bodies, these cells are not fully functional and they cannot be used for clinical applications. 
The reason for this failure is that many key factors which determine HSC development have 
not been identified yet and used in culture protocols. Additionally, because animal products 
or animal model organisms are many times used in culture protocols to understand human 
physiology, discrepancies arise between studies and species.  
An important regulator of HSC development is the transcription factor HOXB4. 
Transcription factors are proteins that act by regulating, in a well-orchestrated manner, the 
expression of other genes and consequently inducing the completion of biological processes. 
In this study, we investigated the effects that certain HOXB4 target genes have on the 
generation of HSCs in culture from PSCs and we compared these effects between mouse and 
human cells in well-defined conditions free of animal products.  
Initially, we established a culture protocol for mouse PSCs, as the mouse is the most reliable 
and widely used experimental model that has provided great insight into human physiology. 
In our protocol we ensured that our culture medium and substrate contained no animal 
products or undefined factors, which might have influenced our results. We compared the 
differentiation potential of two cell populations, the mouse embryonic stem cells (ESCs) and 
mouse epiblast stem cells (EpiSCs), with the latter being more comparable to human ESCs. 
We found that our protocol could generate HSC-like cells with great efficiency and more 
stably for mouse ESCs. Therefore, we proceeded to testing the HOXB4 targets in mouse 
ESC cultures. We tested three HOXB4 targets alone or in combination: FGF17, RSPO3 and 
APLN. We demonstrated that the factor FGF17 can enhance the generation of HSC-like 
cells, RSPO3 reduces their production and APLN does not have any effects. We then used a 
similar well-defined protocol to assess the effects of the factors in human cells. We tested 
two human cell populations, human embryonic stem cells (hESCs), which are derived from 
embryos, and human induced pluripotent stem cells (hiPSCs), which are derived from adult 
skin cells. We showed that none of the added factors had an effect on hiPSCs. On the other 
hand the generation of HSC-like cells was reduced in hESCs treated with FGF17 or RSPO3, 
while APLN did not confer any changes.  
Conclusively, our study identified two new regulators of haemopoietic development, FGF17 
and RSPO3. Interestingly, these two regulators have different effects not only between 
mouse and human cells, but even within different cell types of the same species, in our case 
the human. Our study therefore, stresses the necessity of conducting comparative studies, 
where multiple cell populations are being tested in order to draw definite conclusions 
regarding the factors that regulate haemopoietic development and how they can be used in 
the lab for the generation of therapeutic cells. Finally, we demonstrate the effectiveness of 
using well-defined, xenogeneic-free culture conditions to achieve the above objectives. 
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The haemopoietic system, which produces more than 10 different mature blood cell types 
with variable functions, and life spans of just a few days up to several years, is one of the 
most complex and yet well-regulated systems of the human body. The easy isolation of large 
numbers of blood cells and their high tolerance in ex vivo conditions have enabled the study 
of haemopoiesis over the last couple of centuries and established the haemopoietic system as 
a paradigm for the study of tissue development and regenerative medicine. It has been long 
demonstrated that remarkably, all blood cells derive from a single progenitor cell, the 
haemopoietic stem cell (HSC), which has the ability to self-renew, maintaining an adequate 
stem cell pool throughout the life of an organism, while continuously providing the organism 
with short lived mature cell types through differentiation (1, 2, 3). Haemopoiesis occurs 
through successive stages of HSC maturation and amplification during which potency gets 
restricted progressively leading to the segregation of different haemopoietic lineages (Figure 
1.1).  
The transplantation of adult HSCs from bone marrow, umbilical cord or peripheral blood, 
has become the most successful and widely used clinical cell therapy for hematologic 
disorders (4). However, this clinical treatment is often hampered by the limited donor supply 
and the difficulty in expanding HSCs ex vivo. Such limitations heighten the demand for an 
alternative source of HSCs, free from infections and with unlimited availability. The 
discovery of human embryonic stem cells (hESC) (5), as well as, the generation of human 
induced pluripotent stem cells (hiPSC) (6) brought up exciting opportunities for their use in 
regenerative medicine. Pluripotent stem cells have the ability to self-renew for extended 
periods of time in an undifferentiated state, and to generate all the mature cell types found in 
the adult body, under the appropriate culture conditions. These properties render them an 
incomparable model for the detailed study of haemopoiesis, as well as, an efficient tool for 
the generation of transplantable HSCs and mature blood cells. Laying the foundations for the 
clinical use of hESCs and hiPSCs, decades of previous studies using mouse ESCs as a model 
have provided a wealth of information regarding haemopoietic development and have led to 
the development of pioneering in vitro differentiation protocols which have been in many 
occasions directly translated to use in human cells.  
However, while both in vivo and in vitro studies have proven that the haemopoietic 
differentiation process is highly conserved between mouse and human species, they have 
also shown that there are critical differences between mouse and human HSC development 
3 
(7). Although the murine model overcomes many technical and ethical restrains posed by the 
human model allowing a more detailed examination of developmental haemopoiesis, years 
of evolutionary pressure have left a translational gap between the two species. These species 
differences emphasize the importance of conducting parallel studies between the two 
organisms. Examining differences in the activity of key factors involved in haemopoiesis 
between mouse and human systems will help narrow the translational gap for the successful 
generation of transplantable human HSCs.  
During differentiation HSCs lose their self-renewal capacity and progressively get lineage 
restricted to become mature functional cells. LMPP, lymphoid-primed multipotent 
progenitor; CLP, common lymphoid progenitor; CMP, common myeloid progenitor; DC, 
dendritic cell; EP, erythrocyte progenitor; GMP, granulocyte/macrophage progenitor; GP, 
granulocyte progenitor; HSC, hematopoietic stem cell; MacP, macrophage progenitor; MEP, 
megakaryocyte/erythrocyte progenitor; MkP, megakaryocyte progenitor; MPP, multipotent 
progenitor; NK, natural killer (8, 9).  








T cells B cells NK cells DC
s
Macrophages Granulocytes RBCs Platelets 
Figure 1.1: Haemopoietic hierarchy. 
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1.2 Embryonic haemopoiesis 
Although research on the murine model has dominated over other organisms, the origin of 
HSCs has been tracked down in a variety of vertebrates including frog, chick, zebrafish and 
with many recent advances human. It is now known that haemopoiesis is an evolutionary 
conserved process which occurs in distinct yet overlapping stages during embryogenesis, in 
multiple anatomic locations. Haemopoiesis had long been distinguished in two major types 
related to the location and type of blood cells it generated. The primitive one which occurred 
extra-embryonically in the yolk sac and gave rise only to short-lived blood cells of restricted 
lineage, and the definitive one which occurred intra-embryonically in the aorta-gonad-
mesonephros (AGM) region and generated HSCs capable of long-term multilineage 
differentiation. However, due to increasing evidence indicating the contribution of the yolk 
sac, as well as other embryonic tissues to the long-term adult pool of HSCs it is currently 
considered more appropriate to define primitive and definitive haemopoiesis exclusively 
based on the type of cells it produces and not on the embryonic location it ensues.   
Taking into consideration decades of studies on the time, location and cells produced, 
haemopoietic development can now be described as follows (Figure 1.2). The first wave of 
haemopoiesis, the primitive one, appears in the extra-embryonic yolk sac (YS) early in 
embryogenesis, around embryonic day E7.25 in the mouse (10) and during week 3 of human 
gestation (11). This wave gives rise to transient nucleated erythrocytes and primitive myeloid 
cells (10), which lack the ability to engraft when transplanted into irradiated recipients (12) 
and their purpose is to oxygenate tissues of the developing embryo. Following the onset of 
circulation, on E8.25 for the mouse and around day 21 for human, a second transient wave of 
definitive haemopoiesis follows, again in the yolk sac and later colonising the fetal liver 
(FL), which generates erythro-myeloid progenitors (EMP) with a high proliferative erythroid 
and myeloid lineage potential persisting through adulthood, however, without bone marrow 
homing ability (10, 13, 14, 15). The third wave of blood development, which gives rise to 
bona fide HSCs with multilineage potential and repopulating activity, occurs in multiple 
locations including the placenta, vitelline and umbilical arteries, yolk sac and predominately 
the aorta-gonad-mesonephros (AGM) region, on E10.5 (16) and week 5 (17) for mouse and 
human respectively. These definitive HSCs later colonise the fetal liver where they expand, 
before finally homing to the bone marrow (BM) and maintaining haemopoiesis for the whole 
adult life.  
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Figure 1.2: Embryonic haemopoiesis. 
Haemopoietic cell development occurs in distinct yet overlapping waves. The first primitive 
wave in the yolk sac generates short lived primitive erythrocytes and macrophages. The 
second transient wave also occurs in the yolk sac and produces high proliferative, mixed 
lineage cells persisting until late gestation. The third wave gives rise to definitive HSCs in 
multiple anatomic locations that finally home the bone marrow through adult life.   
1.2.1 Emergence of the first haemopoietic progenitors in the yolk sac 
The emergence of the first blood cells in the yolk sac of the developing embryo, through the 
formation of cell clusters called blood islands, led for many years to the belief that the yolk 
sac is the source of definitive HSCs. The first experiments suggesting the yolk sac origin of 
HSCs were conducted in 1967 by Moore and Owen using the avian model (18). They 
demonstrated using markers between male and female animals that transplantation of 7 day 
yolk sac cells into 14 day old irradiated chicken embryos led to the colonisation of adult 
haemopoietic organs by yolk sac cells. Confirmation of their findings soon came from the 
murine system in 1970 by Moore and Metcalf (19). Transplantation of cultured yolk sac and 
fetal liver cells into irradiated adult recipients showed that the day 8 yolk sac could 
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reconstitute adult hosts, whereas, fetal liver could only reconstitute recipients after day 10 of 
gestation, with the establishment of circulation. Additional data from the culture of 7-day old 
embryos with intact yolk sacs and separated embryos or yolk sacs showed that cells capable 
of haemopoietic colony formation in vitro were found only in the yolk sac. The first 
challenge of the yolk sac as the ultimate source of HSCs came in 1975 by Dieterlen-Lievre 
(20). Using chimeras of quail embryos grafted on chick yolk sacs before the establishment of 
circulation, it was demonstrated that all blood cells colonising the spleen, thymus and bone 
marrow were of quail origin, thus suggesting an intra-embryonic source of HSCs. Ever since 
a debate on the role of yolk sac in definitive haemopoiesis began which remains unanswered 
until today.  
In the early 1990s accumulating data in the murine system confirmed that the yolk sac can 
only generate transient cells and the source of definitive HSCs is found intra-embryonically.  
Medvinsky and Dzierzak demonstrated, using explant culture of rudiments from embryos as 
early as E9, that the intra-embryonic AGM region had a much higher capacity of forming 
colonies in the spleen of irradiated mice (CFU-S) than the yolk sac (21). Later work by 
Cumano and colleagues, who again isolated and cultured yolk sacs prior however to the 
onset of circulation on E8, showed that the yolk sac cells were unable to generate lymphoid 
progeny and had a reduced myeloid potential in in vitro colony forming assays, while in 
vivo, they could only provide short-term myeloid reconstitution when injected into Rag2γc
-/-
 
adult recipients (22, 23). Extensive work by Yoder questioned the above findings and 
complicated once again our understanding of yolk sac haemopoiesis. He demonstrated that 
even though E9.5 yolk sac cells lack the ability to home the bone marrow of adult recipients, 
they can exhibit long-term reconstitution activity when injected into the facial vein or liver 
of newborn mice and that bone marrow from these pups can reconstitute adult recipients (24, 
25). This work suggests that precursor yolk sac cells are indeed capable of multilineage long-
term engraftment, yet, they need to proceed through further maturation inside the embryo 
proper.  
Work on Ncx1-null embryos, which fail to generate a heartbeat and die by E10.5, came to 
support the above hypothesis. It was shown that Ncx1-null embryos can produce normal 
numbers of early erythrocytes and CFU-Cs in their yolk sac but the embryo bodies were 
nearly devoid of any haemopoietic progenitors, confirming that intra-embryonic 
haemopoiesis is dependent on colonisation and further maturation of yolk sac cells (26). A 
recent study using an in vitro single-cell multipotency assay also showed that a well-defined 
cell population capable of multilineage differentiation is predominantly localized to the yolk 
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sac compared to the AGM and fetal liver between E9.5 to E10.5 which can yield far greater 
engraftment potential when cultured in vitro prior to transplantation (27). Further evidence 
supporting the long-term reconstituting ability of yolk sac HSCs come from studies focusing 
on Runx1. Lineage tracing experiments used a Runx1 Cre-estrogen receptor (ER) reporter 
and showed that induction of the reporter on E7.5, when the yolk sac is the only tissue to 
express Runx1, resulted in the marking of fetal liver and adult haemopoietic cells (28). 
However, this study has been disputed by some as interpretation of the data is dependent on 
timing of Runx1 expression which is considered not clearly defined. Additionally, inducible 
rescue of Runx1 expression in Runx1 knockout embryos demonstrated that definitive 
haemopoiesis could only be rescued at the developmental stages when Runx1 expression was 
restricted to the YS (29).  
Due to ethical limitations and the scarcity of human embryos, the role of yolk sac in human 
haemopoiesis has not been as extensively studied. Nonetheless, the majority of studies so far 
indicate that contrary to the mouse, the human yolk sac solely provides a primitive wave of 
blood cells. The first functional study of human yolk sac haemopoiesis in 1986 (15), 
examined the kinetics of haemopoietic progenitors in embryos from 4.5 to 10 weeks of 
gestation. It showed that 4.5 week yolk sac cells were able to give rise to multipotent 
progenitors, as well as, early or late erythroid and granulomacrophage progenitors, as 
monitored by in vitro colony assays. The clonogenic ability of the yolk sac dropped 
dramatically by week 6 with the liver becoming the major haemopoietic site. Later studies by 
Huyhn and co-workers confirmed the multipotent potential of yolk sac cells (30). When 
placed in colony assay, yolk sac cells gave rise to both erythroid and non-erythroid colonies 
since gestation day 25. Interestingly, cells from the embryo could also generate both types of 
colonies and a higher proportion of non-erythroid progenitors in later stages of development, 
indicating an intra-embryonic origin of blood progenitors. These studies, however, were 
performed after the onset of circulation not excluding the possibility of cells migrating from 
the yolk sac to the embryo proper. More recent work of Tavian and colleagues, using explant 
organ culture before the onset of circulation, proved that the human yolk sac is only capable 
of limited myeloid lineage while the intra-embryonic para-aortic splanchnopleura region can 
generate multilineage lympho-myeloid progenitors as assessed by in vitro differentiation 
(31). Finally, in vivo work by Ivanovs has demonstrated that yolk sac cells are capable of 
reconstituting adult recipients only after the generation of repopulating HSCs intra-




1.2.2 The AGM as the prominent site of intra-embryonic haemopoiesis 
Since the first proof of an intra-embryonic source of HSCs (20), nearly a decade past before 
its location was characterised in the Xenopus model. Transplantation of tissues between two 
Xenopus subspecies demonstrated that haemopoietic progenitors arise in two different 
locations of the developing embryo, the ventral blood island (VBI) and the dorsal lateral 
plate mesoderm (DLP), which comprises the prospective mesonephros (32). It was later 
confirmed that the VBI produced progenitors of early larval haemopoiesis, mainly transient 
erythroid cells, whereas, the DLP generated precursors of late larval and adult haemopoiesis, 
including myeloid and lymphoid cells (33). Extensive work by the Dzierzak group identified 
as the equivalent of the DLP region in the mouse system the AGM region, which develops 
from lateral plate mesoderm through the initial formation of the para-aortic splanchnopleura 
(P-Sp).  It was shown that AGM cells of E10 embryos, when directly transplanted into adult 
hosts, could restore their haemopoietic system, albeit in low frequency, while yolk sac and 
liver cells failed to do so. By day E11 all organs could repopulate the recipients, though the 
AGM with a much higher repopulation frequency (12), indicating the generation of 
definitive HSCs in the AGM region and their subsequent migration to other organs. Later 
work of the group, using an explant culture system of embryonic organs to prevent cell 
circulation amongst them, showed that the AGM is indeed able to autonomously generate 
definitive HSCs by embryonic day E10 and that the AGM can further expand in vitro the 
HSCs (16). Work by Cumano and Godin (22, 23) confirmed the AGM as an autonomous 
source of HSCs. Cultured explants of mouse E8 para-aortic splanchnopleura before the onset 
of circulation could give rise to multilineage progenitors in vitro, and to multipotent in vivo 
reconstituting cells in immunocompromised Rag2γc
-/- 
recipients, whereas, mouse yolk sac 
tissue could not. The reconstitution efficiency was however, strikingly lower than that of the 
E11 AGM.  
The specific location of HSC development within the AGM region has been investigated in 
more recent studies. The transplantation of E11.5 dorsal aorta and urogenital ridges (UGR) 
into adult hosts showed that the dorsal aorta and particularly its ventral domain could give 
long-term reconstitution (34). Explant culture of E10.5 dorsal and ventral parts of the aorta, 
stage at which high-level repopulating HSCs are absent, followed by transplantation into 
irradiated hosts, revealed the exclusive capacity of the ventral part to generate HSCs.   
Additionally, more recent imaging work showing the emergence of haemopoietic cells 
directly from the endothelium of the ventral part of the dorsal aorta, either in AGM sections 
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of the mouse embryo in culture (35) or in live zebrafish embryos (36, 37, 38), left no doubt 
of the ability of the region to autonomously generate HSCs. 
In humans, Tavian and colleagues have contributed greatly to the understanding of intra-
embryonic haemopoiesis. The first indication of haemopoietic progenitors arising inside the 
embryo came with the detection of CD34
+
 haemopoietic clusters on the ventral side of the 
dorsal aorta (39), which appeared on day 27, expanded rapidly and disappeared on day 40 of 
development, shortly before liver colonisation (11). The co-culture of CD34
+
 cells with MS-
5 stromal cells resulted in much higher numbers of progenitor cells compared to the liver as 
monitored by methylcellulose colony assay (39). Further analysis before and after gestation 
day 21, which marks the onset of circulation, confirmed the AGM as the site of an 
independent origin of adult blood cells (31). Successively the splanchnopleura, para-aortic 
splanchnopleura and AGM region tissues, in parallel with matching yolks sacs, were 
dissected, cultured in vitro and assayed on their haemopoietic potential. It was demonstrated 
that as opposed to the yolk sac, even 19-day splanchnopleura had the ability to form long-
term haemopoietic cell cultures. Looking into lineage potential, explanted yolk sac cells 
could only give rise to myeloid and NK cells in vitro, while P-Sp and AGM cells generated 
both myeloid and lymphoid cells. In more recent studies of Ivanovs and colleagues, 
functional in vivo analysis confirmed the AGM as the intra-embryonic source of adult HSCs 
(17). Transplantation of human AGM cells into NSG mice resulted in long-term multilineage 
reconstitution as early as gestation day 32 with a very high self-renewal potential, whereas, 
human yolk sac cells could repopulate the recipients at least 5 days later. These highly 
regenerative HSCs were particularly localised in the ventral part of the dorsal aorta, similarly 
to the mouse model, as proven by transplantation of bisected aortas and urogenital ridges 
into irradiated mice, which resulted into increasing levels of human haemopoietic 
engraftment exclusively from the ventral part of the aorta (17, 40).               
1.2.3 Other sites of haemopoietic activity in the embryo 
Besides the yolk sac and the AGM region, additional haemopoietic sites contributing to the 
HSC pool have been discovered in vertebrate embryos. Initial studies in avian embryos 
revealed that the allantois generates haemopoietic cells, as quail allantois grafted into 
chicken embryos resulted in partial colonisation of the bone marrow with quail cells (41). In 
mammals the allantois gives rise to the umbilical vessels which fuse with the chorionic plate 
to form the placenta. The umbilical vessels together with the vitelline vessels, which connect 
the embryo with the yolk sac, have been shown to harbour HSCs in the mouse model by de 
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Bruijn and colleagues. In E10.5 embryos, umbilical and vitelline HSCs are found in 
frequencies comparable to the AGM region, and increase through days E11 and E12. Mice 
injected with cells from umbilical and vitelline arteries show long-term multilineage 
repopulation as well as haemopoietic reconstitution of secondary recipients (42). 
Nonetheless, explant cultures of these tissues have been unsuccessful, thus their ability to 
autonomously generate definitive HSCs remains unclear. 
The placenta has been identified as another major haemopoietic organ. Haemopoietic 
progenitors in the E9 mouse placenta were first identified by in vitro assays (43). Later in 
vivo repopulating assays demonstrated that the E10.5-11.5 placenta contains long-term 
reconstituting HSCs in numbers parallel to those of the AGM region (44, 45), which 
surprisingly, can expand rapidly between E11.5-12.5 up to 15-fold more than the AGM (44). 
In Ncx1-null mice, devoid of circulation, it has be shown that placenta explant cultures can 
still produce multilineage precursors in vitro, though in lower numbers compared to wild 
type animals (46). These data indicated that the placenta can independently generate HSCs, 
yet transplantation experiments were not performed to confirm the engraftment potential of 
the cells. In human development it has been shown that placentas from gestation week 6 and 
onwards, contain progenitors capable of multilineage differentiation in vitro and of homing 
the bone marrow of NSG mice (47). However, early human placentas of weeks 4-6 provide 
only long-term T cell repopulation potential of maternal origin in NSG mice (17) leaving 
unanswered whether the placenta initiates HSC development or it can only support the 
maturation of HSCs originating from other sites.  
The fetal liver in mid-gestation becomes the main haemopoietic organ where HSCs expand 
rapidly and differentiate until they colonise the bone marrow before birth. Although little is 
known about the fetal liver HSC niches, it is believed that the liver cannot produce HSCs de 
novo but it is seeded by cells emerging in other haemopoietic locations (48, 49). Very 
recently additional haemopoietic sites in the embryo have been discovered. The head 
vasculature has been shown to generate de novo HSCs with multilineage engraftment 
potential (50), while the endocardium, even in the absence of circulation, can give rise to 
erythro-myeloid progenitors that persist until late gestation (51).  
Evidently all these studies emphasise that developmental haemopoiesis is a particularly 
complex and dynamic process and that our understanding of it is far from complete. The 
variability of extra- and intra-embryonic tissues that contribute to the adult HSC pool 
complicates the analysis of when and where these cells are initially generated. Furthermore, 
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the stringent assay of transplanting embryonic cells into adult recipients to test their HSC 
properties may be hindering the results by not providing the required microenvironment for 
the full potential of the cells to unravel. What can be concluded with certainty is that 
multiple sites within the embryo have intrinsic HSC potential which is timely dictated by the 
in vivo microenvironment. However, in order to understand how HSCs first appear in these 
sites it is essential to take a step back and look into their molecular pathways and cellular 
sources.   
1.3 Cellular origins of haemopoietic progenitors 
The close spatial and temporal association of endothelial and haemopoietic cells during 
embryogenesis has long been observed by researchers and has led to various stipulations 
regarding the cellular origin of HSCs. The two prevailing theories are those of the 
hemangioblast, a common bipotent progenitor, and the one of hemogenic endothelium, 
specialised vascular endothelial cells with blood forming potential.  
1.3.1 The hemangioblast 
In the early 1900s Sabin and Murray observed in the chick yolk sac that early blood islands 
appear as tight clusters of cells surrounded by mesenchyme. These clusters soon differentiate 
with the inner cells becoming erythrocytes and the outer cells forming an endothelial lining. 
This morphological observation led to the hypothesis of a bipotent common progenitor, 
which gives rise to both haemopoietic and endothelial lineages, the hemangioblast (52, 53).  
Gene targeting experiments firmly supported this common developmental pathway of 
endothelial and haemopoietic cells by identifying a number of genes indispensable for 
normal development of the two lineages. Extensive work by Shalaby and co-workers on the 
mouse system proved that embryos deficient for the vascular endothelial growth factor 
receptor 2 (Vegfr2 or Flk-1) fail to develop blood islands in the yolk sac or any organised 
blood vessels in the embryo body and yolk sac resulting in embryonic lethality (54). They 
also demonstrated that Flk-1
-/-
 ESCs fail to contribute to primitive and definitive 
haemopoiesis or to endothelial development in chimeras (55). In the zebrafish, the cloche 
mutation results in lack of endocardium and greatly reduced numbers of blood cells, while 
Scl knockdown causes loss of primitive and definitive haemopoiesis, and vasculogenic 
defects predominately in the dorsal aorta (56, 57). Moreover, deletion of the Etsrp/Er71 gene 
has been found to affect critically the development of endothelial and haemopoietic lineages 
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in the mouse and zebrafish (58, 59). Despite the valuable evidence in these studies linking 
the two lineages, they could not directly identify a common cell progenitor.   
In vitro culture studies were the first to successfully identify and characterise cells with 
hemangioblast properties. In the avian embryo, mesodermal cells isolated from the early 
blastodisc expressing the Flk-1 homologue could form either haemopoietic or endothelial 
colonies when cultured in the absence or presence of VEGF respectively (60). Using mouse 
and human ESC differentiation cultures the Keller group has provided the strongest evidence 
for the existence of hemangioblasts to date. The mouse hemangioblast was initially identified 
as a blast colony-forming cell (BL-CFC) that appeared transiently, expressed both 
endothelial and haemopoietic markers, including CD34, CD31 and Flk-1, and was capable of 
differentiating into both cell lineages in response to VEGF and SCF (61). Nearly a decade 
later the existence of the human hemangioblast, that expresses the VEGFR2 (also known as 
KDR) and has the ability to generate endothelial and blood cells, was similarly confirmed in 
ESC cultures (62).  More importantly, the same group using GFP-Bry
+/-
 mouse embryos was 
the first to detect cells with properties similar to the BL-CFC in vivo (63). They identified a 
population of Brachyury and Flk-1 positive cells appearing transiently in the posterior region 
of the primitive streak of E7-7.5 embryos which could give rise to endothelial and 
haemopoietic colonies when cultured in vitro. However, the ability of these cells to also 
generate smooth muscle cells, in addition to the fact that their differentiation potential was 
measured using in vitro assays, similarly to the previous studies, raised doubts as to whether 
there is indeed an exclusive bipotent precursor in vivo or whether the BL-CFC is just an in 
vitro artefact.  
Lineage-tracing studies in a variety of species have not yet answered this question with 
certainty. Orthotopic transplantation of LacZ expressing E6.5-7.5 primitive streak cells into 
wild type mouse embryos showed that labelled cells could give rise to either endothelial or 
haemopoietic cells in the yolk sac blood islands, with slightly different timing, thus not 
supporting the presence of hemangioblasts (64). Work by Ueno and Weissman also did not 
favour the concept of the hemangioblast. They established multichimera mice by injecting 
three ESC lines marked with different flourogenic proteins into blastocysts and demonstrated 
that E7.5 yolk sac blood islands were of polyclonal origin, mainly with separate progenitors 
giving rise to endothelial or haemopoietic cells (65). Nevertheless, the existence of 
hemangioblasts could not be negated as they also found individual progenitors within an 
island contributing to both lineages, in lower but yet considerable frequency. Similar results 
were produced in single-cell labelling experiments in the zebrafish. Vogeli and colleagues 
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found that while most labelled cells gave rise to either Flk-1 expressing or Runx1 expressing 
cells, indicating endothelial or haemopoietic cells respectively, a substantial subset of 
labelled cells co-expressed the two markers, contributing to both lineages and confirming the 
presence of hemangioblasts in vivo (66). Very recent work by Padron-Barthe and colleagues 
presents evidence against the existence of hemangioblasts. Using a clonal labelling 
technique, where inducible Cre and reporter alleles were ubiquitously expressed, once again 
only a small percentage of bilineage clones was identified in the yolk sac blood islands. 
These clones however, appeared to derive from labelled cells in the early epiblast before 
specification of the blood- and endothelial-forming regions. To narrow down more on rare 
hemangioblasts they used an inducible Tie2-Cre model which resulted in significantly 
reduced bilineage cells labelling the yolk sac endothelium. The writers therefore concluded 
that the two lineages are specified independently in the epiblast, migrate sequentially in the 
yolk sac where finally haemopoietic cells arise from the yolk sac hemogenic endothelium 
(67).     
The conflicting data have still neither proven nor rejected with certainty the theory of the 
hemangioblast. The rarity of bi-potent hemangioblasts in vivo constitutes the main argument 
refuting their existence. Nonetheless, the presence of bipotent cells in the developing embryo 
even in low numbers cannot be disregarded. As the majority of in vivo and in vitro reports 
stress the transient presence of cells with hemangioblast properties, it is quite possible they 
could have been missed in tracing experiments due to the short time window of their 
presence. Moreover, the possibility of studies focusing at a stage after the segregation of the 
endothelial and haemopoietic lineages cannot be excluded. Additional single-cell tracing and 
live imaging experiments during early stages of embryogenesis are required to clarify the 
existence of the hemangioblast and the lineage identity of its direct progeny. 
1.3.2 Hemogenic endothelium 
About a century ago, clusters of haemopoietic cells attached to the endothelial lining of the 
dorsal aorta were first observed, leading to the idea that blood cells are generated by 
specialised endothelial cells termed hemogenic endothelium (68). Evidence of the capacity 
of aortic endothelial cells to generate haemopoietic progenitors came many decades later. It 
was first observed in the chick embryo that aortic cells harboured multipotent progenitors, as 
demonstrated by their ability to give rise to all types of haemopoietic colonies in vitro (69). 
Soon after, the hemogenic potential of CD34
+
 intra-aortic clusters was confirmed in human 









endothelial cells, capable of yielding myeloid and lymphoid progenitors in culture, not only 
in the aorta but also in the yolk sac, liver and bone marrow of human embryos (70). 
Additionally, in the mouse, both the yolk sac and embryo proper were found to contain VE-
Cadherin, CD31, Flk-1 and CD34 expressing endothelial cells which could generate erythro-
myeloid and lymphoid colonies in vitro (71). Further research revealed that other major 
arterial regions in the mouse embryo, such as the vitelline and umbilical arteries, could give 
rise to HSCs supporting even more the idea of an endothelial origin of blood cells (42).  
A large number of lineage tracing and in vivo imaging studies have also provided direct 
evidence of an endothelial origin of blood cells in vivo. Lineage tracing experiments were 
first performed in the avian embryo (72). Jaffredo and co-workers labelled the aorta with 
AcLDL-Dil, which was specifically uptaken by Flk-1
+
 endothelial cells, prior to the 
emergence of CD45
+
 haemopoietic cells. It was found that newly formed haemopoietic 
clusters on the ventral side of the dorsal aorta contained cells expressing CD45 while 
retaining Dil labelling. Interestingly some CD45
+
 Dil labelled cells were also located in the 
underlying mesenchyme implicating it in the early specification of HSCs. Similar Dil 




 endothelial cells in the mouse yolk sac and embryo 
that gave rise to definitive erythroid progenitors, confirmed the hemogenic potential of 
endothelium (73). Work by de Bruijn and colleagues, using Sca-1 (Ly-6A)-GFP mouse 
embryos, identified transgene expression in cells of the endothelial layer of the dorsal aorta, 
vitelline and umbilical arteries, but not in the surrounding mesenchyme. GFP
+
 cells 
expressed additional haemopoietic and endothelial markers and were capable of long-term 
reconstitution of irradiated recipients (74). More recent work by Zovein and colleagues used 
an inducible Cre-lox system to track the lineage of VE-Cadherin expressing cells. They 
demonstrated that hemogenic endothelial cells are present in the aorta, yolk sac, placenta, 
vitelline and umbilical arteries of the developing mouse embryo and that the haemopoietic 
cells emerging from this endothelium are capable of long-term, multilineage differentiation. 
The underlying aortic mesenchyme was found unable to directly generate HSCs and could 
only do so through an endothelial intermediate, suggesting once again that within the 
subendothelial mesenchyme lie the precursors that give rise to hemogenic endothelium (48).        
Inarguably, the strongest proof for the presence of hemogenic endothelium came from recent 
in vivo and in vitro time-lapse imaging of endothelial cells in the ventral wall of the dorsal 
aorta. Zebrafish embryos, which are transparent and therefore a unique tool for live imaging, 
were used by three different groups to monitor the generation of haemopoietic cells from the 
aortic wall. In all three cases lineage tracing of Flk-1, cMyb, CD41, or Runx1 expressing 
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cells revealed that endothelial cells acquire their haemopoietic identity through progressive 
morphological and phenotypical changes. The endothelial cells contract and bend in the sub-
aortic space, while upregulating haemopoietic markers, before finally rounding up and 
entering the blood circulation without further cell division to colonise the thymus and 
kidneys (36, 37, 38). In the mouse, live sections of embryos, which maintain free cell 





 endothelial cells from the ventral endothelium budded into 
the lumen of the aorta and co-expressed the haemopoietic markers c-kit and CD41 upon their 
emergence (35). 
As both conflicting concepts of the hemangioblast and hemogenic endothelium have 
received confirmation a definite answer regarding the exact cellular origins of HSCs has not 
been provided. Moreover, even though the existence of hemogenic endothelium has been 
proven beyond doubt, little do we know about the origin of these cells. Whether there is a 
lineage relationship between hemangioblasts and hemogenic endothelium also remains 
unclear. In an effort to address this question Lancrin and co-workers showed that 
haemopoietic cells develop from hemangioblasts through a hemogenic endothelium 
intermediate (75). ESC-derived mouse hemangioblasts defined by Bry and Flk-1 expression 






 endothelial cells. As 
differentiation progressed these cells acquired a round non-adherent morphology while 
downregulating Tie2 and c-kit to eventually become CD41
+







 hemogenic endothelial cells were also identified in the embryo in 
developing blood islands and the AGM region, and were capable of forming haemopoietic 












 hemogenic endothelium in the yolk sac and AGM.  The identification of 
appropriate markers and the direct lineage tracing of hemogenic endothelium precursors in 
vivo will answer many questions and generate more information critical not only for our 
understanding  of haemopoiesis but also for the generation of haemopoietic stem cells in 
vitro in the hope of developing successful regenerative medicine applications.  
1.3.3 Phenotype of developing HSCs  
As demonstrated above, cell surface markers have played a pivotal role in defining the 
lineage relationships between early mesodermal precursors and HSCs. Common hemogenic 
endothelial origins have been revealed for yolk sac, placenta and AGM-derived 
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haemopoietic cells, nonetheless, the cells behave differently in transplantation studies, 
depending on their site of origin. Functional differences between developing HSCs may be 
reflected on phenotypical ones, which in turn can enable the characterisation and isolation of 
fully functional HSCs from different anatomic locations. Indeed many studies have 
confirmed that the phenotype of HSCs changes throughout development, with different sets 
of markers being characteristic of early and late haemopoiesis. 
Work by Ferkowicz and colleagues demonstrated that the first haemopoietic progenitors 




 and represent the primitive erythroid 
progenitors (76). Soon after on E8.25 a second CD41
bright 
population emerges which marks 
the onset of definitive haemopoiesis (76). As confirmed by Mikkola and colleagues, by E9.5 






 and are capable of generating multilineage 
haemopoietic colonies and repopulating irradiated newborn recipients (76, 77). CD45 
expression is also initiated in E9.5 yolk sac cells, however, clonogenic progenitor activity is 












 fractions (77). With 
development progressing, CD41
+
 cells emerge in the vitelline and umbilical arteries as well 
as the AGM region (77). Detailed work by Rybtsov and colleagues has confirmed that 
specification of HSCs in the AGM region is initiated by CD41 expression and has shown 









population of pro-HSCs appears in the dorsal aorta. Pro-HSCs 
mature rapidly into type I pre-HSCs with the upregulation of CD43, followed by 
upregulation of CD45 in type II pre-HSCs by E11.5, before becoming fully competent HSCs 
(78, 79). All types of HSCs are also marked by c-kit expression, while, the gradual increase 
in CD43 and CD45 expression levels is accompanied by the gradual decrease in CD41 
expression (79). Sca-1, a hallmark of adult HSCs, and CD41 co-expression also appears in 




 reconstituting HSCs 
which are heterogeneous for CD41 as its levels decrease (44, 81). Work from various groups 
has demonstrated that as haemopoiesis transitions to the liver, repopulating HSCs are 








 fraction of the E12.5 and E14.5 fetal 
liver (76, 77, 80).  Expression of CD34 is finally downregulated and with the establishment 






 cells (76). Further analysis of bone marrow cells has identified HSC activity 








population, while the use of SLAM antigens allows 











(82, 83). Interestingly, SLAM markers also identify repopulating HSCs in the E14.5 fetal 
liver, but not in the earlier yolk sac, placenta or AGM region, where CD150 and CD48 are 
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absent (84, 85). Conclusively, in the mouse, c-kit marks all HSC populations throughout 
development. In the early yolk sac and AGM stages between E8.5 and E11.5 when HSCs 
first emerge, CD41 and CD34 identify repopulating HSCs. Downregulation of CD41 and 
later on of CD34, together with the increase in expression of CD45 after E11.5 in the AGM 
region marks the transition to liver haemopoiesis and further HSC expansion. With the 
establishment of the fetal liver as the major site of haemopoiesis around E14.5, SLAM 
antigens mark fully mature repopulating HSCs that finally home the bone marrow. 
Although detailed examination of haemopoietic tissues for HSC markers throughout human 
gestation is more challenging than in the mouse, human haemopoietic cells have been 
successfully characterised in different anatomic locations. Early work by Huyhn and co-






 cells capable of generating 
haemopoietic colonies in vitro as the first blood cells in the 35-40 gestation day human yolk 
sac and embryo proper (30). Subsequent analysis of haemopoietic clusters in the developing 
AGM region further characterised a population of CD34+CD31+CD45+CD38-Lin- cells  
capable of multilineage differentiation in vitro as early as gestation day 27 (31, 39). As later 
proven by Ivanovs and colleagues it is those AGM residing haemopoietic cells on gestation 
day 32 that are the first fully functional reconstituting HSCs in human development and are 



















  (17, 40). As embryogenesis progresses HSCs are 
identified in the 6 week placenta with their repopulating activity peaking on week 9 and 




 fractions, however, as 
time progresses it becomes restricted to the CD34
+
 fraction. Immunostaining of placental 
villi stroma shows co-expression of CD34 and CD45 in cells budding from the vasculature. 











subsequently appear in the 7-8 week embryonic liver (86). Analysis of human cord blood 
and bone marrow by the Dick group has demonstrated that fully mature human HSCs are 














 population of hematopoietic 
cells (87, 88). CD34 is thus the marker identifying HSCs throughout human development, 
while the use of CD45 and CD38 can further specify HSC populations in different sites of 
haemopoietic activity.  
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1.4 Molecular regulation of haemopoiesis 
Equally important to tracing HSC precursors in vivo and determining their phenotype, is 
unravelling the intrinsic determinants of their development. It is only by understanding HSC 
regulators and using them in vitro that cells for clinical transplantation can be generated. 
Studies focusing on this task have revealed a complex genetic program consisting of a large 
number of transcription factors and signalling pathways. These molecular regulators have a 
highly dynamic expression pattern during development, and it is their interaction at different 
stages of haemopoiesis that eventually determines cell fate. The major molecular 
determinants of haemopoiesis are highlighted below. 
1.4.1 Transcription factors involved in haemopoietic development 
Two transcription factors that act early in development and largely regulate primitive 
haematopoiesis, are Gata1 and Pu.1. Gata1 is a central mediator of erythroid and 
megakaryocytic development, as Gata1 null mice die between E10.5 and E11.5 from severe 
anaemia with cells arrested at the pro-erythroblast stage (89). On the other hand Pu.1 is a 
master regulator of myeloid development, with disruption of the gene leading to defects in 
macrophage and granulocyte generation, and death at late gestation (90). The two proteins 
have been found to interact physically and antagonize each other’s activity. In the zebrafish, 
Gata1 knockdowns switch blood progenitors to the myeloid fate, whereas, inhibition of Pu.1 
promotes erythroid development at the expense of the myeloid fate (91, 92). 
The basic-loop-helix-loop (bHLH) factor Scl/Tal1, and the Lim-domain containing Lmo2 are 
two more transcription factors that act in parallel and have drown a lot of scientific interest. 
They are involved in both primitive and definitive haemopoiesis, and play a critical role in 
the transition to hemogenic endothelium. The two factors are expressed in vascular 
endothelial and haemopoietic tissues during development (93, 94). It has been shown, using 
Scl or Lmo2 null mice, that both factors are essential for primitive haemopoiesis as mutant 
embryos die in utero around E9.5-E10.5 due to failure of yolk sac erythropoiesis (95, 96). 
Because of the early embryonic lethality, the effects of Scl and Lmo2 in definitive 
haemopoiesis were studied using chimeric mice made by injecting blastocysts with 
embryonic stem cells deficient in the factors. The stem cells failed to contribute to any of the 
haemopoietic lineages in adult mice, while reintroduction of gene expression could rescue 
the ability of the cells to contribute to blood cell development, confirming the necessity of 
the genes in definitive haemopoiesis (97, 98, 99). Lmo2 directly interacts with Scl to form a 
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complex which regulates haemopoietic lineage specification, and evidence have suggested 
this complex functions within the hemangioblast to specify a haemopoietic rather than a 
vascular fate (100, 101). Interestingly, it has been shown that although Scl is crucial for the 
transition of the hemangioblast to the hemogenic endothelium stage, it is then dispensable 
for the emergence of HSCs from it (102, 103).  
Another member of the GATA family of transcription factors, Gata2, has been identified as 
an essential regulator of definitive haemopoiesis. Initial work by Tsai and co-workers 
demonstrated that Gata2 is essential for definitive haemopoiesis. Gata2
-/-
 mice die by E11.5 
due to severe anaemia, and Gata2
-/-
 embryonic stem cells cannot contribute to definitive 
haemopoietic cells in mouse chimeras (104). Later studies showed that Gata2 is expressed in 
the endothelium of haemopoietic sites, including the AGM region and the fetal liver, and its 
presence is required for HSC emergence from the endothelium (105, 106). More recently, 
work by the Dzierzak group revealed a dual role for Gata2. It is not only required for HSC 
generation in the AGM region, but also for HSC survival and proliferation at later stages of 
development (107). Transcription factor Runx1 has also been identified as an essential factor 
for the endothelial-to-haemopoietic transition in the AGM region. Runx1 deletion in mouse 
embryos results in severe haemorrhaging and eventual embryonic death around E12.5. 
Although the embryos are capable of undergoing primitive haemopoiesis, they fail to 
proceed to definitive HSC development (108, 109). North and colleagues showed that Runx1 
is expressed in intra-aortic clusters of the dorsal aorta in the AGM region, as well as, the 
endothelium of the yolk sac, the vitelline and umbilical arteries. However, in Runx1 deficient 
embryos, haemopoietic clusters in the dorsal aorta are absent and sequentially HSCs do not 
form (110). As opposed to Gata2, once HSC emergence is completed, Ruxn1 function is no 
longer required (111). 
1.4.2 Signalling pathways regulating haemopoiesis 
Notch signalling plays a key role in vascular development and HSC specification. In 
mammals, four transmembrane receptors (Notch 1-4) interacting with five ligands located in 
adjacent cells (Jagged1, Jagged3, Delta1, Delta3, Delta4) have been identified (112). This 
interaction leads to two proteolytic cleavages of the receptor, allowing its intracellular 
domain to translocate to the nucleus and regulate gene transcription. It has been proven that a 
number of Notch signalling pathway proteins are critical for definitive HSC specification. In 
mouse and zebrafish embryos, targeted disruption of Cls or Mib, both of which are required 
for Notch signalling, does not impair primitive haemopoiesis but diminishes HSC 
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development (106, 113, 114). As shown by Krebs and co-workers Notch1
-/- 
mouse embryos 
display severe vascular and aortic defects (115). Interestingly, later work by Kumano and 
colleagues demonstrated that Notch1
-/-
 embryos do not have a decrease in the population of 
hemogenic endothelial cells, suggesting that Notch1 is dispensable for hemogenic 
endothelium specification. Nonetheless, the embryos have severely impaired HSC 
development indicating that Notch1 activity is essential for the endothelial-to-haemopoietic 
transition (116). Additionally, the fact that Notch1
-/-
 embryonic stem cells can give rise to 
short-term haemopoietic progenitors in chimeric mice but show no contribution to the adult 
haemopoietic system, indicates that Notch1 has to act in a cell-autonomous manner in order 
to switch to definitive haemopoiesis (117). More recently, it has been shown that Notch3 
within the somites exhibits a non-cell-autonomous activity and can specify HSCs in the 
neighbouring precursor cells (118). The Notch ligand, Jagged1, has also been found to 
contribute to HSC specification. Jagged1 knockout mouse embryos have normal arterial 
development but decreased numbers of Gata2 and Runx1 expressing HSCs on E10.5, 
suggesting multiple Notch regulators are required for HSC specification (119).    
The Wnt pathway is another important regulator of many biological processes, with HSC 
specification among them. The pathway comprises of 19 secreted glycoproteins that function 
by associating with the G protein-coupled Frizzled receptors (Fzd) and the LDL-receptor 
related proteins (LRP) co-receptors (120). Wnt signalling is either β-catenin dependent 
(known as canonical pathway) or β-catenin independent (known as non-canonical pathway). 
Upon binding of Wnt proteins to the receptors, the canonical pathway inhibits the 
degradation of β-catenin in the cytoplasm and results in its translocation to the nucleus and 
the activation of target genes. On the contrary, the non-canonical Wnt pathway leads to β-
catenin degradation and is rather mediated by intracellular calcium ion or JNK. Similar to the 
Notch pathway, various Wnt proteins are required for HSC regulation. As shown by Luis 
and colleagues Wnt3a deficient mice have decreased numbers of fetal liver HSCs and 
impaired reconstituting capacity upon serial transplantation (121). Work by the same author, 
using a negative modulator of the canonical Wnt pathway, showed that the haemopoietic 
system is highly sensitive to Wnt signalling dosage. Low Wnt levels enhanced HSC self-
renewal, whereas, high levels skewed lineage distribution and impaired HSC function (122). 
A dose- and time-dependent β-catenin requirement has also been demonstrated in the mouse 
AGM endothelium for the successful production of HSCs. Deletion of β-catenin in VE-
Cadherin
+
 endothelial cells results in loss of haemopoietic potential without affecting 
endothelium development. However, β-catenin deletion in committed haemopoietic 
precursors has no effect on HSC production, indicating that Wnt signalling is crucial for the 
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initial haemopoietic specification of the endothelium (123). Finally, in the zebrafish both 
canonical β-catenin and non-canonical Wnt16 signalling are required for HSC specification 
(124, 125).      
Bone morphogenic proteins (BMPs) are part of the transforming growth factor-β (TGFβ) 
superfamily, an important group of morphogens involved in many cellular processes and fate 
decisions during early embryonic development. BMPs bind to type I and type II receptors 
and trigger their heterodimerisation. These complexes will in turn phosphorylate Smad 
proteins which regulate the expression of multiple genes (126). BMP4 is required for 
mesoderm development (127) and also has a key role later in HSC emergence. In the E11 
mouse AGM region BMP4 is expressed in the mesenchyme underlying HSC aortic clusters. 
When BMP signalling is inhibited HSC numbers are reduced, whereas, when AGM explants 
are cultured in the presence of BMP4 HSCs display enhanced repopulating potential (128). 
Similarly, in the zebrafish embryo BMP4 is expressed in the mesenchyme surrounding the 
developing dorsal aorta and conditional knockdown results in a loss of HSCs in the ventral 
wall of the dorsal aorta (129). Inhibition of the downstream effectors of BMP signalling, 
Smad1 and Smad5, in the zebrafish embryo represses the specification of hemogenic 
endothelium and ultimately the generation of definitive HSCs (130, 131). Interestingly, 
however, knockout of Smad1 and Smad5 in specified fetal liver and bone marrow HSCs does 
not affect their self-renewal or their reconstituting capacity (132). Collectively, these data 
suggest that BMP signalling is essential during HSC specification from the endothelium but 
dispensable after HSC commitment. 
Additional pathways have been implicated in the specification of hemogenic endothelium 
and HSCs. As shown by Peeters and colleagues, components of the Hedgehog signalling are 
expressed in the murine E10 AGM region, mainly in the mesenchyme underlying the dorsal 
aorta (133). When early E10 AGM explants are cultured with low doses of Hedgehog 
proteins HSCs display enhanced repopulating activity, while, when anti-Hedgehog 
antibodies are added HSC function is reduced. These data suggest a time- and dose-
dependent requirement of Hedgehog signalling in HSC specification. Studies on the 
developing zebrafish embryo demonstrated that Hedgehog proteins are expressed in the 
notochord and floor plate, and are required for the formation of the dorsal aorta and the 
maintenance of its arterial identity. Additionally, targeted deletion or inhibition of Hedgehog 
signalling components leads to loss of definitive haemopoiesis (134, 135). More importantly, 
these studies have shown that Hedgehog acts upstream of the vascular endothelial growth 
factor (Vegf) signalling, another major regulator of endothelial and haemopoietic 
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development, which in turn regulates the Notch pathway. Particularly, Hedgehog induces the 
expression of the Vegfa ligand in the somites which binds to the Vegf receptor expressed 
throughout the vasculature. Subsequently, Vegf signalling in endothelial cells activates the 
expression of Notch receptors, therefore, allowing the cells to receive the required signals for 
HSC specification (134, 135). 
In conclusion, a lot of progress has been made in defining the molecular signals that 
determine HSC emergence. Although further work is required to accurately synthesise their 
interaction network, many transcription factors and signalling pathways have been 
characterised and successfully used in replicating, to a certain degree, haematopoietic 
induction in vitro. The development of the appropriate culture systems is equally important 
and has attracted a lot of interest in HSC research.    
1.5 In vitro haemopoietic differentiation from pluripotent stem cells  
Despite the detailed study of in vivo haemopoiesis and the wealth of information it has 
provided regarding the development and characteristics of adult HSCs, attempts to maintain 
and expand these cells ex vivo have been unsuccessful (reviewed in 136). With HSC 
transplantation remaining the most established cellular therapy and the only curative 
treatment for a variety of life-threatening haematologic disorders including anaemias, blood 
cancers, autoimmune and immune deficiency syndromes, the demand for engraftable HSCs 
is soaring. The only current sources of HSCs are bone marrow and cord or peripheral blood, 
which pose severe limitations due to the scarcity of donors. In addition the efficiency of the 
transplantations and the patient survival rate are significantly reduced by the transmission of 
infectious diseases and immunocompatibility problems. Therefore, many studies have 
focused on the generation of transplantable HSCs from alternative sources, with pluripotent 
stem cells (PSCs) either ESCs or iPSCs, being the most promising, if not the only alternative 
resource. As mentioned earlier, in many occasions PSCs have been successfully used in 
developmental studies of early haemopoiesis as they can recapitulate development in vitro 
(61-63, 75). With the same rational, a large number of protocols have focused on the directed 
differentiation of PSCs into fully mature HSCs that like their in vivo counterparts will have 
long-term multilineage engraftment potential. 
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1.5.1 Pluripotent stem cells 
Pluripotent stem cells (PSCs) can either be derived from blastocyst-stage embryos, 
embryonic stem cells (ESCs), or from adult somatic cells, induced pluripotent stem cells 
(iPSCs). Regardless of their origin PSCs are distinguished by two important features that 
make them an unparalleled in vitro tool for biomedical applications. Firstly, they have the 
ability to self-renew robustly in an undifferentiated state in culture, thus providing an 
unlimited renewable source of cells. Secondly, under the appropriate conditions they can 
differentiate into any mature cell type of the adult body, creating enormous potential for the 
treatment of a large number of diseases. Moreover, PSCs can readily be genetically 
manipulated which allows the generation of cells with desirable genetic features. Finally, the 
ability to culture and differentiate PSCs under sterile conditions provides a source of safe, 
infection-free transplantable cells. 
1.5.1.1 Embryonic stem cells  
The study of PSCs began with the derivation of the first stable mouse embryonic stem cell 
lines (mESCs) from the inner cell mass of blastocyst-stage embryos in 1981 (137, 138). 
Mouse ESCs can differentiate into all three germ layers in vitro and can form chimeras or 
teratomas when reinjected into developing embryos or adult mice respectively. The first cell 
lines were maintained in an undifferentiated state by co-culture with mouse embryonic 
fibroblasts (MEFs) supplemented with fetal calf serum (FCS) and/or conditioned media from 
teratocarcinoma stem cell cultures. The use of leukaemia inhibitory factor (LIF) allowed for 
the maintenance of mESCs in feeder-free cultures on gelatinised surfaces supplemented with 
FCS (139). To further minimise the animal-derived factors and the variability they present a 
number of serum- and feeder-free culture conditions have been established to date. Ying and 
co-workers initially used a combination of LIF and bone morphogenic protein 4 (BMP4) to 
efficiently derive and maintain mESCs, while more recently they showed that use of GSK 
and MEK inhibitors, 3i medium, can successfully maintain undifferentiated mESC self-
renewal (140, 141). 
The first successful generation of human ESCs occurred in 1998 by Thompson and 
colleagues (5). Human ESCs were derived from donated embryos produced by in vitro 
fertilisation and like mESCs, they could retain their pluripotency when co-cultured with 
mouse MEFs and generate teratomas when injected into immunocompromised mice. As the 
use of animal-derived culture products can prevent the use of hESCs in clinical therapies due 
to transfer of pathogens or increased risk of immune reactions, the development of serum- 
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and feeder-free culture systems has also been a priority in hESCs. Extracellular matrices 
such as matrigel and fibronectin have been widely used to substitute for feeder cells. 
Nonetheless, MEF conditioned media supplemented with basic fibroblast growth factor 
(bFGF) was initially required for the maintenance of hESCs in feeder-free conditions (142, 
143). It was later demonstrated that high concentrations of bFGF together with ActivinA or 
the BMP inhibitor noggin can sustain the feeder and serum-free undifferentiated proliferation 
of hESCs. (144, 145). Commercially available xeno-free culture media supplemented with 
human recombinant proteins has also been used, however, with limited efficiency (146). 
1.5.1.2 Induced pluripotent stem cells 
Despite the exciting clinical potential of hESCs, the destruction of human embryos for the 
derivation of hESC lines has raised major ethical and political concerns. Additionally, while 
undifferentiated ESCs express low levels of MHC antigens, their expression significantly 
increases during differentiation therefore also increasing the risk of immune reactions and 
rejection upon transplantation in mismatched hosts. The groundbreaking generation of 
induced pluripotent stem cells (iPSCs) from somatic cells can overcome ethical limitations 
and more importantly allow for patient-specificity. 
The first mouse iPSCs were initially generated by the Yamanaka group through retroviral 
transduction of the pluripotency-associated transcription factors Oct3/4, Sox2, Klf4, c-Myc 
to embryonic and adult fibroblasts (147). Similarly to mESCs they could form multilineage 
teratomas upon transplantation into immunodeficient hosts and contribute to the 
development of chimeric mice following injection into blastocysts. A year later human 
iPSCs were generated using the same methodology by both the Yamanaka and Thompson 
groups (6, 148). Although the efficiency of human iPSCs generation was significantly lower 
than the murine, human iPSC lines could again contribute to all three germ layers in 
teratomas or in vitro conditions. Even though iPSCs resolve the issue of immune rejection, 
they bring up the risk of malignant transformation due to the use of viral vectors and proto –
oncogenes. Recent studies have tried to overcome this problem with the viral-free transient 
gene expression or the direct delivery of reprogramming proteins (149, 150, 151). Although 
questions regarding the similarities and differentiation potential of iPSCs compared to ESCs 
remain, this technology is evolving rapidly and holding great promises for the generation of 
patient-specific HSCs.            
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1.5.1.3 Mouse epiblast stem cells 
Even though there are currently a number of established human ESC lines, mouse cells still 
serve as an efficient tool to further decipher haemopoietic development and translate the 
acquired knowledge to the human system. However, fundamental differences between 
mouse and human ESC maintenance and differentiation strategies do not allow for the direct 
application of knowledge produced from one species to the other. Particularly, LIF which is 
essential for the maintenance of mESCs does not have an effect on hESCs, while BMP4, 
required for mESC self-renewal, induces differentiation of hESCs. In addition, bFGF an 
essential factor for hESC maintenance induces neural differentiation of mESCs. Another 
critical factor for hESC maintenance, ActivinA, fails to maintain mESCs. Differences in the 
regulatory pathways of mouse and human ESCs may reflect not only differences between 
species but also between the developmental stage and origin of the cells.  
Mouse epiblast stem cells (EpiSCs), derived from post-implantation blastocyst embryos, 
share similar expression and signalling patterns with hESCs (152, 153). EpiSCs cannot be 
derived in the presence of LIF and/or BMP4, the two critical factors for mESC maintenance 
and self-renewal. Conversely their pluripotency depends on the Activin/Nodal pathway 
similar to hESCs. EpiSCs maintain the expression of pluripotency genes such as Oct4, Sox2 
and Nanog, however, they are characterized by the downregulation of inner cell mass 
markers (Klf4, Stella) and the upregulation of early germ layer genes including Foxa2, Fgf5 
and T (Bry). The similarities between human ESCs and mouse EpiSCs make EpiSCs a 
promising new model for the understanding of human development. More important, the 
primed state of EpiSCs towards the mesoderm lineage, marked by the expression of T, may 
confer to them a developmental advantage over mESCs for the study of haematoendothelial 
specification. 
1.5.2 Approaches for the directed haemopoietic differentiation from PSCs 
 A variety of protocols for the directed differentiation of PSCs into the haemopoietic lineage 
have been developed to date using different technical approaches that include co-culture with 
feeder cells that mimic the embryonic haemopoietic environment, embryoid body (EB) 
formation that spontaneously differentiate into the three germ layers mimicking the 
embryonic development, and growth in extracellular matrix-coated dishes that promote 
proliferation and provide an attachment scaffold (Figure 1.3). The addition of serum or 
haemopoietic cytokines is used in these protocols to increase their efficiency and indeed the 
successful production of hematopoietic progenitor cells (HPCs) and mature blood cell types 
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has been well documented. However, the generation of HSCs capable of long-term 
engraftment in adult recipients and multilineage reconstitution has been more challenging 
and current protocols are constantly being improved. 
1.5.2.1 Differentiation of PSCs in feeder cell co-culture 
The 2-dimensional co-culture of PSCs together with a layer of feeder cells has proven quite 
successful in inducing and supporting haemopoiesis. Feeder cells provide the necessary 
cellular interactions and signalling molecules for the maturation of HSCs, similar to those 
found in haemopoietic niches in vivo. Even though future clinical applications will require 
feeder-free generated HSCs, feeder cell lines have been derived from a variety of anatomical 
sites including the bone marrow, the AGM region, the yolk sac and the fetal liver, and have 
been widely used alone or in combination with serum or haemopoietic factors both in mouse 
and human PSC cultures.  
One of the most widely used feeder cell lines derived from mouse bone marrow, the OP9, 
was first used by Nakano and colleagues in mouse ESC cultures and was capable of 
supporting their erythroid, myeloid and lymphoid differentiation as shown by haemopoietic 
colony assay and cell surface marker expression (154). OP9 feeder cells were later 






 haemopoietic cells capable of 
multilineage differentiation in vitro through a Flk-1-expressing mesodermal progenitor from 
mouse iPSCs (155). Similar to the mouse, human ESCs and iPSCs have been co-cultured 




 multipotent yet not engraftable 
haemopoietic progenitors (156, 157). In addition to the OP9 line, work by Kauffman and co-
workers showed that the mouse bone marrow cell line S17 and the mouse yolk sac 
endothelial cell line C166 were capable of inducing the haemopoietic differentiation of 
human ESCs (158). Following the co-culture, hESCs gave rise to CD34
+
 progenitors that 
expressed the haemopoietic transcription factors TAL-1, LMO-2 and GATA-2, and were 
capable of generating myeloid, erythroid and megakaryocyte colonies in vitro similar to 
those produced by human adult bone marrow cells.  
In addition to bone marrow derived lines, feeder cells from the AGM region, mainly from 
the aorta-mesonephros subregion, have been extensively used in co-culture strategies and 
have proven quite successful in enhancing haemopoietic progenitor production from mouse 
and human PSCs. Weisel and colleagues generated a large panel of AGM-derived cell lines 
and evaluated their ability to support the haemopoiesis of mESCs. They demonstrated for the 





cell to levels comparable with the OP9 line (159). Similar findings were provided by 
Krassowska and co-workers. Co-culture of mESCs with primary AGM region resulted in 
significantly enhanced haemopoiesis compared to mESCs in feeder-free culture as assayed 
by in vitro colony formation. Moreover, co-culture with the AM20-1B4 feeder cell line 
derived from the aorta and surrounding mesenchyme subregion yielded high numbers of 
haemopoietic colonies and c-kit, Sca-1 or CD45 expressing progenitors, while the 
haemopoietic potential of the urogenital ridge-derived UG26-1B6 and the fetal liver-derived 
EL08.1D2 lines was limited (160). The effects of primary feeder cells from the murine AGM 
region and fetal liver, as well as the established AM20-1B4, UG26-1B6 and EL08-1D2 cell 
lines on hESCs differentiation were subsequently tested. In all cases CD34 expressing cells 
were increased compared to non-feeder controls and most importantly some of these 
progenitors could reconstitute primary and secondary recipients, albeit in low numbers (161). 
Feeder cell lines derived from human fetal liver or bone marrow have also been reported to 
induce the generation of CD34+ progenitors in hESC differentiation, however, their use has 




Figure 1.3: In vitro haemopoietic differentiation of pluripotent stem cells. 
Embryoid body formation, feeder cell co-culture and extracellular matrix-coated dishes can 
be used for the directed haemopoiesis of mouse and human ESCs and iPSCs. Progenitors and 
mature blood cells are tested for their properties both in vitro and in vivo. Image adapted 
from Lim et al., 2013 (164).   
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1.5.2.2 Differentiation of PSCs in EB cultures 
When removed from culture conditions that maintain self-renewal, mouse ESCs 
spontaneously form 3-dimensional spherical cell aggregates that closely mimic the early 
stages of embryonic development as they exhibit cell movement, form all three germ layers 
and differentiate into committed cell types (165). EBs are formed through a number of 
methods including suspension culture, hanging drops, spin EBs and are subsequently 
cultured in defined media with various combinations of cytokines and growth factors. EB 
mediated differentiation can overcome problems imposed by feeder cells such as passage 
limitation, feeder cell senescence, variability due to undefined factors and presence of 
animal-derived components, thus allowing highly reproducible and efficient yields.  
The spontaneous generation of blood cells in EBs grown in the presence of serum has been 
long recorded in the mouse ESC system by Doetschman and colleagues (166). A number of 
cytokines, IL-3, IL-1, M-CSF, GM-CSF, were later identified that in combination with FCS 
enhanced haemopoietic differentiation of mouse ESCs (167). Interestingly, Burt and co-
workers reported the long-term repopulating ability of c-kit+CD45+ cells generated from 
EBs treated with SCF, IL-3 and IL-6 in the presence of serum (168). However, their protocol 
has not been reproduced suggesting that FCS variability may have inhibitory effects and 
stressing the need for well-defined serum-free conditions. Early work by Nakayama and co-
workers showed that serum-free differentiation of mouse EBs, particularly in the presence of 







 progenitors with multilineage in vitro potential (169). Park and 





cells, while VEGF for the expansion of SCL
+
 haemopoietic 
progenitors. Activin A was also found to augment the BMP4 and VEGF synergistic effect 
(170). Nevertheless, KOSR still contains unknown components that may affect some steps of 
the differentiation. Therefore, more robust and well-defined serum-free EB differentiation 
protocols were subsequently developed which did not contain KOSR and mainly relied again 





forming haemopoietic progenitors was greatly enhanced by the combined effects of BPM4, 
VEGF and TPO, while in another similar results were obtained by the step-wise addition of 
BMP4, Activin A, bFGF and VEGF (171, 172). However, none of these studies have 
demonstrated in vivo repopulating ability of the EB-derived haemopoietic progenitors.  
Similar to mouse, human ESCs can differentiate into all three embryonic germ layers upon 
EB formation (173). Initial work by Chadwick and colleagues showed that EB culture in the 
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 progenitors of multiple lineages, however the particular 
approach included the use of serum in the first steps of the protocol (174). Extensive work by 
the Elefanty group has led to the development of a highly efficient serum-free EB 
differentiation protocol. To generate EBs of uniform size a defined number of hESCs were 
spun down to enforce aggregation and cultured in low-attachment plates. The spin EBs 
resulted in significant increase in the number of CD34 and RUNX1 expressing haemopoietic 
progenitors compared to protocols published by others, and were capable of generating 
colonies of the erythroid and myeloid lineages (175). Further work by the group proved that 
the culture of spin EBs in the presence of BMP4, VEGF, SCF and bFGF maximised the 
yield of haemopoietic progenitors as shown by the high numbers of colonies and the 
expression of transcriptional factors, SCL, GATA2, RUNX1, and cell-surface haemopoietic 
markers, CD34, CD45, CD117 (176). This serum- and feeder-free spin EB protocol has also 
been applied in human iPSCs successfully generating CD34, CD43 and CD45 expressing 
haemopoietic progenitors (177). 
1.5.2.3 Differentiation of PSCs on extracellular matrix-coated dishes 
While the 3-dimensional environment, provided by EBs, mimics quite faithfully the early 
stages of embryogenesis it may not be ideal for modelling later events. The limited cellular 
movements and lack of anatomical structures can inhibit the diffusion of critical molecules 
and important cellular interactions for optimal haemopoietic differentiation. To overcome 
these limitations novel 2-dimensional serum- and feeder-free differentiation systems have 
been developed that allow the development of PSCs as a monolayer on extracellular protein 
matrices. 
Chiang and Wong developed a defined, serum-free differentiation protocol, where mESCs 
were plated in low density onto laminin-, Matrigel or Cell-Tak-coated plates and 





 haemopoietic precursors, capable of haemopoietic colony formation in vitro, 
arose with high efficiency budding off from adherent endothelial cells. More importantly, 
this differentiation system allowed the direct time-lapse imaging of the differentiation 
process from single progenitors. In the same year, work by two different groups 
demonstrated the serum- and feeder-free monolayer haemopoietic differentiation of human 
ESCs and iPSCs. Human PSCs plated onto human fibronectin or mouse or human collagen 




haemopoietic progenitors that under the appropriate 
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cytokine cocktails could further mature into several blood lineages (179). Interestingly, 
hypoxic conditions resembling the in vivo environment of the developing embryo increased 
the efficiency of the protocol. In a similar approach hPSCs were plated onto growth factor-





 HPCs capable of multilineage differentiation in vitro (180). More recently, a 
combination of the EB and monolayer culture systems has been developed by Park and co-
workers that takes advantage of the benefits the two systems provide. Human PSCs were 
allowed to initially form suspension EBs in defined serum-free conditions giving rise to 
hemato-endothelial precursors. The EBs were then dissociated and plated as single-cells onto 
human fibronectin-coated plates. The floating progenitors arising from the monolayers were 
characterised by CD34 and CD45 expression and high CFC activity (181). The ability of the 
progenitors generated in these studies to repopulate adult recipients has not been 
demonstrated yet.  
1.5.3 Enhancing haemopoietic engraftment by genetic manipulation  
While the differentiation protocols described above have been quite successful in generating 
haemopoietic progenitors that express haemopoietic markers and form multilineage colonies 
in vitro, studies reporting the engraftment of PSC-generated haemopoietic cells show either 
very low engraftment efficiency or limited reproducibility. In an effort to increase the 
repopulating potential of these in vitro progenitors, researchers have focused on the upstream 
molecular regulators of haemopoietic development and have identified a number of key 
transcription factors directing HSC specification. The enforced expression of these genes has 
been used in combination with the above protocols and in many occasions have resulted in 
enhanced in vivo engraftment. 
In the mouse system Stat5 overexpressing ESCs co-cultured with OP9 feeders have 
repeatedly been reported to not only increase the number of colony-forming haemopoietic 
cells but most importantly enhance their repopulating ability in primary and secondary 
recipients (182, 183). The LIM-homeobox transcription factor, Lhx2, was initially 
demonstrated to generate multipotent haemopoietic precursors from mouse ESCs capable of 
remaining in an undifferentiated state in culture for prolonged periods of time (184). More 







 cells capable of in vivo long-term engraftment (185). In human ESCs and 
iPSCs expression of RUNX1a, a RUNX1 isoform, during EB differentiation produces 
progenitors expressing haemopoietic-related factors that demonstrate multilineage 
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haemopoietic reconstitution in vivo (186). An important transcription factor of definitive 
haemopoiesis that has attracted a lot of attention due to its ability to enhance the production 
of PSC-derived haemopoietic progenitors in both the mouse and the human system, as 
reported in a large number of studies, is HOXB4. However, while HOXB4 can confer long-
term repopulating activity in precursors produced in mouse ESC cultures, it has not to date 
led to the maturation of repopulating HSCs in the human system (187, 188). Therefore, a 
huge amount of research has been invested in understanding the regulatory network behind 
HOXB4 activity and identifying critical factors that mediate its activity in an effort to 
advance the generation and expansion of PSC- derived HSCs. 
1.6 HOXB4: an effector of definitive haemopoiesis 
Overexpression of the transcription factor HOXB4 is currently the most efficient strategy for 
expanding adult HSCs, inducing repopulating activity in embryonic yolk sac HSCs and 
increasing the haemopoietic differentiation potential of PSCs. This remarkable ability, has 
subjected HOXB4 to extensive analysis of its mechanism of action and resulted in the 
development of a variety of protocols for HSC expansion and differentiation in vitro. 
Nonetheless, the critical factors triggered by HOXB4 necessary for the generation of human 
functional HSC remain elusive and warrant further investigation. 
1.6.1 HOXB4 in development and haemopoiesis  
HOXB4 is a member of the highly conserved family of the homeotic, HOX genes that encode 
DNA-binding transcription factors. In mammals HOX genes are organised into four major 
genomic clusters, A, B, C and D, and play a crucial role in directing the position of tissue 
development along the anterior-posterior axis during embryogenesis. Interestingly, the order 
of the HOX genes on their chromosome mirrors the order in which HOX genes are expressed 
along the head-to-tail axis in the developing embryo, a characteristic known as spatial 
colinearity (189). Genes involved in head formation are located in the 3’ end of the 
chromosome, while, genes linked to the posterior are found on the 5’ end. In vertebrates 
HOX genes also display temporal colinearity. Genes become progressively activated during 
development in a temporal sequence that corresponds to their position on the chromosome, 
with 3’ genes being expressed before 5’ genes (190). As described by Deschamps and 
colleagues the earliest 3’ HOX gene expression is initiated during the late streak stage in the 
posterior primitive streak, in a cohort of cells that contributes to extraembryonic mesoderm. 
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Expression of more 5’ genes also initiates in the posterior primitive streak at progressively 
later stages and in different cells due to cell movement during gastrulation. Hox expression 
then expands rostrally along the streak past the node reaching the definitive anteriormost 
boundaries, earlier for 3’ genes and later in more posterior positions for 5’ genes, in 
neurectoderm, mesoderm and endoderm structures (191. 192). Retinoic acid gradients, Fgf, 
and Wnt signalling are among the factors modulating early Hox gene expression, possibly 
through the jointed action of the Cdx transcription factors. Finally, once the anteriormost 
boundaries of Hox expression are established, the Polycomb and the Trithorax group genes 
start operating and maintaining them throughout embryonic development (191,192).   
The majority of HOX genes, mainly clusters A, B and C have also been implicated in 
patterning haemopoietic mesoderm into definitive HSCs. They are highly expressed in stem 
and progenitor populations and downregulated upon lineage commitment (193, 194, 195). 
Using a YFP reporter, Hills and co-workers were able to track HOXB4 expression in the 
developing haemopoietic niches in the mouse embryo (196). They showed that HOXB4 is 
expressed in emerging haemopoietic cells in the AGM region, the yolk sac and the placenta. 
Although HOXB4 expression appears reduced in the fetal liver it increases again upon 
homing of the bone marrow with HOXB4-expresssing HSCs displaying long-term 
repopulating ability. Consistently, HOXB4-deficient mice exhibit significantly decreased 
cellularity of haemopoietic organs including bone marrow and spleen, and reduced numbers 
of haemopoietic progenitors (197). Thus HOXB4 is required for normal haemopoietic 
development, yet its loss can be compensated by other HOX genes.       
Overexpression of several HOX genes followed by transplantation has been used to enhance 
the proliferation and expansion of HSCs. However, in many cases it has resulted in 
myeloproliferative disorders, leukaemias and defects in the differentiation of various 
lineages (198, 199, 200). Surprisingly, HOXB4 is the only factor that can significantly 
enhance HSC self-renewal in the murine system without leading to malignant transformation 
of the cells. As demonstrated by the Humphries group, transplantation of HOXB4-
transduced bone marrow cells into lethally irradiated mice promotes competitive 
reconstitution of all haemopoietic lineages (201). Additionally, HOXB4-transduced HSCs 
display significantly increased in vitro expansion levels, without exceeding normal 
repopulation levels upon their transplantation (202). Retrovirally mediated HOXB4 
expression in adult human bone marrow and cord blood HSCs has also been proven to 
enhance their repopulating ability without impairing differentiation or causing disease (203). 
Direct delivery of HOXB4 protein, which minimises genetic intervention, has also been 
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successful in expanding mouse and human HSCs and increasing their engraftment potential 
(204, 205). The initial excitement of the potent effects of HOXB4 on the expansion and 
engraftment in non-human primate CD34
+
 HSCs demonstrated by Zang and colleagues, was 
hampered by his later work showing that HOXB4 overexpression can increase the risk of 
leukaemogenesis in larger animal models (206, 207). Additionally, high level of HOXB4 
expression in CD34
+ 
human cells have been shown to result in impaired lymphoid and 
myeloerythroid differentiation, thus indicating the concentration dependent nature of 
HOXB4 activity and the need for extreme caution in its clinical applications (208). 
1.6.2 Improving in vitro HSC differentiation by HOXB4 induction 
The enhancing effects of HOXB4 on the ex vivo expansion of adult HSCs sparked a lot of 
interest in its use for improving the in vitro haemopoietic differentiation of PSCs. The first 
breakthrough came by Kyba and colleagues over a decade ago (187). Using a tetracycline-
inducible HoxB4 transgene, they induced HoxB4 expression in EB-derived mouse cells 
followed by OP9 co-culture, which resulted in the generation of haemopoietic cells capable 
of reconstituting the myeloid and lymphoid pools of primary and secondary recipients. 
Interestingly, in the same study HoxB4 also conferred repopulating activity on early 
embryonic yolk sac cells. Since then a variety of HOXB4 overexpression studies have been 
produced that despite variations in the induction strategy, they have resulted in enhanced 
HSC differentiation and in many cases long-term engraftment while providing insight on 
HOXB4 action. Work by Pilat and co-workers examined the effects that different ectopic 
HOXB4 levels have on the lineage decisions of EB-derived reconstituting cells and 
demonstrated that increased amounts of HOXB4 expression enforced myeloid development 
while supressing lymphoid and erythroid development (209). Accordingly, later work 
showed that transient rather than constitutive HOXB4 expression can significantly increase 
the generation of CD41, CD45 or Sca-1 expressing cells derived from mouse ESCs and 
iPSCs (210). Wang and colleagues showed that combined ectopic expression of HoxB4 and 
another homeobox transcription factor Cdx4, further increased multilineage engraftment and 
improved the generation of lymphoid cells than HoxB4 alone in mouse haemopoietic cells 
derived from EBs followed by OP9 co-culture (211). All the above approaches, however, 
included the use of serum or feeders that can obscure HOXB4 activity, the reproducibility of 
results and their clinical translation. Work by Lesinski and colleagues has successfully 
overcome these problems. They managed to develop a serum- and feeder-free protocol 
where ectopic HOXB4 expression together with hypoxic conditions is sufficient to produce 
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ESC-derived haemopoietic cells, phenotypically similar to definitive bone marrow HSCs and 
capable of long-term multilineage engraftment (212). 
Generation of mouse PSC-derived definitive HSCs using HOXB4 raised the expectations 
that the same results can be achieved in human PSCs. However, while many studies have 
reported the enhanced generation of haemopoietic progenitors in vitro, the robust production 
of transplantable human HSCs based on HOXB4 expression has not been achieved to date. 
Bowles and co-workers reported that stable HOXB4-expressing hESCs generated 
significantly higher numbers of CD45
+
 progenitors with upregulated levels of GATA1 and 
SCL/Tal1, yet in vivo reconstitution was not examined (213). Work by Wang and colleagues 
also demonstrated that lentiviral-based ectopic HOXB4 expression increased the total cell 
expansion of ESC-derived haemopoietic cells in culture, however, it failed to enhance blood 
colony formation in vitro or in vivo engraftment (188). Similar results were obtained by Lu 
and co-workers, who in an effort to avoid the potential risks associated with genetic 
manipulation of ESCs in clinical applications, they added a recombinant tPTD-HOXB4 
protein in their differentiation protocol. Their approach resulted in increased numbers of 
multilineage colony forming progenitors but not in repopulating capacity (214). As in the 
murine system, expression levels of HOXB4 have been shown to affect the differentiation 
potential of human ESCs, and it can therefore be possible that modulation of HOXB4 levels 
may be the key for improving the efficient differentiation of repopulating human HSCs 
(215).  
Despite the variability between reports it does appear that HOXB4 is the most powerful in 
vitro tool for adult HSC expansion and PSC-derived haemopoiesis. In order to eventually 
achieve the production of reconstituting human HSCs it is essential to understand the 
molecular mechanisms behind HOXB4 activity. Therefore, a number of gene expression 
studies have been performed on adult and ESC-differentiating haemopoietic cells that have 
uncovered a wealth of information regarding the molecular pathways controlled by HOXB4 
and opened up the door for novel approaches in the use of HOXB4.  
1.6.3 Characterising molecular pathways underlying HOXB4 activity 
In an effort to identify HOXB4 target genes, genome-wide expression profiling was 
performed by Scheindlmeier and co-workers in murine adult bone marrow HSCs/HPCs and 
ESC-derived haemopoietic cells that expressed inducible forms of HoxB4 (216). They 
identified 133 gene targets of HOXB4 in adult HSCs/HPCs the majority of which were 
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confirmed by qRT-PCR assays. The targets included genes shown to be crucial for self-
renewal, survival and maintenance of adult HSCs such as Cdkn1b, Mad, Foxo3a, Ptgs2, and 
Zfx. A much larger number of HOXB4 targets, >700, was identified in differentiating ESCs, 
as they included non-haemopoiesis related genes of the three germ layers formed in 
developing EBs. Between the two datasets they found 52 overlapping genes which were 
characterized as ‘universal targets’ of HOXB4. Genes in this list are involved in pathways 
important for HSC self-renewal, maintenance and differentiation such as Wnt/β-catenin, 
Notch, TGF-β/Activin/BMP and FGF, as well as genes associated with cell cycle, apoptosis 
and response to stress. A later study by Oshima and colleagues combined ChIP-on-Chip with 
microarray analysis on ESC-derived HPCs overexpressing HoxB4, to provide further insight 
on direct and indirect HOXB4 targets (217). The ChIP-chip analysis revealed that HOXB4 
regulates genes involved in a variety of functions, including cell proliferation, cell cycle and 
chromosomal organization and biogenesis. Most importantly they identified transcription 
factors essential for the maturation of developing HSCs into repopulating cells such as 
Gata2, Scl/Tal and Runx1 as direct targets of HOXB4.  Unexpectedly, none of the top 20 
ranked direct HOXB4 targets have been characterized before as related to haemopoiesis. 
Additionally, their set of differentially expressed HOXB4 targets contained 13 genes 
overlapping with the universal HOXB4 targets identified by Scheindlmeier. More recently, 
ChIP-Seq coupled with gene expression analysis at 4 sequential time points of HOXB4-
mediated ESC differentiation by Fan and colleagues, demonstrated that the HOXB4 
regulatory network is highly dynamic as it expands during the differentiation process and 
different pathways are activated at distinct developmental stages (218). HOXB4 targets in 
the early stages of differentiation included genes related to early embryonic development and 
patterning such as Dll1, Sox2, Nodal, Tbx3 and Gli2. At later time points HOXB4 induced 
genes already implicated in early hematopoiesis including Meis1, Gata2, Runx1, Cited2, Id2 
and Stat5, as well as genes of later lineage specific stages such as myeloid and lymphoid 
proliferation. Interestingly, it was shown that HOXB4 regulates haemopoiesis by targeting 
several chromatin modification enzymes.   
Despite the insight that the above studies provided into HOXB4 activity, they only focused 
on its cell autonomous effect in partially or fully mature HSCs. Our group, based on the 
observation that HOXB4 is expressed in the primitive streak of the gastrulating embryo prior 
to the onset of hematopoiesis, looked into its potential hematopoietic inductive effect on the 
developing mesoderm of differentiating ESCs (219). Using an inducible HOXB4 expression 
system it was demonstrated that activation of HOXB4, before the emergence of 
hematopoietic progenitors, can increase hematopoietic differentiation. Expression profiling 
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at this stage of ESC differentiation, identified for the first time as targets of HOXB4 genes 
associated with paraxial mesoderm (Tbx6, Frzb, Dll1, Dll3, Foxc1, Fst, and Noggin), from 
which the hematopoietic niche is derived. This suggested a role for HOXB4 in the generation 
and/or modulation of the niche in differentiating ESCs. Target genes identified in this 
analysis also included a large number of secreted factors such as VEGFA and SCF that act as 
ligands for cell surface receptors of HPCs. Cell mixing experiments of HOXB4 
overexpressing cells with constitutively expressing eGFP cells, resulted in increased 
hematopoietic differentiation of GFP+ cells indicating a paracrine mechanism of HOXB4 
activity. Collectively these data suggest that HOXB4 might induce hematopoietic 
differentiation by regulating the formation of the hematopoietic microenvironment which 
further enhances hematopoiesis through a paracrine effect. Results of earlier work conducted 
in our group further support this hypothesis. When HOXB4 overexpressing ESCs were co-
cultured on AGM-derived feeder cell lines, the HOXB4-mediated and feeder-mediated 
induction of hematopoiesis, were not additive, suggesting that this could be due to shared 
mechanisms (220).  
A wide range of novel candidate regulators for HSC specification and development targeted 
by HOXB4 have been identified. These target genes allow HOXB4 to act not only in a cell 
autonomous but also in a paracrine mechanism. It remains to be tested whether the 
manipulation of these targets can improve the in vitro generation of engraftable HSCs.  
Additionally, as the above studies have been conducted exclusively on the murine system, it 
is interesting to see if the identified HOXB4 regulatory mechanisms also apply in humans 












HOXB4 regulates the expression of genes involved in different stages of development and 










Frzb           β-catenin 
Rspo3        Snai2 
Dact1         Tie4  
Wnt6          Tie1 
TGFβ 
BMP7        Smurf2  
Cer1          Tgfb1  
Nog           Bambi 
Smad1      Nodal 
Etv1          Smad3 
Notch 
Dner            Delta-like 3 
Notch1        Notch2 
Jagged1      Delta-like 1  
Jagged2 
Hedgehog 
Gli1          Gli2 
Pitch1      Sim2 
HSC specific 
Sox17       Meis1 
Lom2        Stat5 
Scl            Cited 2 
Gata2        Fli1 
Runx1 
Jackson et al., 2012 (219) 
Scheindlmeier et al., 2007 (216) 
Oshima et al., 2011 (217) 
Fan et al., 2012 (218) 
Embryonic patterning 
Lhx1         Sox2 
Mesp1      Tbx3 
Evx1         Pbx1 
Eomes      Eomes 
Tbx6 
Cell cycle/Apoptosis 
Erg3               p21                 
Cyclin G2       Mat2a   
Hspa1b          Bcl2l11 
Bre 
Chromatin modification 
Cbx2, 7      Ezh1, 2     
Hist1h3f     Mll2, 5 
Jarid1a, 2   Ncoa3  
Myst1, 3     Sirt1  
Dnmt3b      Kdm1a, 5b 
Figure 1.4: Selected important genes regulated by HOXB4. 
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1.7 Thesis aims 
The overall aim of the thesis is to further investigate the paracrine mechanism of HOXB4 
action on HSC specification suggested by our group. Identifying secreted factors that 
mediate this paracrine haemopoietic effect will not only further clarify HOXB4 regulatory 
network, but also lead to a differentiation method based on simply adding these factors in the 
cell culture. This method will have the great advantage of avoiding the genetic manipulation 
of ESCs, and therefore, providing not only a more practical but also safer source of definitive 
HSCs. 
1.7.1 Hypothesis 
HOXB4 expression in pre-hematopoietic mesoderm promotes paraxial mesoderm 
differentiation and could therefore result in the formation of the hematopoietic niche. 
Downstream HOXB4 targets secreted by the niche can promote the formation, maintenance 
and survival of engraftable HSCs. (Figure 1.4). 
1.7.2 Experimental strategy 
In order to test the above hypothesis the specific aims are: 
1. Develop a feeder-free, serum-free mouse haemopoietic differentiation system to 
provide a well-defined, reproducible background in which to test HOXB4 induced 
secreted factors. Mouse ESCs as well as EpiSCs, were cultured in feeder- and 
serum-free conditions and assessed on their differentiation potential by colony-
forming assay and surface phenotype.  
2. Identify secreted factors induced by HOXB4 critical for haemopoietic 
differentiation. HOXB4 target genes identified in our previous microarray analysis 
were validated by qRT-PCR analysis and were used in the novel culture system to 
monitor their effects on haemopoietic differentiation. 
3. Translate the above findings into the human system. Using a serum-free and feeder-
free human haemopoietic differentiation system established in our group the secreted 
factors tested in the mouse system were used in human ESC and iPSC cultures to 







Figure 1.5: Proposed mechanism of HOXB4 activity. 
Overexpression of HOXB4 modulates mesoderm differentiation by inducing genes 
associated with paraxial mesoderm that gives rise to the hematopoietic niche. Secreted 
factors by the niche are also upregulated in response to HOXB4 and enhance the 
differentiation of hematopoietic progenitors. 
            




















2.1 Tissue Culture 
All cell culture procedures were carried out under aseptic conditions in a specialised tissue 
culture facility fitted with laminar flow hoods. Cells lines were tested mycoplasma free 
before use in experiments by Mrs Helen Henderson and Mrs Marilyn Thompson. Serum 
batch testing, LIF production and some of the preparation of tissue culture stock, were 
carried out by Mrs Helen Taylor, Mrs Helen Henderson and Mrs Marilyn Thompson. Human 
cells were maintained and passaged by Mrs Helen Taylor. All cells were incubated at 37
o
C in 
a humidified 5% CO2 atmosphere in the absence of antibiotics unless otherwise stated.  
2.1.1 Maintenance and differentiation of mouse embryonic stem cells (mESCs) 
2.1.1.1 Maintenance of mESCs 
A subclone of CGR8 ESCs, known as CGR8.5, was routinely maintained onto 0.1% gelatin 
(Sigma) coated 25cm
2
 tissue culture flasks, in 1x Glasgow Minimal Essential Medium 
(GMEM) (Gibco) supplemented with 10% fetal calf serum (FCS) (Lonza), 1% non-essential 
amino acids (Gibco), 0.1mM L-glutamine (Gibco), 2mM sodium pyruvate (Gibco) and 
0.1mM β -Mercaptoethanol (Sigma). The medium was supplemented with 100U/ml 
Leukaemia Inhibitory Factor (LIF) as required.  
Cells were passaged every 2 or 3 days when they reached 80-90% confluency. Prior to 
passaging, a new 25cm
2
 flask was coated with 5ml of 0.1% gelatine in PBS for 10 minutes. 
Old medium was aspirated and cells washed with 5ml PBS to remove residual medium. Cells 
were subsequently incubated at 37
o
C for 3min with 2ml trypsin solution (0.025% trypsin 
(Sigma), 1% chick serum (Gibco) and 1.3mM EDTA in PBS). The flask was tapped sharply 
to lift the cells, which were then transferred in 8ml of medium to deactivate the trypsin in the 
presence of FCS, and finally centrifuged at 120g for 5 minutes. The supernatant was 
aspirated and cells resuspended in single cell suspension with 10ml of fresh medium. Cell 
number was determined using a Neubauer haemocytometer. 1x10
6
 cells were seeded onto the 
new gelatinised flask and supplemented with medium to 10ml and LIF at 100U/ml before 
placed in the incubator. 
2.1.1.2 Thawing and cryopreservation of mESCs 
Cells were thawed rapidly by placing the cryovials at 37
o
C. Cell suspension from one 
cryovial was then transferred into 8ml of medium and centrifuged at 120g for 3 minutes. 
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After aspirating the supernatant, the cell pellet was resuspended in 10ml of fresh medium 
and transferred onto a gelatinised 25cm
2
 flask with 100U/ml LIF. Medium was replaced after 
5 hours or the following day.  
To freeze mESCs, cells from an 80-90% confluent 25cm
2
 flask were trypsinised and pelleted 
down as for passaging. After centrifugation the cell pellet was resuspended in 1ml of 
freezing medium, which consisted of maintenance medium with 10% dimethyl sulphoxide 
(DMSO) (Sigma). The cell suspension was then divided into 2 labelled cryovials and placed 
on dry ice for 10 minutes. The vials were then kept at -80
o
C overnight and transferred at -
150
o
C for long-term storage.    
2.1.1.3 Serum-based differentiation of mESCs 
In this method, also known as the hanging drop method, mESCs were differentiated for 6 
days under the influence of FCS without the addition of any other cytokines.  
Day -2 
Cells were treated as for passaging and counted. 6x10
5 
cells were added in 20ml final volume 
of maintenance medium with 100U/ml LIF. Using a multi-channel pipette 10μl droplets (300 
cells per droplet) were pipetted onto the upturned lid of a square petri dish. The lid was then 
turned over and placed back onto the petri dish so that the droplets were hanging down. This 
allowed the cells in suspension to congregate at the bottom of the droplet and form an 
embryoid body (EB). 10ml of tissue culture grade water was added at the bottom of the petri 
dish to keep the EBs hydrated and then placed in the incubator.  
Day 0 
After 48 hours, EBs were harvested by tapping the corner of the dish on the bottom of the 
hood, to allow for droplets to run down the edge of the dish. Using a plastic pipette the 
suspension was transferred into a centrifuge tube and spun down at 80g for 3 minutes. 
Supernatant was aspirated and the EBs were gently resuspended in 20ml of fresh medium 
without LIF to initiate differentiation. The EB suspension was placed into a 90mm bacterial 
grade petri dish which would prevent the EBs from attaching on the bottom of the dish and 
1:100 dilution of Penicillin/Streptomycin (2000 units of Penicillin and 2mg of Streptomycin, 





Day 1 to day 6 
After 24 hours new flasks were gelatinised, typically two 75cm
2 
flasks per 20ml of EB 
suspension. EBs were collected from the petri dish and transferred into a 20ml tube. EBs 
were gently pipetted a couple of times to disperse them and the suspension was then split 
into the two flasks. Medium was topped up to 40ml and flasks were placed in the incubator. 
On day 4 of differentiation a complete medium change was performed by aspirating the old 
medium and adding 40ml of fresh. On day 6 of differentiation, EBs were collected and 
dissociated into single cells for further analysis following the typical trypsinisation process 
as for passaging.    
In experiments done with the HOXB4-ER
T2
 clone, 4-OHT at 200nM final concentration was 
added in the flasks on day 1 and cells were harvested on day 3 of differentiation.  
2.1.1.4 Serum-free differentiation of mESCs 
In the serum-free protocol, cells were differentiated for 6 days in the absence of serum under 
the influence of cytokines in N2B27 medium. The N2B27 medium consisted of 1:1 ratio of 
Neurobasal : DMEM/F12 without L-Glutamine (Invitrogen), supplemented with 0.5% N2 
(Invitrogen), 2% B27 (Invitrogen), 1% non-essential amino acids (Gibco), 0.1mM L-
glutamine (Gibco) and 0.1mM β -Mercaptoethanol (Sigma).  
Day -2  
2 days prior to differentiation mESCs, typically maintained in FCS supplemented GMEM 
medium, were plated onto a 25cm
2
 gelatinised flask in N2B27 medium supplemented with 
100U/ml LIF and 10ng/ml BMP4 to remove any FCS residues and allow the cells to adjust 
to serum-free conditions.   
Day 0 
On Day 0 of differentiation the N2B27 medium was aspirated and the cells washed with 5ml 
PBS. 1ml of Accutase solution (Sigma) was added in the flask and incubated at 37
o
C for 2-3 
minutes. The flask was then tapped to lift the cells, the cells were quenched in 9ml of N2B27 
medium and spun at 120g for 3 minutes. The supernatant was aspirated, cells resuspended in 
single cell suspension in fresh N2B27 and counted. 3x10
5 
cells were put in a clean tube and 
N2B27 was added to a final volume of 10ml supplemented with the cytokines outlined in 
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Table 2.1. The cell suspension was then placed in a 60mm bacterial grade petri dish or split 
in 3 wells an ultra-low attachment 6-well plate (Stemcell Technologies), depending on the 
experiment plan. Embryoid bodies were formed in suspension by the next day. 
Day 2 to day 6 
On day 2 of differentiation 2ml of 0.1% gelatine were placed per well of a 6-well tissue 
culture plate and allowed to incubate for 10 minutes. The EB suspension was transferred in a 
centrifuge tube and spun at 80g for 3 minutes. The media was aspirated and the EBs were 
gently dispersed in 30ml N2B27 media supplemented with the appropriate cytokines (Table 
2.1). 5ml of the EB suspension were placed in each well and incubated for 4 more days. By 
day 4 of differentiation the EBs had fully attached to the bottom of the plate and were fed 
with 0.5ml N2B27 with fresh cytokines.   
To harvest the cells on day 6, the floating fraction, with any cells present in it, was 
transferred into a centrifuge tube. The EBs were gently washed with 2ml of PBS and this 
was added to the tube with the floating fraction. 500μl of Accutase were added per well and 
incubated at 37
o
C for 5min. EBs were quenched with 3ml fresh media, pipetted a few times 
to dissociate and added to the centrifuge tube with the rest of the floating fraction. The 
suspension was spun down for 3 minutes at 120g. Cells were resuspended in the appropriate 
volume of N2B27 medium and counted before further analysis.    
To examine the effects of HOXB4 targets, the recombinant proteins of interest were added 
from day 0 to day 6 in the following concentrations: mRSPO3 (RnD Systems) at 10, 30, 100 
and 300ng/ml, mFGF17 (RnD Systems) at 10, 30, 100 and 300ng/ml, APELIN13 and 









Day of differentiation Cytokines 
Day 0 to 2 ActivinA 5ng/ml, bFGF 10ng/ml, BMP4 5ng/ml 
Day 2 to 6 bFGF 10ng/ml, BMP4 5ng/ml, VEGF 15ng/ml 
 
Table 2.1: Cytokines used in serum-free haemopoietic differentiation of mESCs  
 
2.1.2 Generation, maintenance and differentiation of mouse epiblast stem cells 
(mEpiSCs) 
2.1.2.1 Generation and maintenance of mEpiSCs 
Mouse epiblast stem cells were generated in vitro by culturing mouse embryonic stem cells 
in the appropriate conditions. Particularly, mESCs were prepared in single cell suspension as 
for passaging and plated at a density of 8 x 10
4 
cells per well of a 6-well tissue culture plate 
pre-coated for 30 minutes with 8μg/ml of human Fibronectin (Sigma) in PBS. For the first 
24 hours the cells were grown in conventional mESC maintenance medium, thereafter, the 
cells were kept in N2B27 medium supplemented with 20ng/ml ActivinA (Peprotech) and 
10ng/ml bFGF (RnD Systems).  
The cells were passaged every 2 or 3 days when they reached 70-80% confluency. At the 
beginning cells were passaged at high density, 1/3 or 1/4, and once established after a 
minimum of 5 passages at lower density, 1/6 to 1/8 depending on confluency. To passage the 
mEpiSCs, the cells were washed gently with 2ml of PBS and then incubated in 300μl 
Accutase for 5 minutes at 37
o
C. Following this period 3ml of N2B27 medium were used to 
collect the cells into a centrifuge tube and they were spun down for 3 minutes at 120g. The 
pellet was then resuspended in N2B27 supplemented with ActivinA and bFGF by gently 
pipetting up and down and the appropriate amount of cells was plated onto a new Fibronectin 
pre-coated 6-well plate. Culture medium was replaced daily.  
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2.1.2.2 Thawing and cryopreservation of mEpiSCs 
Cryovials were placed at 37
o
C to allow for rapid thawing of the cells. The cells from one 
cryovial were transferred into 9ml of N2B27 medium and spun down for 5 minutes at 130g. 
The supernatant was aspirated and cells resuspended in 3ml of N2B27 medium 
supplemented with ActivinA and bFGF before being plated onto a Fibronectin pre-coated 
well of a 6-well tissue culture plate. The medium was replaced 5 hours later or the following 
day after the cells had adhered to the plastic. 
Mouse EpiSCs were frozen down using knock-out serum replacement (KOSR, Invitrogen) 
with 10% DMSO. One confluent well was washed with PBS and the cells lifted with a 3 
minute Accutase incubation at 37
o
C. The cells were quenched with fresh N2B27 medium 
and pelleted down for 3 minutes at 120g. The supernatant was aspirated and the pellet 
resuspended with 1ml of freezing medium. The cell suspension was placed into one cryovial 
and quickly frozen on dry ice for 10 minutes. The vial was then kept at -80
o
C overnight and 
transferred at -150
o
C for long-term storage.     
2.1.2.3 Serum-free differentiation of mEpiSCs 
Mouse EpiSCs were differentiated using the same protocol described for the serum-free 
differentiation of mouse ESCs (Table 2.1). One confluent well of mEpiSCs was washed with 
PBS and incubated with 300μl of Accutase to lift the cells as for passaging. Following the 
centrifugation, the pellet was resuspended in 10ml of N2B27 supplemented with day 0 
cytokines. The cell suspension was divided into 3 wells of an ultra-low attachment 6-well 
plate. Following the protocol detailed above, on day 2 of differentiation the EBs were 
collected and plated onto a Fibronectin pre-coated 6-well tissue culture plate where they 
were further matured up until day 6.  
2.1.3 Maintenance and differentiation of human embryonic and induced 
pluripotent stem cells (hESCs and hiPSCs) 
2.1.3.1 Maintenance of hESCs and hiPSCs 
hESCs and hiPSCs were maintained on CELLstart (Invitrogen) coated 6-well tissue culture 
plates (Costar) in StemPro medium comprising of DMEM/F12 with Glutamax (Invitrogen), 
1.8% BSA (Invitrogen), StemPro supplement (Invitrogen), 0.1mM β-Mercaptoethanol 
(Invitrogen) and 20ng/ml human basic FGF (Invitrogen). Maintenance medium was replaced 
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daily. Cells were passaged mechanically when they reached about 80% confluency using EZ 
passage tool (Invitrogen). Prior to passaging, cells were fed with fresh medium and new 





1:50 dilution for an hour minimum at 37
o
C. Cells were then cut into small pieces with EZ 
passage tool, gently suspended by pipetting with a plastic Pasteur pipette and finally 
transferred into the new coated plate with fresh medium at appropriate ratios.  
Cell lines used in the study were the hESC line H1 (5) and the hiPSC line SFCi55. The 
SFCi55 cell line was generated by Roslin Cells (http://roslincells.com/) from skin fibroblasts 
using episomal expression of Yamanaka factors. SNP analysis performed by Edinburgh 
Genomics (https://genomics.ed.ac.uk/) to detect deletions, duplications and other 
abnormalities across the genome detected no abnormalities.  
2.1.3.2 Thawing and cryopreservation of hESCs and hiPSCs 
To thaw the cells, the cryovials were warmed up quickly in the operator’s palms. Cells from 
one cryovial were immediately transferred into 1ml of pre-warmed media and centrifuged 
for 5 minutes at 200g. After aspirating the supernatant, the cells were resuspended in fresh 
maintenance medium and transferred into a CELLstart coated 6-well plate. Medium was 
replaced 24 hours later that the cells had adhered to the plastic.  
To freeze cells, cells were fed with fresh medium and Mr Frosty (Nalgene) was cooled down 
at 4
o
C for a minimum of 30 minutes prior to freezing. The EZ passage tool was used to cut 
the cells of an 80-90% confluent well. Cells were spun down for 5 minutes at 200g, 
supernatant was aspirated and cells were resuspended in 1.5ml of cold Cryostor CS 10 
reagent (Biolife Solutions). 0.5ml of the cell suspension was finally transferred in labelled 
cryovials. The vials were then placed in Mr Frosty and into 4
o
C for 10 minutes. Mr Frosty 
was subsequently transferred at -80
o
C overnight, after which time, vials were placed at -
150
o
C for long-term storage. 
2.1.3.3 Differentiation of hESCs and hiPSCs 
hESCs and hiPSCs were differentiated under serum-free conditions for a total of 10 days as 
outlined in Table 2.2. Cells were collected and analysed on days 7 and 10. One confluent 




Day 0 to day 2 
On day 0, the maintenance medium was aspirated and replaced by 1ml of Stemline II 
haemopoietic cell expansion medium supplemented with cytokines as described in Table 2.2. 
Cells were cut with EZ passage tool, suspended by gentle pipetting and split into 2 wells of 
an ultra-low attachment 6-well plate (Stemcell Technologies) which allows for formation of 
suspension EBs. Cells were topped up with 2ml of Stemline II with the appropriate cytokines 
before being placed in the incubator. On Day 2 cells were checked for the formation of EBs 
and each well was topped up with 0.5ml of Stemline II media supplemented with the 
required cytokines. 
Day 3 to day 7 
On day 3 EBs were harvested into centrifuge tubes and spun down for 3 minutes at 200g. 
The supernatant was aspirated and 0.5ml Accutase (Life Technologies) was added to the 
cells and allowed to incubate at 37
o
C for 3 minutes. EBs were dissociated to single cell 
suspension by pipetting a few times and quenched with 2ml of medium. They were 
subsequently spun down for 3 minutes at 200g and resuspended in 1ml of fresh medium. 
Cells were counted using a Neubauer haemocytometer and 2x10
5 
cells were plated per well 
of a 6-well tissue culture plate. Wells were topped up with 3ml of Stemline II with day 3 
cytokines. On day 5 cytokines were renewed by adding 0.5ml of cytokine supplemented 
medium.  
Day 7 to day 10 
On day 7, cells to be analysed were collected into centrifuge tubes by repeatedly pipetting a 
few times to detach them from the culture plastic and disperse any clumps. They were then 
spun down for 3 minutes at 200g and resuspended in 1ml of medium before being counted to 
use in flow cytometry and colony forming assays. For the cells to be propagated to day 10 a 
complete media change was performed on day 7. The medium was gently aspirated from the 
wells, to disturb the cells the least possible, and transferred into a centrifuge tube. 1ml of 
fresh medium with day 7 cytokines was added to the wells to prevent cells from drying while 
the old medium with any cells present in it was centrifuged for 3 minutes at 200g. Following 
the centrifugation, the supernatant was discarded and the cell pellet was resuspended in 2ml 
of medium with cytokines and finally added to the wells. On day 9 cells were fed with 0.5ml 
medium with fresh cytokines. On day 10 cells were collected and their number was 
determined for further analysis as described for day 7.  
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For the testing of HOXB4 targets, the recombinant proteins were added from day 0 to day 10 
in the following concentrations: hRSPO3 (RnD Systems) at 30 and 100ng/ml, hFGF17 (RnD 
Systems) at 30 and 100ng/ml, APELIN13 and APELIN36 (AnaSpec) at 100nM.  
 
Day of differentiation Cytokines 
Day 0 to 2 BMP4 10ng/ml, VEGF 10ng/ml, Wnt3a 10ng/ml 
Day 2 to 3 BMP4 20ng/ml, VEFG 20ng/ml, Wnt3a 10ng/ml 
Day 3 to 7 BMP4 20ng/ml, VEGF 30ng/ml, FGFa 10ng/ml, SCF 30ng/ml, 
IGF2 10ng/ml, TPO 10ng/ml, Heparin 5μg/ml 
Day 7 to 10 BMP4 20ng/ml, VEGF 30ng/ml, FGFa 10ng/ml, SCF 30ng/ml, 
IGF2 10ng/ml, TPO 10ng/ml, Heparin 2.5μg/ml 
 
Table 2.2: Cytokines used for the haemopoietic differentiation of hESCs and hiPSCs 
 
 
2.1.4 Methylcellulose-based haemopoietic progenitor colony assay 
Methylcellulose-based haemopoietic progenitor assay was routinely used to enumerate 
haemopoietic progenitors at single cell level for both mouse (MethoCult™ GF M3434, 
Stemcell Technologies) and human (MethoCult™ H4434, Stemcell Technologies) cells. 
Cells were collected from culture and prepared into single cell suspension. 1.5ml of 
methylcellulose medium were added into a 35mm low attachment dish. For each cell 









 for human cells unless otherwise stated. The dishes were placed in big 
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round dish containing a 60mm petri dish with 10ml of tissue culture grade water to prevent 
the methylcellulose from drying out. The dishes were incubated at 37°C for 12-14 days. The 
colonies were classified based on the morphology using light microscopy and scored 
according to the manual.   
2.1.5 Proliferation assay 
1x10
6
 mouse cells, were seeded onto 25cm
2
 tissue culture flasks in the appropriate medium 
and cultured for 48 hrs. The cells were then dissociated into single cell suspension and 
counted using a Neubauer haemocytometer. Proliferation rates, denoted as cell doubling 
times (DT), were calculated using the following formula: DT = (t−t0) log2/(logN−logN0) 
where t, t0 indicate time points at counting and initial plating, respectively, and N, N0 
indicate number of cells at respective time points. Results are presented as mean doubling 
times + standard deviation of 5 consecutive passages. 
 
2.2 Molecular biology techniques 
2.2.1 RNA extraction and cDNA synthesis 
Total RNA from fresh or frozen cell pellets was extracted using the RNeasy Mini Kit 
(Qiagen) according to manufacturer’s instructions. On-column DNaseI digest was performed 
with the RNase-Free DNase Set (Qiagen) to remove residual genomic DNA. RNA 
concentration was measured on Nanodrop and the samples used directly for cDNA synthesis 
or stored at -80
o
C. 
For cDNA synthesis, the SuperScript® VILO™ Master Mix Kit (Invitrogen) was used. The 
reaction was set up with 400ng of RNA per 10μl reaction. Samples were incubated at 25
o
C 
for 10 minutes for primer annealing, then at 42
o
C for 60 minutes for cDNA synthesis and 
finally at 85oC for 5 minutes to inactivate the reaction. cDNA was normally stored at -20°C.   
2.2.2 Quantitative RT-PCR analysis 
qRT-PCR reactions were set up in triplicate in 96-well plates and performed on a ABI 7500 





C for 3 seconds, followed by 40 cycles of at 95
o
C for 20 seconds to denature the 
cDNA and 60
o
C for 30 seconds to allow annealing and extension. For SYBR Green based 
analysis, a final dissociation step was added to check primer specificity. Two types of 
primer-probe systems were used, the TaqMan and the UPL, which were designed by the 
author.  SYBR Green primer sequences were given by Dr Anestis Tsakiridis. The 
housekeeping genes Hprt or Tbp were used as endogenous controls to normalise cDNA 
quantity loaded. Data analysis was performed using the SDS v1.4 software (Applied 
Biosystems). Gene expression was calculated using the ΔΔCT method, where each gene of 
interest was first normalized to the endogenous control and the data was then shown as fold 
change to a calibrator chosen according to each experiment.   
Primer and probe sequences are listed in Appendix Table S1. 
2.3 Flow cytometry analysis 
At different time points during differentiation cells were harvested for flow cytometric 
analysis of surface marker expression. A minimum of 2x10
5
 to a maximum of 1x10
6
 cells 
were added in each FACS tube. Antibodies were then added according to predetermined 
optimal concentrations and incubated for 20 minutes at 4
o
C. Cells were washed in 2ml of 
DPBS containing 1% BSA and centrifuged at 400g for 5 minutes. Pellets were resuspended 
in 200μl of DBPS with 1% BSA and stained with 7-AAD viability dye (eBioscience).  
Samples were analysed on a 5 laser BD LSRFortessa™ flow cytometer (Becton Dickinson) 
at the Centre for Inflammation Research, Queen’s Medical Research Institute (QMRI), with 
the help of Mrs Shonna Johnston and Dr Will Ramsay, or on a BD Accuri™ C6 cytometer 
(Becton Dickinson) at the MRC Centre for Regenerative Medicine, with the help of Mrs 
Fiona Rossi and Dr Claire Cryer. Data were analysed using FlowJo or the BD Accuri™ C6 
cytometer analysis software.  
Gating strategy and controls used are outlined in Supplementary Figures S1 and S2 for 
mouse and human cell respectively. Antibodies used for the analysis of mouse and human 
cells are listed in Appendix Table S2. 
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2.4 Protein analysis 
2.4.1 Immunofluorescence  
Cells were grown on appropriately pre-coated 24-well tissue culture plates to 90% 
confluency. Cells were washed twice with PBS and fixed with 4% PFA for 10 minutes at 
room temperature. Following a quick wash with PBS, the cells were incubated in PBST 
(0.1% Triton-X 100 in PBS) for 10 minutes at room temperature to permeabilise and then the 
fixation was stopped by adding 0.5M Glycine for 15 minutes at room temperature. Cells 
were then washed 2 x 5 minutes with PBST and blocked with 3% donkey serum in PBST for 
2 hours at room temperature. Cells were subsequently incubated with primary antibodies, 
Oct4 (Santa Cruz) and Brachyury (RnD Systems), at 1:200 dilution in blocking buffer 
overnight at 4
o
C. 3 x 5 minutes followed by 4 x 25 minutes washes with PBST at room 
temperature on shaking platform at the lowest speed were applied the next day. Secondary 
antibodies, Alexa fluor 488 and 568 at 1:1000 dilution in blocking buffer were then added 
for 2 hours at room temperature in the dark. Unbound antibodies were removed by final 
washes of 3 x 5 minutes followed by 4 x 25 minutes with PBST. DAPI at 1:7000 dilution 
was added for 10 minutes before the final wash. PBST was added in the wells and cells were 
observed under an Olympus IX51 inverted fluorescence microscope using the Volocity 
imaging software. 
2.4.2 Protein extraction 
To extract proteins, ice cold RIPA buffer (Thermo Scientific) with 1% protease inhibitor 
(Sigma) was added to cell pellets and incubated for 30 minutes on ice. The solution was 
vortexed for 10 seconds every 10 minutes during this incubation and finally centrifuged at 
13000 rpm for 20 minutes at 4
o
C. Supernatants were transferred to clean eppendorf tubes and 
used directly for Western blots or stored at -20oC.    
2.4.3 Gel electrophoresis and Western blot 
Protein electrophoresis was performed using the NuPAGE® SDS-PAGE Gel System 
(Invitrogen) with 4-12% Bis Tris Gels. The protein extracts were warmed up for 10 minutes 
at 80
o
C with 1/10 volume of β-Mercaptoethanol and loaded onto the gel. Gels were run at 
200V for about 35 minutes in MES buffer according to manufacturer’s instructions. Semidry 
transfer onto nitrocellulose membranes was performed using the Biorad transfer system with 
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cold transfer buffer (25 mM Tris, 192 mM glycine and 20% methanol) at 15V for 1 hour. 
Membranes were subsequently blocked with 5% semi skimmed milk in TBST (25mM Tris-
HCl, pH 8.0, 125mM sodium chloride, 0.1% Tween-20) over night at room temperature. 
Primary antibodies diluted in blocking buffer were incubated for 1 hour, followed by TBST 
washes of 3 x 15 minutes. Horseradish (HRP)-conjugated secondary antibodies, were 
subsequently added at 1:1000 dilution in blocking buffer for an hour at room temperature 
and finally washed 3 x 15 minutes with TBST. Equal volumes of ECL reagent A (0.1M Tris-
HCl pH 8.6, 25mM luminal, 0.4mM coumaric acid) and reagent B (0.1M Tris-HCl pH 8.6 
and 0.02% hydrogen peroxide) were mixed and added to the membrane for 1 minute before 
exposure to film to visualise the proteins. Primary antibodies used were: rat anti-HOXB4 
(DSHB) diluted at 1:500 in blocking buffer and goat anti-mouse GAPDH (Santa Cruz), 
serving as loading control, at 1:1000 dilution. 
2.5 Data analysis 
Data presented in this thesis were analysed and plotted with Microsoft Office Excel 2013 
and GraphPad Prism software (version 6.0). Data are summarised as average + standard 
deviation. Statistical significance was evaluated using two-tailed Student’s t-test. Image 
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Since their discovery mouse ESCs have been the gold standard for the investigation of 
haemopoiesis in vitro, generating a significant amount of knowledge regarding the required 
lineage induction events. As detailed in Chapter 1, numerous differentiation methods have 
been developed leading to the successful generation of haemopoietic progenitors, mainly 
relying in the use of serum and/or supportive feeder cells. Nevertheless, the presence of 
serum or feeders in the differentiation medium increases variability and introduces many 
undefined molecules that can affect positively or negatively the haemopoietic process and 
interfere with the analysis of signalling factors. Therefore, many research groups have turned 
to the use of defined culture conditions that increase reproducibility and allow for better 
understanding of the molecular mechanisms of cell fate specification. Similarly, our group 
until today, has used either serum or feeder cell lines for the investigation of haemopoietic 
development, which despite their efficiency and the valuable data they have provided, they 
still require the tedious work of serum batch testing to ensure reproducibility and involve the 
presence of unknown regulating factors. Since the overall aim of this study is to investigate 
the effects that newly identified HOXB4 targets have in the differentiation output, it was 
deemed necessary to establish a feeder-free and serum-free differentiation protocol in the lab 
that would allow testing individual factors in a well-defined and controlled background. 
Another major issue to be tackled in the mouse ESC differentiation system is the 
translational gap with the human system. Even though major developmental pathways are 
highly conserved, critical interspecies differences in the activity of regulatory factors exist 
that would have an impact on the clinical translation. Such is the case of HOXB4, which 
unlike in the mouse system, its in vitro use has not yet generated engraftable human ESC-
derived HSCs. Mouse EpiSCs are considered more comparable to human ESCs not only due 
to similarities in the signalling pathways controlling their maintenance and self-renewal but 
also due to their shared mechanisms regulating early cell fate decisions and linage 
commitment (221, 222). The ultimate purpose of this study is to assess the data produced in 
the mouse system regarding HOXB4 activity, in our human ESC differentiation system. 
Therefore, the haemopoietic potential of mouse EpiSCs was also assessed in the novel 
differentiation protocol. Additionally, the primed state of EpiSCs towards the mesoderm 
lineage as indicated by their T (Bry) expression (152), may offer them a developmental 




1. Develop a defined, feeder-free and serum-free mouse haemopoietic differentiation 
protocol to use in the study of HOXB4 targets. 
2. Assess whether mouse EpiSCs under defined conditions provide an improved 
system for haemopoietic differentiation compared to ESCs. 
3.3 Experimental strategy 
1. To test whether the new feeder-free and serum-free protocol is capable of supporting 
haemopoietic differentiation, mouse ESCs were cultured in parallel in the new and 
our standard serum-based protocols. The differentiation efficiency was assessed by 
flow cytometry analysis of surface haemopoietic markers and haemopoietic colony 
formation as a functional readout. 
2. To ensure maximum comparability between ESC and EpiSC populations, EpiSCs 
were derived from the ESC cell line used in the study. The two populations were 
then differentiated in the new serum-free protocol in parallel and assessed for HPC 
production at different time points to closely monitor their developmental 












3.4 Results  
3.4.1 Development of a well-defined mouse ESC haemopoietic differentiation 
system   
Mouse ESCs were cultured in feeder- and serum-free conditions, from now referred to as 
serum-free/SF, using EB formation in the presence of four growth factors (BMP4, Activin A, 
bFGF and VEGF) that have been implicated in the differentiation of both mouse and human 
ESCs to haemopoietic lineages (127, 223, 224). Cells were passaged in serum-free 
conditions two days prior to the onset of differentiation to ensure serum traces that might 
affect the outcome are eliminated and allow for the cells to adapt to the new culture medium. 
As a control cells were cultured in parallel in our routinely used EB differentiation protocol 
which relies on the use of FCS to induce haemopoietic development, and will be referred to 
as serum-based/SR. The two protocols are outlined in detail in Figure 3.1.  








In serum-based conditions EBs were formed by the hanging drop method and induced to 
differentiate in suspension upon LIF withdrawal after two days. The EBs were then plated on 
gelatin and allowed to fully differentiate to day six. In serum-free conditions ESCs were 
passaged once in media supplemented with LIF and BMP4, and subsequently placed in 
suspension to form EBs with the specified cytokines. After two days the EBs were plated on 
gelatin in the appropriate medium and cultured up to six days. Cells were collected for 
analysis at different time points as specified in the text. 
Suspension EBs 
BMP4, FGF2, ActA 
Plated EBs 
BMP4, FGF2, VEGFA 
D0 D2 D4 D6 D1 
Suspension 











Serum-based differentiation of ESCs 
Serum-free differentiation of ESCs 
Figure 3.1: Mouse ESC differentiation protocols. 
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3.4.1.1 Serum-free conditions are capable of maintaining ESCs in an undifferentiated 
state 
The serum-free ESC culture protocol established by Ying and colleagues (141) was used for 
cell maintenance before initiation of differentiation. A critical point to test before proceeding 
with the study was whether the particular culture system could support expansion of our cell 
line without inducing differentiation and therefore affecting the results. To this end ESCs 
were passaged in serum-free N2B27 medium supplemented with LIF and BMP4 for 5 
consecutive times and compared on their proliferation rates and expression profile to cells 
maintained in our conventional FCS and LIF supplemented medium for the equivalent time 
period. Morphologically the two culture media showed no obvious morphological 
differences. Colonies of cells in serum-free medium maintained a dense, rounded, dome-like 
morphology characteristic of ESCs even after 5 passages similar to the cells maintained in 
FCS with no signs of spontaneous differentiation and maintaining their adherent properties 
(Figure 3.2 A, B). The proliferation rates of each cell culture system were assessed based on 
the cell doubling times for 5 sequential passages. Interestingly, serum-free maintenance 
conditions enhanced the proliferation rate, by significantly reducing the doubling time to 13 
hours, from 15 hours observed in the serum-based culture (Figure 3.2 C).  
Finally, after 5 passages the cells were collected and analysed on the expression of genes 
specific for undifferentiated ESCs, as well as, genes characteristic of early germ layer 
specification. As expected, the pluripotency related markers Oct4, Sox2 and Nanog, 
exhibited similar expression levels without any significant differences in the two culture 
systems (Figure 3.2 F). Likewise expression levels of inner cell mass related genes, Klf4 and 
Rex1, remained equivalent in the two cell populations without any distinct differences 
(Figure 3.2 E). Comparing the expression levels of Fgf5 and Bry, which can be indicative of 
spontaneous cell differentiation, it was observed that cells in serum-free conditions had a 2-
fold and 10-fold reduction in expression levels respectively, compared to serum grown cells 
(Figure 3.3 D). Even though the experiments were repeated only twice our data strongly 
demonstrate that serum-free conditions have no detrimental effects on the maintenance of 
mESCs. On the contrary, the enhanced proliferation rates together with the reduced levels of 
germ layer genes suggest that serum-free culture conditions are capable of maintaining ESCs 





Phase-contrast photographs of ESC colonies grown in serum A or serum-free B conditions 
(20x). Cells were passaged for 5 consecutive times and assessed on their doubling time C, 
results are means + sd for 5 passages (n=2). Quantitative RT-PCR at passage 5 for ESC 
associated and early germ layer genes, D-F. Tbp expression was used for normalisation and 
ESCs grown in serum as a calibrator. Cells were analysed in triplicate from 2 independent 



















































































































3.4.1.2 Serum-free conditions enhance the haemopoietic differentiation of mouse ESCs 
Mouse ESCs were differentiated with the two protocols detailed in Figure 3.1 and cells were 
collected for analysis on day 6 of the protocols. On microscopic examination of day 6 EBs 
the two differentiation systems exhibited profound morphological differences. EBs grown in 
the presence of serum retained an intact core with very little visible differentiation in the 
periphery (Figure 3.3 A, B), whereas, EBs grown in serum-free conditions under the 
influence of cytokines displayed extensive differentiation and had separated into two 
fractions, an adherent stroma-like one, which covered the entire area of the culture plastic, 
and a non-adherent, floating fraction of various sized cells (Figure 3.3 C-F). When cells were 
harvested it became obvious that serum-free conditions had generated mature blood cells, 
which were mainly found in the floating population when the fractions were separated, as 
indicated by the red colour of the pellet (Figure 3.3 H, I), something that has never been 
observed in the serum-based system (Figure 3.3 G). Cells were then examined in detail on 
their haemopoietic activity and phenotype.  
Dissociated cells were plated in methylcellulose medium to assess the presence of HPCs. 
Even though haemopoietic colonies were generated by cells grown in serum-based 
conditions, their numbers were notably low. Additionally, secondary EBs with no signs of 
haemopoietic differentiation formed upon replating were mainly present in the 
methylcellulose medium (Figure 3.4 E-G). In contrast, serum-free conditions yielded very 
high numbers of colonies of various types (Figure 3.4 H-M). Particularly, serum-free 
conditions generated 6-fold higher numbers of CFU-M and CFU-GM than serum conditions 
(Figure 3.4 A, B). Additionally, CFU-Mix colonies, which are evident of multipotent 
progenitors, showed a 10-fold increase in the serum-free protocol (Figure 3.4 C). Finally, 
erythroid colonies, BFU-E, were only formed in serum-free conditions (Figure 3.4 D).  
Flow cytometry was also used to determine the phenotype of cells generated in the protocols. 
A variety of haemopoietic markers were used which are characteristic of mouse HSCs at 
different stages of development. Cells differentiated in serum-free conditions showed a 
dramatic, more than 4-fold increase in CD41 expression compared to serum conditions, 
marking about 45% of the population (Figure 3.5). CD41 was also expressed on more than 
half of the population of VE-Cadherin or CD144 expressing cells, which appeared as a very 
distinct population in the case of serum-free conditions (Figure 3.5 B). CD45 expression 





population of cells more apparent again in serum-free conditions. Expression 
61 
 
of c-Kit was high in both protocols, however as it is not an exclusively haemopoietic marker, 
its co-expression with other markers was assessed. The serum-free protocol generated nearly 




 cells compared to the serum-based protocol, reaching 20% of 
the population. When c-Kit, Sca-1 co-expression was assessed, double positive populations, 


































EBs grown in the presence of serum show minimum differentiation while they maintain their 
compact morphology A, B (20x). EBs cultured in serum-free conditions separate into two 
fractions of differentiated cells, an adherent stromal fraction and non-adherent of floating 
single cells C, D (20x) E, F (40x). There are no visible signs of mature blood cells in serum 
grown EBs G, whereas, mature blood cells are evident by the red colour of EBs C or cell 
pellets upon harvesting H in serum-free conditions. When the two serum-free fractions are 
centrifuged separately the majority of mature cells is found in the non-adherent fraction 


















Number of colony types produced by day 6 EBs A-D. Data represents 3 independent 
experiments + sd. P values calculated with Student’s t test. Representative pictures of 
haemopoietic colonies in methylcellulose assay (10x). Serum conditions yielded mainly 
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Representative scatter plots of cells differentiated in serum A and serum-free conditions B. 
Expression levels of haemopoietic markers on day 6, C. Data are representative of 3 
independent experiments, error bars represent standard deviation.  P values calculated with 






























































Figure 3.5: Flow cytometry analysis of day 6 EBs. 
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3.4.1.3 Localisation of HPCs in serum-free conditions 
The distinct cell populations observed in the serum-free protocol prompted us to investigate 
whether haemopoietic progenitors were exclusively localised in one of the two fractions. It 
has been well documented in vivo that haemopoietic cells emerge through an epithelial-to-
mesenchymal transition and it could be possible that this was the case in our system with 
progenitors budding off from the adherent layer into the supernatant (33-36). Cells were 
differentiated to day 6 of the protocol and the two resulting fractions were separated for 
analysis. Particularly, media containing the non-adherent population was collected and the 
remaining cells were washed with PBS to ensure all non-adherent cells were collected. The 
adherent population was then lifted off the culture plastic and the two fractions were 
analysed in parallel.  
The functional potential of the two cell populations were assessed by haemopoietic colony 
formation. Interestingly, the total number of haemopoietic colonies from the adherent 
fraction were slightly yet significantly increased compared to the non-adherent one (Figure 
3.6 A). When the various types of colonies were analysed in detail this increase was not 
found significant for any of the colonies types, thus suggesting that there is no pronounced 
distinction of HPC presence in the two populations (Figure 3.6 B). However, flow 
cytometric analysis of surface marker expression, showed there are distinct differences 
between the two fractions (Figure 3.7). The non-adherent population consisted almost 
exclusively of CD41 expressing cells, which were nearly 3 times more than in the adherent 
fraction, marking more than 50% of the population (Figure 3.7 B, C). On the other hand, 
adherent cells exhibited higher expression levels of all other surface markers compared to the 
non-adherent cells (Figure 3.7 A, C). Adherent cells were mainly characterised by c-Kit 
expression, present in 50% of the population. CD41 was expressed in 22% of the adherent 














 cells, though in low numbers, were predominately found in the adherent fraction, more 
clearly demonstrated in representative scatter plots (Figure 3.7 A, B). Yet the presence of 












 cells in the floating 
population is sufficient to account for the observed colonies in the CFU-C assay. Therefore, 
in order to ensure that the maximum number of HPCs is collected for analysis both fractions 






ESCs were differentiated in the serum-free protocol and the resulting fractions were 
separated and placed in CFU-C assay. A. Total colony numbers. B. Detailed analysis of 
numbers of different colony types. Data are representative of 4 independent experiments, 
























































Figure 3.6: Assessment of haemopoietic colony formation by day 6 adherent and non-





Representative scatter plots of day 6 adherent A and non-adherent fractions B. Quantification 
of haemopoietic marker expression in the two fractions C. Data representative of 4 
independent experiments. Error bars represent standard deviation. P values calculated by 



































































3.4.2 Assessment of EpiSCs as a model of haemopoietic differentiation 
Mouse EpiSCs were discovered several years ago, nonetheless, their in vitro differentiation 
potential has not been fully explored. It is now considered that pluripotency exists in two 
distinct states, the naïve and the primed one, with ESCs and EpiSCs being the in vitro 
representatives of each state respectively (226). These two classes of pluripotency are 
marked by epigenetic and gene expression differences, which may favour or restrict lineage 
choices. With Bry expression marking the primed state of EpiSCs we sought to investigate 
whether they may exhibit a developmental advantage over ESCs in haemopoietic 
differentiation. 
3.4.2.1 In vitro derivation of EpiSCs from ESCs 
Mouse EpiSCs can be derived in two different ways, either in vivo from the post-
implantation embryo or in vitro by culturing ESCs under the appropriate conditions (227). In 
order to allow for maximum comparability between ESC and EpiSC haemopoietic potential, 
EpiSCs were derived in vitro from the ESC line used for the establishment of the serum-free 
differentiation protocol. ESCs were plated in standard culture media for one day before 
changing to EpiSC culture media consisting of N2B27 plus ActivinA and bFGF. After an 
initial wave of cell death in the first 2 or 3 passages, the cells recovered quickly and started 
forming typical EpiSC colonies by passage 5. The colonies consisted of cells displaying a 
high nuclear to cytoplasmic ratio with big nucleoli typical of stem cells, however, they 
appeared more flat as opposed to the more domed colonies of ESCs (Figure 3.8 A, B). The 
produced EpiSCs were assessed on their gene expression profile compared not only to the 
ESC line they were derived from but also to embryo-derived EpiSCs. Quantitative RT-PCR 
analysis showed that they expressed the core determinants of pluripotency, Oct4, Sox2 and 
Nanog, while they displayed a dramatic downregulation of inner cell mass genes such as 
Rex1 and Klf4, which are expressed at high levels in mouse inner cell mass but silenced in 
early epiblast cells after implantation (Figure 3.8 C, D). In contrast, the expression of Fgf5 
and Bry was significantly higher in EpiSCs compared to ESCs that had barely detectable 
levels of expression (Figure 3.8 E). Similar expression pattern was observed in the embryo-
derived EpiSCs. Immune staining was also performed to confirm that Bry was co-expressed 
with Oct4 in stem populations and not in spontaneously differentiating cells. Indeed Bry and 






















Mouse ESCs were cultured in N2B27 medium supplemented with Activin A and bFGF for a 
minimum of 5 passages to convert to EpiSCs. Typical ESC A and EpiSC colonies B (10x). 
Quantitative RT-PCR analysis to confirm the conversion of ESC to EpiSC assessing 
expression of pluripotency genes C, inner cell mass genes D and epiblast related genes E. 
Tbp expression was used for normalisation and ESCs grown in serum as a calibrator. Cells 
were analysed in triplicate from 3 independent experiments and represent means plus 
standard deviation, sd. Representative photos of Oct4 and Bry expression in ESC F and 
EpiSC G cultures analysed by immunofluorescence. Dapi was used as nuclear staining.  


































































































Figure 3.8: Generation of EpiSCs. 
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3.4.2.2 EpiSCs display a developmental advantage over ESCs 
As a first attempt to test whether the primed state of EpiSCs can result in differences in their 
haemopoietic potential compared to ESCs, cells were put directly in colony forming assay 
without any of the prior steps of EB formation and subsequent culture. When placed in the 
methylcellulose both cell types formed secondary EBs which did not show any signs of 
differentiation in the first 7 days of incubation. However, by the end of the second week 
EpiSCs had differentiated at very high rates giving rise to various types of colonies (Figure 
3.9 D-F), whereas, ESCs remained as undifferentiated EBs (Figure 3.9 A-C). In order to 
verify that the increase in colony number is due to the different developmental stage and not 
an in vitro effect of the cytokines used for EpiSC maintenance, embryo-derived EpiSCs were 
also placed in methylcellulose assay without any prior differentiation steps. Similarly to 
ESC-derived EpiSCs, the embryo-derived EpiSCs differentiated into haemopoietic colonies 
(Figure 3.9 G-I).  
It should be noted however, that the majority of colonies observed were EB associated 
colonies both in the case of embryo-derived and ESC-derived EpiSCs (Figure 3.9 J). These 
colonies do not represent mature haemopoietic progenitors. They develop from 
undifferentiated EBs that form in the methylcellulose medium following cell plating and 
differentiate under the influence of haemopoietic cytokines present in the medium. They 
have a compact EB-like core with few erythroid and/or myeloid cells developing in the core 
or the periphery (Figure 3.9 D, E, G, H). More mature haemopoietic colonies were also 
present (Figure 3.9 F, I), though in much lower numbers (Figure 3.9 K). As no prior in vitro 
differentiation occurred, their development can possibly be due to more primed state EpiSCs 
that again managed to differentiate under the influence of methylcellulose cytokines. 
Additionally, even though EpiSCs never failed to give rise to mature colonies they did have 
a quite high variability rate between experimental repeats suggesting they are a more 
dynamic system than ESCs. Nonetheless, it was certain that EpiSCs display a developmental 






















ESCs A-C, ESC-derived EpiSCs D-F and embryo-derived EpiSCs G-I plated in 
methylcellulose assay without any prior differentiation. Numbers of EB associated 
haemopoietic colonies scored in the assay J. Mature haemopoietic colony numbers K. Data 
represent means of 5 independent experiments, error bars represent standard deviation, p 













































































Figure 3.9: Initial assessment of EpiSC haemopoietic potential. 
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3.4.2.3 Detailed characterisation of differences in the haemopoietic differentiation of 
ESCs and EpiSCs 
In order to further clarify the differences in developmental progression between ESCs and 
EpiSCs the novel serum-free protocol was implemented. The two cell populations were 
cultured in parallel and cells were analysed on day 0, day 2, day 4, day 5 and day 6 of 
differentiation by colony forming assay and flow cytometry. ESCs were also cultured in the 
serum-based protocol to serve as a baseline of differentiation.  
ESCs grown in serum-based conditions formed very low numbers of colonies, as expected, 
which only appeared on days 5 and 6 of differentiation (Figure 3.10 A). ESCs in serum-free 
conditions followed a similar trend where colony numbers increased with time, yet in much 
higher numbers as previously shown. The first colonies appeared on day 4 and by the end of 
the differentiation protocol their total number had increased more than 4-fold (Figure 3.10 
B). EpiSCs displayed a different progression pattern to the two other culture systems (Figure 
3.10 C). As observed in previous colony assays, Day 0 EpiSCs had a high degree of colony 
formation. Surprisingly though, day 2 cells failed to generate any haemopoietic colonies. By 
day 4, however, cells rebounded generating many colonies. A slight increasing trend was 
observed the following time points of analysis however the change was not significant. Day 
6 colony numbers were analysed more thoroughly to compare in more detail differences 
between the culture systems (Figure 3.11). Numbers of CFU-M, CFU-GM and CFU-Mix 
were very comparable between ESCs and EpiSCs grown in serum-free conditions. Both cell 
populations had a more than 5-fold increase in each colony type compared to ESCs grown in 
the presence of serum. BFU-E numbers were more than double in serum-free ESCs 
compared to EpiSCs and again ESCs in the serum-based protocol failed to generate any of 
this type of colonies. Strikingly, although EpiSCs generated at times much higher numbers 
of haemopoietic colonies compared to ESCs in serum-free conditions, they exhibited large 
variation between experimental repeats, thus the difference between the two cell types was 
not found significant.       
Time course expression of haemopoietic surface markers was conducted in parallel to 
provide more insight on the HPC populations that developed in the different culture systems. 
Similarly to the CFU-C assay, ESCs differentiated in serum-free conditions had overall 
higher marker expression levels compared to both EpiSCs and serum grown ESCs. 
Particularly, CD144 expression remained low for serum grown ESCs throughout 
differentiation (Figure 3.12 A). In serum-free conditions for both ESCs and EpiSCs CD144 
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reached a peak of expression on day 4, at around 20% of the populations, and then steadily 
declined, with ESCs expressing higher levels than EpiSCs by day 6. Representative scatter 
plots in Supplementary Figure S 1 show the distinct CD144 population that appears on day 4 
serum-free ESCs and EpiSCs and gradually disappears in the case of EpiSCs. CD45 levels 
remained low and comparable between all three culture systems peaking on day 6 (Figure 
3.12 B). CD41 showed a steady increase in ESCs both in serum and serum-free conditions 
with serum-free cells expressing significantly higher levels (Figure 3.12 C). EpiSCs, 
however, had a sharp CD41 increase on day 4, followed by a sharp decrease by day 5 





 cells dramatically increased on day 4 in serum-free conditions, coinciding 
with the appearance of haemopoietic colonies, with ESCs maintaining significantly high 
expression levels and EpiSCs decreasing by day 6 (Figure 3.11 D). Co-expression of CD41 
and CD45 remained low for all cell populations (Figure 3.11 E), however, double positive 
cells formed a well-defined population clearly visible in serum-free ESCs and EpiSCs scatter 
plots (Supplementary Figure S.2). Expression of c-Kit remained at similar levels for all 
culture systems throughout the differentiation process (Figure 3.11 F), with the population 





 cells appeared on day 4 and continued to increase until day 6 in all populations, with 




 cells (Figure 3.11 G). Sca-1 
levels appeared comparable in serum-free differentiated cells and increased compared to 




 cells were detected only in serum-free 
ESCs and EpiSCs, with ESCs expressing stably higher levels compared to serum ESCs 
(Figure 3.11 I).       
The above data clearly demonstrate that despite the initial developmental advantage EpiSCs 
showed over ESCs, they fail to further enhance haemopoietic differentiation. It should be 
noted that even though EpiSCs always generated significantly more HPCs than ESCs in 
serum-based conditions, at times they performed poorer compared to serum-free ESCs. This 
variability makes them a more unpredictable model even under controlled differentiation 
conditions. It was therefore decided to use mouse ESCs is serum-free conditions for the 






Cells were cultured under serum or serum-free conditions and collected for CFU-C assay at 
different time points. ESCs were differentiated in serum conditions as a baseline A. The 
serum-free protocol was used for the differentiation of ESCs B and EpiSCs C. Plots 
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Serum-free conditions were used for the differentiation of ESCs and EpiSCs, while serum 
ESC differentiation was used as a control. Despite similar numbers of colonies generated by 
both cell populations in serum-free conditions, only ESCs were found statistically 










































































































Expression levels of surface molecules marking emerging haemopoietic progenitors were 
measured at different time points of serum and serum-free differentiation of ESCs and 
EpiSCs. Data represent means of 3 experiments +sd. Representative flow cytometry charts 
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Sca-1 
A. B. C. 
D. E. F. 
G. H. I. 
p=0.01 




A well-controlled system of in vitro haemopoietic development of mouse ESCs was 
developed. The protocol was used to compare the haemopoietic potential of mouse ESCs and 
the previously uncharacterised EpiSCs. The data generated indicate that: 
 The use of just four factors in minimal concentrations was sufficient to direct the 
differentiation of ESCs to mature haemopoietic cells (Figure 3.3).   
 The serum-free conditions could dramatically enhance the generation of HPCs 
capable of multilineage differentiation in vitro compared to serum conditions 
(Figure 3.4). 
 The serum-free protocol increased the expression of haemopoietic markers that 













 cells (Figure 3.5). 
 EpiSCs are characterised by a primed state which was reflected not only in their 
expression profile but also in their ability to proceed to haemopoietic commitment 
easier compared to ESCs (Figure 3.8, 3.9).  
 Despite the developmental edge EpiSC display, they were not capable of exceeding 
the haemopoietic potential of ESCs when cultured under the same conditions 
(Figure 3.11, 3.12). 
 
3.6 Discussion  
3.6.1 Haemopoietic progenitor development under the influence of cytokines   
In this chapter we sought to create a defined haemopoietic culture environment that would 
allow us to investigate HOXB4 activity. Haemopoiesis is controlled by the coordinated 
action of many signalling pathways, and various mediators of these pathways have been 
widely used in PSC differentiation protocols (169-177). To allow for the most subtle changes 
that HOXB4 targets to be tested might have in the differentiation output, we used a limited 
number of cytokines and in low concentrations, involved in pathways deemed critical for the 
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directed differentiation of ESCs to the haemopoietic lineage (127, 223-225). We 
demonstrated that the use of Activin A, bFGF and BMP4 for the first 2 days of 
differentiation, followed by substitution of Activin A by VEGF for the remaining 4 day 
culture is sufficient to rapidly generate mature blood cells (Figure 3.3). We were able to 
produce strikingly increased numbers of HPCs compared to the serum control, which could 
develop into multiple blood lineages in vitro (Figure 3.4). More importantly, extensive 
analysis of these HPCs revealed that they phenotypically resemble HSCs emerging during 
embryogenesis in various anatomic sites (Figure 3.5).  
Similar to our findings, work by Park and colleagues had previously shown that the 
combined action of Activin A, BMP4 and VEGF could successfully substitute for the use of 
serum in ESC differentiation (170). Yet their serum-free protocol failed to generate higher 
numbers of HPCs compared to their serum control, as opposed to our system, where the 
difference between serum and serum-free conditions was dramatic. This difference could be 
due to the use of bFGF in our system that appears to be important for the survival and 
proliferation of haemopoietic cells. A recent report demonstrated that treatment with bFGF 
in vivo expanded mouse haemopoietic stem and progenitor cells by inducing proliferation of 
supportive stromal cells and upregulating c-Kit expression in mouse bone marrow and spleen 
(228). It is possible that bFGF acts in a similar mechanism in our system as suggested by the 
development of the adherent stromal population in serum-free conditions and the high 
expression levels of c-Kit. Very recently Pearson and co-workers using the same cytokines 
as we did, though in slightly different timing and combinations, reported the generation of c-
Kit expressing repopulating HSCs. Although they did not proceed to any detailed phenotypic 






 cells were 
significantly lower than the ones generated in our system (229). It would be interesting to see 
if the cells generated in our system are also engraftable, and whether the higher expression 
levels of c-kit, CD41 and CD45 reflect higher engraftment rates.  
An interesting point of our protocol was the separation of differentiating EBs into two 
distinct fractions, an adherent and a non-adherent fraction. We addressed the question of 
whether the haemopoietic progenitors are located in one of the two cell populations. Colony 
forming assays showed no striking differences in the haemopoietic profile of the two 
fractions, which generated quite comparable numbers and types of colonies (Figure 3.6). We 
then proceeded with surface marker expression analysis, which initially indicated that HPCs 
were located in the floating fraction as CD41 expression marked more than half of the cell 
population (Figure 3.7). The emergence of CD41
+
 HSCs from the aortic endothelium of the 
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AGM region into circulation has been monitored in vivo in the mouse and the zebrafish, 
suggesting that our culture system acted in a similar mechanism (35, 36). However, when we 
examined CD41 co-expression with other markers of emerging HSCs, such as CD45 or c-kit, 
contrary to what we expected the majority of HPCs was located in the adherent fraction. This 
can be explained by the fact that the compact 3-dimensional form of the EBs does not 
provide all the in vivo structures and environmental cues present in the AGM region. Cellular 
movements and signalling can therefore be restricted, preventing the release of the majority 
of HPCs into the supernatant. One study using a monolayer differentiation protocol 
monitored the transition of adherent CD144 endothelial cells to floating CD41 haemopoietic 







 cells exclusively in the adherent population 
followed by the accumulation of CD41
+
 floating cells indicates a similar cell lineage 
progression. However, in the above study the CD41
+
 floating cells could generate 
predominately erythroid colonies suggesting it replicated primitive erythropoiesis as opposed 
to our protocol where mixed colonies constituted the majority of the colonies formed. The 
predominant presence of CD41 in the floating population can be explained by taking into 
consideration that it is also a marker of terminally differentiated cells. CD41 was originally 
recognised as a megakaryocyte/platelet marker (230). It is therefore probable that the CD41
+
 
cells found in the floating fraction mainly consist of more differentiated blood cells instead 
of early progenitors. This is further supported by the presence of red blood cells in the 
supernatant (Figure 3.3 I). In summary, differentiating EBs in our system form a stromal 
layer which supports haemopoietic maturation. The core cell population rapidly 
differentiates to the haemopoietic lineage with multipotent HPCs remaining attached to the 
stromal layer, while upon full maturation terminally differentiated cells are released into the 
supernatant.   
It can be deduced from the above that the use of the appropriate cell surface markers is 
critical for monitoring the in vitro generation of haemopoietic cells and how they correspond 
to their in vivo counterparts. As detailed in Chapter 1 the phenotype of HSCs changes during 
development making their identification more challenging. In an effort to closely monitor 
haemopoietic development in our protocol we used various markers widely used to detect 
HSCs in vivo. The most prevalent population of haemopoietic progenitors in our serum-free 




 cells which constituted 20% of the day 6 population. 




 cells are found in the embryonic 
yolk sac, AGM and liver in vivo, and can not only generate multilineage colonies but also 
confer long-term multilineage reconstitution upon transplantation into irradiated recipients 
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(76, 77). Furthermore, CD144 and CD41 co-expression detected in our serum-free protocol 
has been shown to mark AGM type I pre-HSCs (78). With upregulation of CD45 these cells 
transit to CD144+CD41+CD45+ type II pre-HSCs before fully maturing to reconstituting 
CD41+CD45+ HSCs (78). Although we failed to detect intermediate CD144+CD41+CD45+ 




 emergence (Supplementary 




 cells. It is possible that type II 
pre-HSCs appear so transiently in our protocol that their detection was not possible. Day 6 
serum-free cells also co-expressed low yet detectable levels of the more mature HSC 




 cells co-express 
SLAM antigens or whether prolonged culture can result in further maturation of the 
generated cells into adult-type HSCs. Conclusively, our protocol can generate HPCs with 
multilineage potential, phenotypically similar to embryonic rather than adult-type bone 
marrow HSCs.  
3.6.2 Differentiation potential of EpiSCs 
When initially discovered, mouse EpiSCs attracted a lot of scientific interest partly due to 
their similarities to human ESCs and partly due to their potential predisposition to 
differentiate into particular germ-layer derivatives based on the expression of early lineage 
markers in self-renewing conditions. Yet, in the years that followed their discovery, limited 
progress was made towards investigating their differentiation potential. The expression of 
Bry, a known mesodermal and more importantly a pre-haemopoietic marker, also attracted 
our attention. Aiming to establish an efficient mouse differentiation system for our study we 
investigated the haemopoietic potential of EpiSCs compared to conventionally used ESCs.  
In order to minimise genetic variability between cell lines that could affect our results we 
cultured ESCs under the appropriate conditions and successfully generated EpiSCs with the 
morphology and expression profile observed in their embryo derived counterparts (Figure 
3.8). Confirming our expectations initial analysis of their differentiation potential suggested 
that their primed state offers them an advantage over ESCs. Ground state ESCs when placed 
directly in haemopoietic colony assay never managed to form colonies, however, EpiSCs 
could very effectively differentiate and give rise to various types of colonies (Figure 3.9). 
We then examined in more detail differences between the two cell populations by analysing 
the cells at different time points of the serum-free protocol we developed. We demonstrated 
that EpiSCs generally reached the maximum of their differentiation potential by day 4 of the 
protocol without significant increase for the rest of the culture period as shown by colony 
81 
 
assays and analysis of surface markers (Figure 3.10, 3.12). On the other hand ESCs exhibited 
a stable increase of haemopoietic profile which peak later on day 6, confirming that the 
primed state of EpiSCs allows them to proceed faster to haemopoietic maturation. 
Interestingly, on day 2 of the protocol we observed the inability of EpiSCs to generate 
haemopoietic colonies. This can be simply due to the stress caused to the cells by successive 
changes in culture conditions. Single cell dissociation has been repeatedly reported to induce 
wide-spread cell death to EpiSCs and in our protocol the cells were subjected to it twice 
within a very short time frame (152, 153). Cultured EpiSCs were dissociated into single 
cells, cultured in suspension for 2 days and then again dissociated to be used in the CFU-C 
assay. Therefore, the difference in colony numbers between day 2 and day 4 may represent a 
lag time for cell recovery.  
An interesting point regarding EpiSC differentiation was also the more pronounced 
variability they exhibited between experimental repeats. Studies focusing on embryo-derived 
EpiSC lines have shown that there is a great variability not only between independent cell 
lines but even within an individual cell line. Bernemann and colleagues characterized a panel 
of EpiSC cell lines derived in several laboratories and found that although the lines have 
some conserved pluripotent stem cell characteristics, some of them have differences in the 
expression of mesendodermal markers, such as Bry. This expression signature reflects 
slightly different developmental stages, which do not seem to correlate with the embryonic 
day on which cells have been derived, and may have implications for functional readouts 
such as directed differentiation to a particular lineage (231). Additionally, work conducted 





, with different expression profiles and the ability to continuously 
interchange between states (232). These subpopulations represent again distinct 
developmental stages resulting in discrepancies in the pluripotential capacity of EpiSCs. 
Although no insight has been provided for the in vitro derived EpiSCs we did ourselves 
observe a variability in Bry expression between EpiSC colonies in immunofluorescence 
analysis of the cells (Supplementary Figure S6). It can be assumed that similarly to the 
embryonic EpiSCs a shift of subpopulations might occur any time during culture resulting in 
a difference of developmental potential, in our case in colony output and marker expression. 
Therefore, despite the developmental advantage EpiSCs may have over ESCs in terms of 
timing, their haemopoietic efficiency remains comparable, while the instability they exhibit 







 : Investigating the paracrine action of HOXB4: Chapter 4























4.1 Introduction  
The unique ability of HOXB4 to generate repopulating mouse HSCs from ESCs in vitro has 
attracted a lot of interest in the mechanisms though which it exerts its haemopoiesis 
promoting effects. Many studies have focused on understanding HOXB4 activity in fully 
committed haemopoietic progenitors, yet our group has tried to shed light on the role it plays 
in the earlier stages of haemopoietic commitment. Work conducted in our group, using a 
tamoxifen-inducible expression system, revealed a key role of HOXB4 in the specification of 
pre-haemopoietic mesoderm in differentiating ESCs. HOXB4 was activated prior to the 
emergence of haemopoietic progenitors and microarray analysis was performed. We 
identified as HOXB4 targets a large set of paraxial mesoderm genes, a population that 
contributes to the formation of the haemopoietic niche. Additionally, cell mixing 
experiments demonstrated the ability of HOXB4-expressing cells to enhance the 
haemopoietic activity of neighbouring cells. Collectively, these data supported the idea that 
HOXB4 enhances haemopoietic activity by promoting the formation of the haemopoietic 
niche (219).   
The concept of HOXB4 providing a supportive niche environment has been increasingly 
gaining popularity. Liu and Hematti have reported the generation of mesenchymal/stromal 
stem cells (MSCs) from HOXB4-expressing hESCs. These HOXB4-expressing MSCs, 
similar to bone marrow stromal cells, presented the typical MSC phenotype and were able to 
differentiate into adipocytes and osteocytes (233). However, they did not provide any data 
regarding the ability of these MSCs to support the differentiation or proliferation of HPCs. A 
recent study by Chen and co-workers demonstrated that co-transplantation of HOXB4-
expressing MSCs with human bone marrow CD45
+
 cells or umbilical cord blood CD34
+
 
cells into irradiated mice markedly increased their engraftment potential and the 
haemopoietic recovery rates, indicating the contribution of HOXB4 in the regulation of the 
haemopoietic niche and the proliferation of HSCs (234). 
Despite all the proof of this novel role of HOXB4 there is little, if any evidence, regarding 
the exact mechanisms that mediate its activity. Interestingly, among the HOXB4 targets 
identified in our expression analysis we observed a large number of secreted molecules some 
of which have already been implicated with haemopoiesis in vivo and in vitro. We thus 
hypothesised that HOXB4 acts through a paracrine mechanism, where HOXB4-expressing 
cells secrete the necessary molecules for the development and proliferation of neighbouring 
HPCs. The possibility of using these secreted molecules purified and directly in 
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differentiation cultures opens up the prospects for an efficient, reproducible and clinically 
safe method of HSC generation. We therefore, focused on examining whether these targets 
individually or in combination could mediate HOXB4 activity and generate the same 
enhancing effects in our culture system as the ones observed with HOXB4 overexpression.  
4.2 Aims 
1. Validate as HOXB4 targets the genes encoding secreted factors detected in the 
microarray analysis of our inducible overexpression system. 
2. Assess the effects that secreted proteins encoded by HOXB4 target genes have on 
the haemopoietic differentiation of mESCs. 
4.3 Experimental strategy  
1. To validate HOXB4 target genes, wild type and HOXB4-ERT2 expressing cells were 
differentiated under the same conditions as in the microarray analysis study. Cells 
were collected and analysed by qRT-PCR for the expression levels of the genes of 
interest. 
2. To assess the effects of specific HOXB4 targets wild type cells were cultured in the 
serum-free protocol developed in this study. HOXB4 targets were added in the 
differentiation system in various concentrations, alone or in combination and cells 
were analysed by colony forming assay and surface marker expression for changes 












4.4.1 Validation of HOXB4 targets 
The HOXB4 targets identified in the microarray analysis included genes encoding secreted 
factors, transcription factors, signalling receptors and adhesion molecules (219). In this study 
we focused on the secreted factors as potential mediators of the paracrine effect of HOXB4 
and selected targets with a minimum expression increase of 1.5-fold in HOXB4-ER
T2
 cells 
compared to control cells after 4-OHT addition for further analysis. This initial screening 
revealed a number of secreted proteins. Some of these proteins, such as KITL and VEGFA, 
have already been widely used in protocols for mouse and human ESC hematopoietic 
differentiation, while others like NTN1, RSPO3, FST have not been studied previously in 
this context.   
To narrow down the number of secreted factors to be tested for possible enhancing effects on 
haemopoietic differentiation, the microarray targets were validated as HOXB4 targets by 
quantitative real time RT-PCR. Initially primers were designed and validated for the genes of 
interest. Subsequently, HOXB4 induction experiments were repeated under the same 
conditions as for the microarray study to collect material for analysis. Briefly, wild-type and 
HOXB4-ER
T2
 expressing mESCs were differentiated using our serum-based protocol. 
Embryoid bodies (EBs) formed in hanging drops for two days in the presence of LIF and 
serum and then placed in suspension culture for one day in the absence of LIF to initiate 
differentiation. Day 1 EBs were then plated onto gelatinized flasks in the presence or 
absence of 200nM tamoxifen (4-OHT) and harvested two days later (day 3) for RNA 
extraction and subsequent analysis. In order to exclude any leakiness of the system or 
possible effects of tamoxifen on gene expression, comparison was made between HOXB4-
ER
T2
 ESCs plus 4-OHT and control ESCs plus 4-OHT.  
All genes analysed by qPCR were upregulated in response to HOXB4 induction and even in 
much higher levels compared to the microarray data, indicating that they are indeed activated 
by HOXB4 (Figure 4.1 A). More detailed statistical analysis showed that 5 out of the 8 
analysed genes demonstrated a statistically significant increase in expression (p<0.05 t test) 
(Figure 4.1 B) with the level of induction of the three genes that were excluded (Cer1, Ntn1, 






A.  Mean fold increase in expression levels after HOXB4 activation identified by microarray 
and qPCR. B. Quantitative real-time RT-PCR performed on RNA isolated from day 3 EBs 
derived from HOXB4-ER
T2
 ESCs and control wild type ESCs in the presence (+T) or 
absence (-T) of 4-OHT. 5 of the genes showed a significant increase (*≤0.05, **≤0.01, 
***≤0.001 t test) in HOXB4-ER
T2
 ESCs in the presence of 4-OHT compared to control 
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Figure 4.1: Validation of genes identified as HOXB4 targets by microarray analysis. 
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4.4.2 Testing the HOXB4-ER
T2
 induction system in serum-free conditions 
Even though the serum-free ESC differentiation protocol developed in this study provides a 
stable and clear background in which to test HOXB4 targets, it was necessary before 
proceeding with its use to ensure that the haemopoiesis promoting effects of our HOXB4-
ER
T2 
inducible system are reproducible in serum-free conditions. If the HOXB4-ER
T2 
system 
failed to behave in a similar manner in the serum-free conditions, then the testing of HOXB4 
targets in these conditions would not provide any useful information. HOXB4 target analysis 
in serum-based conditions was conducted during a short time window on day 3 before the 
appearance of the first HPCs. Given the significantly faster progression of ESCs grown in 
serum-free conditions to the haemopoietic lineage, as detailed in Chapter 3, it was not 
possible to identify a time point in serum-free conditions corresponding to day 3 of the 
serum protocol and to proceed with a detailed expression analysis. We therefore focused on 
the CFU-C activity of the cells. 
Wild type and HOXB4-ER
T2 
expressing cells were differentiated in serum-based and serum-
free conditions, in the presence or absence of tamoxifen, and collected for analysis on day 6 
of the protocols. In agreement with our previous data (219), induction of HOXB4 in serum-
based conditions resulted in a dramatic nearly 10-fold increase of haemopoietic colony 
numbers in HOXB4-ER
T2
 cells compared to the wild type control in the presence of 
tamoxifen (Figure 4.2 A). HOXB4 overexpressing ESCs differentiated in serum-free 
conditions also resulted in significantly increased colony numbers compared to wild type 
cells after tamoxifen addition (Figure 4.2 B). It was thus evident that our HOXB4 induction 
system even under different culture conditions could still increase the haemopoietic 
differentiation of mESCs. We then continued with the assessment of HOXB4 targets in order 
to determine whether the use of the validated secreted factors is sufficient to produce the 











Wild type and HOXB4-ER
T2 
cells were differentiated in serum A, and serum-free B 
conditions in the presence or absence of 200nM of tamoxifen (4-OHT). Cells were harvested 
on day 6 of differentiation and assayed on their haemopoietic activity by CFU-C assay. 
Graphs represent 3 independent experiments, error bar represent standard deviation. 
Comparison was made between wild type and HOXB4-ER
T2 
cells in the presence of 




























































Figure 4.2: Testing of HOXB4 induction in serum-free conditions. 
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4.4.3 Assessment of HOXB4 targets in haemopoietic differentiation 
Following the validation of HOXB4 target genes and of the ability of our serum-free 
protocol to respond to HOXB4 activation we asked whether the proteins encoded by the 
targeted genes can mediate HOXB4 activity in culture. To this end wild type ESCs were 
initially cultured in the presence of proteins encoded by individual HOXB4 target genes in 
different concentrations to assess specific effects they may have in the haemopoietic output. 
Subsequently, the proteins were added together in various combinations to look into 
synergistic effects they may have on haemopoietic differentiation. 
4.4.3.1 FGF17 enhances the haemopoietic differentiation of mESC  
Fgf17 was the gene that even though had the lowest expression increase in response to 
HOXB4 of all genes analysed in the qRT-PCR analysis (2.7-fold), it was the one with the 
highest statistical significance. Members of the FGF superfamily have been shown to 
regulate haemopoiesis both through autocrine and paracrine mechanisms by acting directly 
on haemopoietic cells or the supporting stromal and endothelial cells (235). FGF17 is a 
member of the FGF8 subfamilly and has been shown to play an important role during 
embryonic development predominately in the patterning of embryonic brain (236, 237). 
FGF17 expression in the mouse embryo has been detected in major wall arteries, including 
the E12.5 descending aorta, mesenchymal cells and osteoblast precursors of the long bones 
implicating it in the development of these tissues (236). Both the aorta and the long bones 
are sites of haemopoiesis in the mouse thus suggesting that FGF17 might have an active role 
in regulating haemopoiesis.   
Recombinant FGF17 was added in differentiation cultures at 10, 30, 100 and 300ng/ml and 
day 6 cells were collected for analysis. CFU-C assays demonstrated that FGF17 at 100 and 
300ng/ml could enhance the generation of HPCs resulting in increased numbers of all types 
of haemopoietic colonies compared to untreated cells, with 100ng/ml giving the most 
significant increase (Figure 4.3). Flow cytometry analysis of HPC markers showed that there 
was not marked change for the majority of markers examined (Table 4.1). Upon closer 
inspection, we detected a significant increase in the expression levels of c-Kit, probably 
accounting for the increase in colony numbers, which was more visible as a defined 
population on scatter plots at 100 and 300ng/ml (Figure 4.4 A, B). Analysis of c-Kit co-
expression with CD41 or Sca-1 also showed an increase in double positive cells, again more 
pronounced at 100ng/ml which was not found however statistically significant (Figure 4.4C).  
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Wild type mESCs were differentiated in serum-free conditions in the presence of 0, 10, 30, 
100 and 300ng/ml FGF17. Cells were analysed for their haemopoietic activity on day 6. Data 
represent 3 independent experiments +standard deviation. P values calculated with Student t 





















































































































CD144 10.7  + 0.3 10.8  +  0.5 11  +  1.4 10.8  +  1 11  +  1.2 
CD41 46 +  2.8 45  +  8.5 45.5  +  2.1 54  +  7 48  +  8 
CD45 2.4  +  0.5 2.2  +  0.2 2.6  +  0.1 2.4  +  0.9 2.5  +  0.3 
CD41/CD144 7.3  +  0.3 6.8  +  0.4 7  +  1 8.6  +  0.5 7.3  +  0.5 
CD41/CD45 1.1  +  0.5 0.8  +  0.1 0.7  +  0.2 1  +  0.4 0.5  +  0.3 
c-Kit 43 +  5 40  +  7 49  +  5 55  +  5.6* 57  +  6* 
c-Kit/CD41 8  +  0.6 9.3  +  0.8 9  +0.9 11.6  +   0.6 9.8  +  2.6 
Sca-1 3.4  +  0.1 3.8  +  0.5 3.8  +  0.9 4.1  +  0.1 3  +  0.9 
c-Kit/Sca-1 1.9  +  0.2 2.2  +  0.2 2.2  +  0.5 2.6  +   0.1 2.3  +  0.6 
 
Table 4.1: Flow cytometry data of day 5 cells treated with FGF17. 
Cells were differentiated in serum-free conditions in the presence of different concentrations 
of FGF17 and analysed for expression levels of surface markers. Data represent 3 








A. Representative plots of CD41/c-Kit co-expression. B. Representative plots of Sca-1/c-Kit 
co-expression. C. Statistical analysis of c-Kit, CD41, Sca-1 expression levels. Data represent 
























































Figure 4.4: Analysis of c-Kit expression of FGF17 treated cells. 
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4.4.3.2 Increasing RSPO3 concentrations reduce the generation of HPCs 
The second validated HOXB4 target to be tested was RSPO3, the expression of which was 
increased 7.4-fold by activation of HOXB4 as assessed by qRT-PCR. R-spondin family 
members (Rspo1-4) are known mediators of Wnt/b-catenin and Wnt/PCP signalling pathway 
(238). RSPO3 has been studied in the developing mouse and Xenopus embryo and found to 
be expressed in the posterior primitive streak and allantois in the mouse, and the dorsal 
lateral plate and ventral blood islands in Xenopus, which are sources of hematopoietic cells. 
Moreover, RSPO3 is essential in the regulation of endothelial cells and it is expressed in 
sites of vasculogenesis and angiogenesis, as well as, the placenta and umbilical cord (239, 
240). Targeted disruption of Rspo3 in mice leads to embryonic lethality due to vascular 
defects in the placenta, yolk sac and embryo (239). The expression pattern of RSPO3, 
relating it to the vascular niche, and the close developmental proximity of hematopoietic and 
endothelial cells, made it an interesting candidate. 
RSPO3 was added in differentiation cultures at a wide concentration range and day 6 cells 
were analysed on their haemopoietic activity. CFU-C assay showed that RSPO3, contrary to 
what we expected, had an inhibitory effect in HPC generation. Increasing RSPO3 
concentrations were accompanied by a decreasing trend in haemopoietic colony numbers. 
Particularly RSPO3 at 100 and 300 ng/ml significantly reduced the numbers of CFU-M, 
CFU-Mix and BFU-E colonies, while CFU-GM colony numbers, even though not 
significantly, also decreased (Figure 4.5). We then proceeded to detailed surface marker 
expression analysis to look into the population of cells affected by the addition of RSPO3 in 
culture. As outlined in Table 4.2, the reduction in colony numbers was due to a small yet 
statistically significant decrease in the CD41
+
 cells (Table 4.2). Even though CD41 
expression was significantly downregulated at 30, 100 and 300ng/ml, the reduction in colony 
numbers was observed only for the two higher concentrations. This was probably due to a 




 cells which was observed at 100 and 300ng/ml. These data 
suggest that RSPO3 acts through different pathways compared to FGF17, which affected 
different cell populations, showing the complexity of HOXB4 regulatory network. Although 
the decrease in CD41 and CD45 expression could be easily missed as it was not clearly 
noticeable on flow cytometry plots (Figure 4.6) it was enough to alter the haemopoietic 
output, suggesting that even the slightest changes can affect the haemopoietic balance and 







Cells were differentiated in serum-free conditions in the presence of increasing RSPO3 
concentrations and assayed on day 6 of differentiation. Data represent 3 independent 


















































































































CD144 12.3  + 1 11  + 1.4 12.7  + 1.7 13  + 2.8 12.3  + 0.4 
CD41 36 + 5 31.5  + 6.3 29.5  + 6 * 29  + 1.4 * 25.5  + 2 * 
CD45 3  + 0.5 2.8  + 0.3 2.5  + 0.5  2.6  + 0.2 2.5  + 0.2 
CD41/CD144 9  + 0.5 9.6  + 0.6 8.8  + 0.4 8.4  + 0.6 9.3  + 0.1 
CD41/CD45 1.5  + 0.1 1.3  + 0.1 1.2  + 0.2 1  + 0.1  1  + 0.06  
c-Kit 38.5 + 3.5 31.5  + 6 35  + 10 34 + 4 38  + 6 
c-Kit/CD41 12  + 0.4 13  + 0.5 12  + 1 14  + 1.7 13  + 1.6 
Sca-1 4  + 0.7 3.5  + 0.5 3  + 0.9 3.5  + 0.7 4  + 0.5 
c-Kit/Sca-1 2  + 0.3 2.5  + 0.1 2.3  + 0.6 2.3  + 0.4 2.2  + 0.4 
 
Table 4.2: Flow cytometry analysis of RSPO3 treated mESCS. 
Cells were differentiated in serum-free conditions in the presence of increasing RSPO3 
concentrations and analysed on day 6 of differentiation for expression levels of surface 






A. Representative scatter plots of CD41/CD45 co-expression. B. Statistical analysis of CD41 
and CD45 expression compared to untreated cells. Data represent 3 independent 

































































Figure 4.6: Detailed analysis of CD41 expression in RSPO3 treated cells. 
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4.4.3.3 Apelin peptides do not alter the haemopoietic activity of mESCs 
The last candidate soluble factor to be examined in culture was Apelin. Apelin had the 
highest significant increase in expression by qPCR analysis (8.8-fold), and the gene 
encoding its receptor, Agtrl1 or Apj was the top upregulated gene by HOXB4 in the 
microarray with a 13.5-fold increase and further validated increase of 6.6-fold by qPCR 
analysis (219). The Apelin gene encodes a 77-amino acid pre-protein, which after 
translocation to the endoplasmic reticulum, can be cleaved to several active peptides whose 
number has been reported to reach up to 46 isoforms, including Apelin 36 corresponding to 
the amino acid sequence 42-77 and Apelin 13 corresponding to the sequence 65-77 (241). 
The Apelin-APJ pathway has been reported widely to play a critical role in the development 
and function of both the cardiac and vascular system (242, 243) that share common 
mesodermal origins with the hematopoietic system. Additionally, it has been reported, using 
a human ESC differentiation system, that the Apelin receptor marks a common mesoderm 
derived precursor of mesenchymal and endothelial stem cells (244). This finding is 
consistent with our hypothesis that HOXB4 can act to induce the formation of a 
stromal/mesenchymal population.  
The two most common isoforms of Apelin (Apelin 13 and Apelin 36) were used separately 
in differentiation experiments at a concentration of 0, 30, 100 and 300nM. Colony forming 
assays, following the addition of Apelin 13 in culture, showed a slight but not significant 
increase of CFU-M, CFU-GM and CFU-Mix colonies at 300nM (Figure 4.7). Flow 
cytometry analysis, however, showed that there was no change in the expression of cell 
surface markers for any of the Apelin 13 concentrations tested (Table 4.3). Looking at the 
Apelin 36 isoform, a similar pattern of increased but statistically insignificant colony 
numbers was observed at 300nM (Figure 4.8). As outlined in Table 4.4, surface marker 
expression again did not differ markedly for any of the tested concentrations. The two Apelin 
isoforms were also added together in culture at 300nM concentration, to look into any 
synergistic effects, yet again there was no marked increase of haemopoietic activity as 
observed in both CFU-C assay and flow cytometry (Figure 4.9). The above experiment was 
conducted only once, as combined with the data of Apelin isoforms used alone in culture, it 
was conclusive to the fact that Apelin does not confer any marked changes on haemopoietic 
activity. Since any changes, even though minimal, were observed at 300nM it is possible that 
Apelin isoforms are required in even higher concentrations than the once used here for any 





Cells were differentiated in serum-free conditions supplemented with different Apelin 13 
(A13) concentrations. Cells were collected and plated in colony forming assay on day 6. 

































































































































 A13 0nM A13 30nM A13 100nM A13 300nM 
CD144 
10  + 1.4 11  + 1.7 10  + 2 12  + 1.4 
CD41 
49 + 9.9 47  + 8.4 45  + 11 42  + 13 
CD45 
1.9  + 0.6 2.2  + 0.5 1.8  + 0.7 2  + 0.2 
CD41/CD144 
7  + 1.2 6  + 0.9 6.8  + 0.5 7.3  + 1 
CD41/CD45 
0.8  + 0.1 0.6  + 0.2 0.7  + 0.2 0.9  + 0.1 
c-Kit 
38.5 +2.1 43  + 8.4 39  + 9.7 37  + 9 
c-Kit/CD41 
7  + 1.4 8  + 1.5 6.2  + 2 8.4  + 1.4 
Sca-1 
2.7  + 0.4 2.6  + 0.1 2  + 0.6 1.8  + 0.7 
c-Kit/Sca-1 
1.3  + 0.5 1.5  + 0.2 1.7  + 0.4 1.1  +  0.3 
 
 
Table 4.3: Flow cytometry analysis of Apelin 13 treated mESCs. 
Cells were differentiated in serum-free conditions in the presence of different concentrations 
of Apelin 13 and analysed on day 6 of differentiation for expression levels of surface 









Cells were differentiated in serum-free conditions supplemented with various Apelin 36 
(A36) concentrations. Cells were collected and plated in colony forming assay on day 6. 






























































































































 A36 0nM A36 30nM A36 100nM A36 300nM 
CD144 
10  + 1.4 10  + 0.6 11  + 1 9  + 1.7 
CD41 
49 + 9.9 43  + 8 37  + 11 35  + 13 
CD45 
1.9  + 0.6 1.5  + 0.2 1  + 0.7 1.8  + 0.4 
CD41/CD144 
7  + 1.2 5  + 1.5 6  + 0.5 7  + 1 
CD41/CD45 
0.8  + 0.1 0.7  + 0.1 0.8  + 0.2 0.5  + 0.3 
c-Kit 
38.5 +2.1 39.07  + 6.8 34  + 9.7 30  + 7 
c-Kit/CD41 
7  + 1.4 5  + 1.2 7  + 0.7 8  +  0.5 
Sca-1 
2.7  + 0.4 2.5  + 0.1 2.5  + 0.3 2.4  + 0.1 
c-Kit/Sca-1 
1.3  + 0.5 1.2  + 0.2 1  + 0.7 1.6  + 0.2 
 
Table 4.4: Flow cytometry analysis of Apelin 36 treated mESCs. 
Cells were differentiated in serum-free conditions in the presence of various Apelin 36 
concentrations and analysed on day 6 of differentiation for expression levels of surface 











Mouse ESCs differentiated in serum-free conditions in the presence of 300nM Apelin 13 
(A13) and Apelin 36 (A36). A. Cells plated in methylcellulose assay on day 6. B. Flow 





























































4.4.3.4 Combined action of HOXB4 targets 
Given the large number of genes induced by HOXB4 it was consider unlikely that the use of 
a single factor is not enough to generate the same response as HOXB4 overexpression. We 
therefore decided to use the factors we individually assessed above, in combination to look 
into any additive effects. The factors were used in various combinations and at 
concentrations that seemed to favour an enhancing effect. Particularly, FGF17 was used at 
100ng/ml as it was the concentration with the most significant increase in HPCs, and Apelin 
peptides were used at 300nM. As RSPO3 at high concentrations had an inhibitory effect, it 
was used at 30ng/ml which was considered high enough to have an effect but not as much as 
inhibiting the differentiation process. 
When cells were analysed on day 6 of the serum-free protocol, we did not observe any 
striking difference in haemopoietic activity between untreated cells and any of the factor 
combinations used. Hematopoietic colonies were formed at comparable numbers for all cell 
treatments with no notable differences in the type of colonies either (Figure 4.10) In the 
cases where FGF17 was added in the differentiation culture an increase in c-Kit cells was 
observed again but not in significantly higher levels compared to its use alone suggesting 
there was no interaction between FGF17 and the other factors (Table 4.5). The experiments 
were repeated twice as it was evident that the factors did not increase the haemopoietic 
potential of the cells to a degree that could be suggesting that they can indeed mediate 














FGF17 was used at 100ng/ml, RSPO3 at 30ng/ml and Apelin peptides A13 and A36 at 























Figure 4.10: Colony forming assay on day 6 mESCs differentiated in different 




RSPO3+FGF17 A13+RSPO3 A13+RSPO3+FGF17 A13+FGF17 A36+RSPO3 A36+RSPO3+FGF17 A36+FGF17 
CD144 
7  + 1.4 6.5  + 0.7 6  + 1.4 7.1  + 0.1 6.2  + 0.2 7  + 1.2 6.5  + 1.3 7.2  + 0.3 
CD41 
48.5  + 9 42  + 2 46  + 2 38.5  + 6 37  + 4 42.5  + 4 37.5  + 6 36  + 3 
CD45 
2.2  + 0.2 2.1  + 0.8 1.4  + 0.1 1.8  + 0.5 2.9  + 1.6 2.2  + 1 2.2  + 1 2.75  + 1.7 
CD41/CD144 
4.7  + 0.3 4.3  + 0.4 3.8  + 0.6 4.4  + 0.5 4.7  + 0.2 5  + 0.8 4  + 0.7 5.5  + 0.5 
CD41/CD45 
0.9  + 0.1 0.9  + 0.3 0.7  + 0.1 0.7  + 0.4 1  + 0.4 1  + 0.2 0.8  + 0.6 0.9  + 0.5 
c-Kit 
47  + 1.4 53  + 4.2 45  + 4.2 52.5  + 1.7 54.5  + 2 46  + 7 54  + 4 57.5  + 2.7 
c-Kit/CD41 
11  + 0.9 14  + 2.8 13  + 1.6 13  + 2.3 10  + 2 13  + 0.3 12  + 1.4 10  + 0.5 
Sca-1 
2  + 0.2 2.7  + 0.1 2.7  + 0.5 2.9  + 0.6 2.7  + 0.1 2.5  + 0.1 2.5  + 0.2 3.2  + 0.8 
c-Kit/Sca-1 
1.4  + 0.1 1.9  + 0.1 2  + 0.3 2  + 0.7 1.8  + 0.2 1.7  + 0.1 1.7  + 0.2 2.3  + 0.7 
 
Table 4.5: Analysis of flow cytometry data of mESCs differentiated in the presence of combined HOXB4 targets. 





The activity of a novel set of HOXB4 targets was assessed in a well-controlled environment. 
It was shown that even though induced by the same transcription factor the tested proteins 
generate different results in haemopoietic differentiation demonstrating the complexity of 
HOXB4 regulatory network. In particular: 
 We identified as HOXB4 targets a number of secreted factors, whose direct role in 
haemopoietic differentiation has not been previously investigated (Figure 4.1). 
 Addition of FGF17 in the differentiation cultures promoted the haemopoietic 
potential of mESCs by increasing c-Kit expression (Figure 4.3, 4.4). 







 cells (Figure 4.5, 4.6). 
 Apelin peptides did not affect the differentiation potential of mESCs even when the 
different isoforms were used together (Figure 4.7, 4.8, 4.9). 
 The combined action of these tested factors in culture was not sufficient to generate 
the same enhancing effects as HOXB4 overexpression in haemopoietic 
differentiation (Figure 10). 
 
4.6 Discussion 
4.6.1 Reproducibility of HOXB4-ER
T2
 induction system in serum-free 
conditions 
An important aim of this chapter was to essentially translate the data obtained by HOXB4 
induction in our serum-based culture system, to the newly developed serum-free protocol. 
Therefore, a major question we came across was whether serum-free conditions can allow 
for HOXB4, and ultimately the factors induced by it, to generate the same enhancing effects 
on haemopoiesis. Since the first study reporting that HOXB4 overexpression can improve 
the definitive haemopoiesis of mESCs a large number of overexpression systems have been 
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developed for mouse and human cells. Even though these overexpression systems have 
generally improved the haemopoietic outcome, variations in the levels of HOXB4 and timing 
of expression among them have many times generated conflicting results. To date there is 
little evidence regarding the reproducibility of these HOXB4 induction systems, let alone the 
regulatory pathways of their action. A retroviral HOXB4 expression system developed by 
Klump and co-workers (245), has been used to compare the growth and differentiation of 
ESC-derived and bone marrow HSCs (209). The authors demonstrated that HOXB4 
transduced bone marrow and ES cells behaved almost indistinguishably both in culture, 
where they exhibited a competitive growth advantage over wild type cells, and in vivo after 
transplantation, showing the same repopulation efficiency and lineage bias. Although they 
did not compare the expression profiles of the two cell populations the data they presented 
were enough to suggest that HOXB4 mediates the same cell fates in the two populations, 
resulting in identical cell behaviour. 
As already mentioned the fast progression to the haemopoietic fate observed in our serum-
free protocol made it difficult to pin point the corresponding time to the day 3 of expression 
analysis in serum-based conditions. We did consider however, following the same reasoning 
with the above study, that if the HOXB4 targets we identified in serum grown cells are 
crucial factors that mediate its activity they should be induced even under different culture 
conditions, enforce the same cell fate decisions and increase the haemopoietic outcome of 
the differentiation process. Hence we focused on analysing the haemopoietic output of 
HOXB4 activation. We showed that our inducible system could indeed generate significantly 
increased numbers of HPCs as shown by colony forming assays (Figure 4.2) in both culture 
conditions confirming its reproducibility and suggesting conserved regulatory factors. We 
then aimed at determining whether the secreted factors we validated were the ones 
accounting for the observed increase in HPCs.  
4.6.2 Assessment of FGF17 effects on mESC haemopoietic differentiation 
FGF17 was one of HOXB4 targets that as we expected increased the haemopoietic activity 
of mESCs. We used a wide range of FGF17 concentrations to detect the appropriate amount 
for it to exert its effects, as well as, any dose-dependent variations. We demonstrated that 
100 and 300ng/ml of FGF17 could markedly increase the number of HPCs capable of 
differentiating into multiple lineages in vitro (Figure 4.3). Flow cytometry analysis suggested 
that the increase in haemopoietic activity was due to the upregulation of c-Kit expression 
which in turn led to an increase in the numbers of c-Kit+CD41+ and c-Kit+Sca-1+ cells 
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(Table 4.1, Figure 4.4). Interestingly, the increase in colony forming and c-Kit
+
 cells was 
more prevalent at 100ng/ml suggesting there is not only a minimum but also a maximum 
threshold for optimal FGF17 activity.  
Similar results have been described in vivo for another member of the FGF superfamily. 
Treatment with bFGF in mice resulted in expansion of bone marrow stromal cells and an 
increase in c-Kit
+
 cell proliferation leading to improved repopulation and CFU formation 
rates (228). It is possible that similarly, HOXB4-induced FGF17 promotes the development 
of a haemopoiesis supportive population while also enhancing the proliferation of c-Kit
+
 
HPCs per se. Although our study did not include detailed analysis of the stromal population 
generated in our serum-free protocol for possible changes induced by FGF17, the increase in 
c-Kit expressing cells clearly points to the proliferative activity of FGF17. A study led by 
Nezu and colleagues, where FGF17 expression was largely detected in human haemopoietic 
tumour cells lines and in patients with acute leukaemia, also confirmed the proliferation 
activity of FGF17 (246). When human haemopoietic tumour cell lines were cultured in the 
presence of FGF17, their growth rates increased in a dose-dependent manner. Even though in 
our study the overall increase in HPCs induced by FGF17 treatment was not equivalent to 
the one generated by HOXB4 overexpression we showed that FGF17 is in part mediating 
HOXB4 activity. It would be interesting to see if this increase in HPC numbers with FGF17 
treatment can also result in improvement of the repopulating ability of the cells. 
4.6.3 Assessment of RSPO3 effects on mESC haemopoietic differentiation 
We and others have identified as targets of HOXB4 genes involved in the regulation of the 
Wnt pathway, which in turn is an important regulator in the development and proliferation of 
HSCs (216, 217, 247, 248). RSPO3, which was in the top ten genes identified as HOXB4 
targets by our group, is a potent activator of the Wnt pathway (238). This led us to 
hypothesise that it might be a major mediator of its enhancing haemopoietic activity. To our 
great surprise, our results indicated a negative role of RSPO3 in haemopoietic 
differentiation. We found that increasing RSPO3 concentrations resulted in decreasing 
numbers of HPCs. We observed significantly reduced numbers of haemopoietic colonies at 







 cells (Figure 4.5, 4.6).  
In agreement with our data, Scheller and colleagues have shown that continuous activation 
of Wnt signalling in the haemopoietic system impairs the function of HSCs. Cells are forced 
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into the cell cycle, thus exhausting the stem cell pool and ultimately blocking their ability to 
repopulate irradiated hosts and to differentiate into all haemopoietic lineages (249). Another 
study monitoring Wnt signalling pathway during mESC haemopoietic differentiation has 
shown that while members of the Wnt signalling are expressed in ESCs and early stages of 
haemopoietic commitment, they are significantly downregulated as differentiation progresses 
(250). It becomes evident from the above studies that well-regulated Wnt stimulation is 
crucial for efficient haemopoiesis to occur. The continuous presence of high RSPO3 
concentrations in our serum-free differentiation protocol might have possibly tipped the fine 
balance required for optimal Wnt signalling activity, therefore leading either to impairment 
of HPC generation or to increased cell death which can account for the reduction in colony 
numbers and CD41, CD45 expressing cells. It is important to keep in mind that in our 
expression analysis RSPO3 induction by HOXB4 was detected on day 3 of differentiation 
prior to the emergence of HPCs. It is possible that RPSO3 expression is subsequently turned-
off to allow for HPCs to develop. A more detailed study where cells are treated with RSPO3 
only for a short period at the early stages of differentiation, or with reducing doses 
throughout the protocol, might provide more evidence regarding its activity. 
4.5.4 Assessment of Apelin in the haemopoietic differentiation of mESCs 
Apelin and its receptor, APJ, were both identified as HOXB4 targets by our group thus 
clearly pointing to their involvement in mediating HOXB4 activity. Combined with our data, 
the expression of APJ in the AGM vasculature of the mouse embryo, as well as, in a 
mesenchymal and endothelial progenitor with enriched hemangioblast colony-forming 
ability in OP9-cultured hESCs, suggested a role for Apelin and its receptor in haemopoiesis 
(251, 244). We looked into the effects of the two more common Apelin isoforms, Apelin 13 
and 36, into haemopoietic mESC differentiation. We did not detect any change in the 
numbers or populations of haemopoietic progenitors developed in our system neither when 
the two isoforms were tested separately nor when they were used in combination.  
Contrary to our data, work by Yu and co-workers, showed that Apelin 13 in hESC 
haemopoietic differentiation cultures increased the number of hemangioblast colony-forming 
cells and the expression of haemopoietic markers (252). The inconsistency between our data 
and the above study might be due to interspecies differences. Nonetheless, it would not 
explain why while it is clearly shown that the mouse Apelin-APJ system is activated by 
HOXB4, addition of Apelin in culture fails to produce any effect. An important issue to 
consider, which could account for our negative data, is the unstable nature of Apelin 
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peptides. The use of Apelin has been repeatedly restricted due to the fast degradation of the 
peptides which results in very short half-life of less than 10 minutes (253, 254). The fast 
degradation of Apelin in our culture system would not allow for any effects to be seen even 
in very high concentrations. Very recently, improved delivery methods that increase peptide 
stability have been developed that will enable the more reliable use of Apelin for research 
and clinical purposes (255).  
4.6.5 Secreted factors and HOXB4 activity 
Taking into consideration that a single secreted factor is unlikely to fully account for the 
haemopoietic promoting activity of HOXB4 we used the factors in combination. 
Nevertheless, the haemopoietic output of the cells did not increase for any of the tested 
combinations (Figure 4.10, Table 4.5). It is possible that a better fine-tuning of the amount 
and timing of factors tested is required for their combined activity to be effective. It is also 
important to consider that the haemopoiesis supporting environment promoted by HOXB4 
similar to in vivo niches may have a more complicated mechanism of action. Haemopoietic 
niches maintain and generate HSCs through a fine balance of secreted and membrane-bound 
factors, cell adhesion molecules and matrix proteins. The expression profiling in our group 
apart from the secreted factors, identified as HOXB4 targets a number of receptors and cell 
adhesion molecules such as APJ, Plexin A, Cdh11, NCAM. It is likely that in addition to the 
paracrine activity of the soluble factors, direct cell-to-cell contact is necessary for the full 
potential of HOXB4 activity to unravel.  
In agreement with this concept a number of studies have demonstrated the importance of 
direct cell contact for development and expansion of HSCs. Previous work in our group has 
shown that cell-to-cell interaction between haemopoiesis supportive feeder cell lines and 
differentiating mESCs is necessary for the feeder lines to enhance the generation of HPCs 
(220). In the same study the combined use of feeder cell lines and HOXB4 overexpression 
did not have an additive effect in the haemopoietic activity of the cells, suggesting common 
molecular mechanisms such as the requirement for direct cell contact. The requirement for 
cell-to-cell contact has also been demonstrated between embryonic HSCs and the feeder cell 
lines, to maintain HSC activity in culture (256). Furthermore, some studies have reported the 
synergistic effects of using recombinant growth factors and supportive feeder cells, in the 
expansion of HSCs (257, 258). An efficient way to define whether paracrine signalling is 
sufficient for mediating HOXB4 activity would be the use of supernatant from HOXB4-
expressing cell cultures in the differentiation protocol. Additionally, the generation of a 
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HOXB4 expressing feeder cell line would clarify if direct cell interaction is an essential part 
for HOXB4 activity and which soluble factors and adhesion molecules are critical in 
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5.1 Introduction  
Mouse and human haemopoietic development bear striking similarities in the molecular and 
cellular events leading to the generation of HSCs. This has allowed scientists to differentiate 
human haemopoietic cells from PSCs in vitro, by directly translating information gained 
from the study of the mouse system. Supportive feeder cell lines derived from mouse 
haemopoietic niches have been successfully applied for the differentiation of human HPCs, 
while, cytokines able to induce the haemopoietic lineage in mouse ESCs have also been used 
for human (161, 174). HOXB4 overexpression, which has been effective in generating 
mouse cells capable of long-term multilineage engraftment, can increase as well the 
generation of human HPCs (213). However, HOXB4 has not been as effective in rendering 
human cells engraftable (188). The observed difference has been attributed to variability in 
the dosage or the temporal window of exogenous HOXB4 which might require further 
optimising (215). Nonetheless, key differences between species, regarding the role of 
HOXB4 or the regulatory mechanisms underlying its activity, cannot be excluded. So far, 
studies looking into the regulatory network of HOXB4 have been conducted exclusively in 
mouse adult and ESC-derived HSCs (216-219). Therefore, the way HOXB4 modulates 
human haemopoietic specification and how it compares to the mouse one remains an 
unexplored area. In this chapter we aimed to gain some insight into HOXB4 interspecies 
differences by testing, in human ESC haemopoietic differentiation cultures, the HOXB4-
induced secreted factors that we had identified in the mouse ESC differentiation system. 
Taking into consideration the fast progress in hiPSCs research and the immense future 
clinical opportunities they offer for patient-specific therapy we decided to also investigate 
the haemopoietic activity of hiPSCs compared to hESCs in our differentiation system and 
their response to treatment with HOXB4-induced factors. Human ESCs and iPSCs are 
remarkably similar not only in their self-renewal but also in their multilineage potential (6, 
148). However, gene expression and DNA methylation analysis of hESC and hiPSC cell 
lines has revealed marked differences between the two cell types which could affect the 
differentiation propensity of the cells (259). Studies focusing on the haemopoietic 
differentiation ability of hiPSCs have shown that despite variations in their efficiency, their 
phenotype and haemopoietic activity is very similar to hESCs (157, 260). Nevertheless, even 
the slightest differences between hESCs and hiPSCs may be critical and lead to variable 
results in identifying factors that can confer repopulating ability to the cells, with important 




1. Monitor the emergence of HPCs in the serum-free and feeder-free haemopoietic 
differentiation of hESCs and hiPSCs.  
2. Assess how HOXB4-induced secreted factors affect the generation of HPCs in hESC 
and hiPSC haemopoietic differentiation cultures. 
5.3 Experimental strategy 
1. Human ESCs and iPSCs were differentiated in serum-free and feeder-free conditions 
to set a baseline for their haemopoietic activity, as well as, for any differences 
between them. Cells were collected at different time points and monitored for the 
generation of HPCs through colony forming assay and flow cytometry analysis of 
surface markers.  
2. To study the effects of secreted factors induced by HOXB4, hESCs and hiPSCs were 
cultured in the presence of the factors in different concentrations and changes in the 
haemopoietic activity of the cells were measured through colony assays, cell 













5.4.1 Human ESC and iPSC lines follow similar stages of haemopoietic 
differentiation 
A robust serum- and feeder-free differentiation protocol has been established in our lab for 
the generation of erythroid cells. Although the ultimate aim of the protocol is to produce 
mature red blood cells, the generation of HPCs is a part of the differentiation process and we 
have observed that HPCs are produced very efficiently over a wide time window. In this 
study we used a modified version of the protocol, where again only the most crucial factors 
required for haemopoiesis were used, to allow for even the slightest changes caused by 
HOXB4 targets to be detected. We differentiated hESCs and hiPSCs and analysed their 
phenotype and lineage potential to identify the time point during the protocol when 
production of multipotential HPCs is optimal. The human differentiation protocol as outlined 
in Figure 5.1 followed similar steps to the mouse protocol. Suspension EBs were formed for 
the first 3 days. EBs were then dissociated and single cells were plated down and allowed to 
mature for a further week. Cells were collected on day 7, when the first colony forming 
progenitors are detected, and on day 10 before their transfer to conditions that favour 
erythroid differentiation.  
Colony forming assay analysis showed that hESCs and hiPSCs follow a similar development 
pattern. A wave of primitive erythroid progenitors is generated on day 7 which is followed 
by more mature multipotent HPCs on day 10. Particularly on day 7 the vast majority of 
haemopoietic colonies for both cell populations consisted of small primitive erythroid 
colonies, EryP (Figure 5.2 A-D). Although myeloid and multilineage colonies were also 
present on day 7 they were of small size and quite low numbers. By day 10 however, there 
was a significant increase in the numbers and size of CFU-M, CFU-GM and CFU-Mix 
(Figure 5.2 E-I). The primitive erythroid colonies had disappeared and mature BFU-E 
colonies had developed. Interestingly, by day 10 a clear lineage bias difference between the 
two cell lines was observed. There were significantly more myeloid progenitors developed 
by hiPSCs compared to hESCs, while, hESCs had a significantly higher yield of multilineage 
progenitors (Figure 5.2 I).  
We conducted flow cytometry analysis to look into the phenotype of the developing HSCs. 
We examined the expression of CD34 which marks haemopoietic stem and progenitors cells 
throughout development in embryonic and adult human haemopoietic tissues (40, 86, 87). 
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We observed that CD34 expression was in comparable levels, 55-60% of cells, between the 
two cell populations on day 7, and was subsequently reduced on day 10 with hiPSCs 
expressing significantly lower levels than hESCs (Figure 5.3). We included in our analysis 
the surface markers CD235a and CD43 which have been shown to mark in vitro primitive 




cells constituted nearly half of the population of day 7 cells, while by day 10 they were 
expressed in less than 10% of the population suggesting that CD235a marks the cells 




 cells were 
present in high numbers on both days of analysis with no significant change for the two cell 




 cells were significantly more in 
hESC differentiation cultures than in hiPSC, suggesting that different PSC lines display 
variable haemopoietic activity in our system.  
It was concluded from the above data that the optimal time of appearance of mature HPCs 
capable of multilineage differentiation was at day 10 of our human differentiation protocol. 
HPCs were characterised by CD34 and CD43 expression and their levels were comparable in 
the two pluripotent cell lines tested (one hESC and one hiPSC line). Cell sorting experiments 
conducted by Dr Rui Ma in our lab have confirmed that the haemopoietic potential of day 10 
cells is predominately found in the CD34+CD43+ fraction. Therefore, analysis in subsequent 
experiments was performed on day 10 cells, and surface marker analysis examined CD34 














Human ESCs and iPSCs were cultured in serum- and feeder-free conditions. Cells were 
scraped from maintenance cultures and placed in suspension in the presence of cytokines to 
initiate differentiation. On day 3 EBs were dissociated and single cells were plated down and 
differentiated for 7 more days in the cytokines outlined above. Cells were collected for 
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Cells formed mainly primitive erythroid colonies on day 7 (A-D), while day 10 cells 
generated mature colonies of multiple lineages (E-H). Detailed analysis of colony numbers 
on days 7 and 10 (I). Graphs represent 4 and 5 independent experiments for hESCs and 
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Cells were differentiated in serum- and feeder-free conditions and analysed for the 
expression of haemopoietic markers. A. Representative flow cytometry plots. B. Percentage 
of cells expressing haemopoietic markers CD34, CD43 and CD235a. Graphs represent 4 and 
5 independent experiments for hESCs and hiPSCs respectively. Error bars represent standard 
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Figure 5.3: Flow cytometry analysis of day 7 and day 10 hESCs and hiPSCs. 
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5.4.2 Effects of HOXB4-induced secreted factors on human HPC differentiation 
Similar to the experiments performed on our mouse differentiation system, we used the 
secreted proteins encoded by HOXB4 target genes in different concentrations to monitor any 
specific effects on the haemopoietic activity of human PSCs.  




 HPC generation by hESCs but not 
hiPSCs 
FGF17 was used at two different concentrations: a low concentration of 30ng/ml and a 
higher concentration of 100ng/ml, which had the most significant enhancing effect on the 
mouse in vitro haemopoiesis (Chapter 4). Haemopoietic colony assays initially showed that 
FGF17 did not have any effects on the number of HPCs generated by hESCs or hiPSCs 
(Figure 5.4). There was no significant difference observed between control and treated cells 
neither in the total numbers of colonies nor in the numbers of individual types of colonies. 
Interestingly, however, flow cytometry analysis revealed that hESCs and hiPSCs respond 
differently to FGF17. While there was no marked change on the percentage of cells 
expressing CD34 or CD43 in the hiPSC line, 30ng/ml FGF17 decreased the portion of 
CD34
+




 HPCs that were generated from ESCs 






 cells was small (approximately 6%) 
but significant. There are a number of reasons for this apparent discrepancy. It is possible 
that this small change detected by flow cytometry would not be detected in CFU-C assays 
because these assays are inherently more variable. Alternatively it is possible that not all 






 cells, and is therefore not reduced 
by the small decrease of these populations.  
It has been demonstrated that FGF17 can regulate the growth rates of human haemopoietic 
tumour cell lines (246). In that study FGF17 had an enhancing proliferative effect. We 






 cells was also due to the action 
of FGF17 on cell growth, which in our experiments could be promoting the growth of non-







 cells in the overall population would be affected. To assess this 
potential explanation we examined the cell expansion rates for the two cell lines following 
FGF17 treatment. As described above, on day 3 of the human differentiation protocol the 
EBs are dissociated and single cells are plated down for further maturation. This allows us to 
monitor cell expansion for the remaining time of the protocol. Cells were seeded at 2 x 10
5
 
cells per well of a 6-well plate and cell numbers were counted on day 7 and day 10 of 
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differentiation. However, we observed that treatment with FGF17 did not confer any positive 























Cells were differentiated in the presence of 0, 30 and 100 ng/ml of FGF17 and analysed on 








































































































































Human cells were differentiated in serum-free conditions in the presence of FGF17 and 
analysed for surface marker expression. A. Quantification of haemopoietic marker 
expression. Data represent 3 independent experiments. Error bars represent standard 


















































































Cells were seeded at 2 x 10
5
 density on day 3 of differentiation and counted on day 7 and day 
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Figure 5.6: Cell growth of FGF17 treated hESCs and hiPSCs. 
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5.4.2.2 RPSO3 decreases the haemopoietic differentiation of hESCs but not of hiPSCs 
Cells were treated with 30 and 100ng/ml of RSPO3. Once again as in the case of FGF17 
treatment, we observed that the two cell lines responded differently to RSPO3. In the case of 
hESCs, CFU-C assay showed that the differentiation was negatively affected by the 
increased concentration of RPSO3. Total colony numbers were significantly reduced at 
100ng/ml, with the difference being more profound for CFU-M and CFU-Mix colonies 
(Figure 5.7). These data are in agreement with our results for RPSO3 effects on mESCs. In 
contrast, addition of RSPO3 in hiPSCs cultures had no effect on the differentiation of HPCs 
as all colony types gave comparable numbers between treated and untreated cells (Figure 
5.7). Flow cytometry analysis demonstrated that in hESCs 100ng/ml of RSPO3 significantly 
reduced the expression of both CD34 and CD43 markers (Figure 5.8). Interestingly, we 




 progenitors not only at 
100ng/ml but also at 30ng/ml of RSPO3. In agreement with the haemopoietic colony assay, 
addition of RSPO3 in hiPSCs did not result in any change in the expression of surface 
markers. We also monitored the cell expansion rates of the cells to look into any effects of 
RSPO3 on cell proliferation. No significant effect on cell proliferation was observed in either 












Cells were differentiated in serum-free conditions in the presence of 0, 30 and 100ng/ml 
RSPO3. Cells were collected and analysed on day 10. Data represent 3 and 4 independent 
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A. Analysis of day 10 cells treated with 0, 30, 100ng/ml of RSPO3. Data represent 3 and 4 
independent experiments +sd. P values calculated with Student’s t test. B. Representative 


























































































Cells were differentiated in serum-free conditions in the presence of RSPO3. On day 3 cells 
were seed at 2 x10
5
 density and counted on day 7 and day 10. Data represent 3 and 4 
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5.4.2.3 Apelin does not affect the haemopoietic differentiation of hESCs and hiPSCs 
The last HOXB4 target we tested in our human differentiation system was Apelin. We tested 
the two Apelin isoforms, Apelin 13 and Apelin 36 at 100nM. Experiments on hESCs were 
performed by Dr Melany Jackson and Mrs Helen Taylor. As shown on Figure 5.10, 
haemopoietic colony forming assay did not detect any changes in the numbers or types of 
haemopoietic progenitors generated by either cell line in response to the two Apelin 
peptides. Although a decreasing trend in total colony numbers of hESCs was observed for 
both Apelin isoforms, the decrease was not statistically significant. In agreement with the 
CFU-C data, flow cytometry analysis showed that neither Apelin 13 nor Apelin 36 affected 
the cell differentiation. Surface markers were expressed in equal percentages for all 
treatments in the two cell populations (Figure 5.11). Nonetheless, the possibility that the 
Apelin peptides degraded too fast when added in culture before exerting their effects cannot 

















Cells were differentiated in serum-free conditions in the presence of 100nM A13 or A36 and 






























































































































































































A. Analysis of day 10 cells treated with 100nM of Apelin 13 (A13) or Apelin 36 (A36). Data 
represent 5 and 3 independent experiments +sd. P values calculated with Student’s t test. B. 






















































































































Figure 5.11: Flow cytometry analysis of surface markers in hESC and hiPSC lines treated 




Human ESCs and iPSCs were differentiated to the haemopoietic lineage in well-defined, 
serum-free conditions. The two cell populations exhibited slight variations in their 
haemopoietic potential, nonetheless they followed a similar developmental pattern. When 
treated with secreted factors induced by HOXB4, the two cell populations responded 
differently not only compared to mouse ESCs but also to one another. Our data suggest: 
 When cultured in serum-free conditions hESCs and hiPSCs follow a differentiation 
pattern similar to in vivo haemopoiesis. A transient wave of erythroid progenitors 
arises on day 7 and is then followed by a second wave of more definitive-type 
multipotent progenitors on day 10 (Figure 5.2, 5.3). 
 Human PSC lines can exhibit lineage bias and variability in their haemopoietic 
efficiency even when differentiated under the same well-defined conditions (Figure 
5.2, 5.3). 
 Low concentration of FGF17 inhibits the haemopoietic differentiation of hESCs by 






 HPCs, while it does not affect 
the haemopoietic potential of hiPSCs (Figure 5.5). 
 Increasing concentrations of RSPO3 reduce the CD34 and CD43 expressing HPCs 
capable of multilineage differentiation, derived from hESCs but not from hiPSCs 
(Figure 5.7, 5.8).  
 Apelin peptides have no effect on the haemopoietic potential of neither hESCs nor 
hiPSCs (Figure 5.10, 5.11). 
 
5.6 Discussion 
5.6.1 Efficient differentiation of human ESC and iPSC lines to haemopoietic 
progenitors 
In this chapter we aimed to assess the effects that specific secreted molecules have in the 
haemopoietic activity of human PSCs. We focused our experiments on factors that we had 
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shown to be regulated by HOXB4 and that we had tested in our mouse ESC differentiation 
system. To this end, we had to ensure that human HPCs could be efficiently generated in a 
well-defined culture system, and that this could provide a clear background to assess and 
control the presence of additional factors. By taking advantage of a robust serum-free and 
feeder-free erythroid differentiation protocol established in our lab we managed to track the 
development of human HPCs in vitro. We demonstrated that our differentiation protocol 
successfully recapitulates early embryonic haemopoiesis and that it is reproducible between 
cell lines.  
Within the first 7 days of differentiation, our protocol generated a striking number of 1000 
CFU-Cs per 10
5
 cells plated in haemopoietic colony forming assay (Figure 5.2). More than 
60% of the colonies were small bright red primitive erythroid colonies, termed EryP. Flow 
cytometry analysis demonstrated that 50-70% of day 7 cells expressed the erythroid marker 
CD235a (261), which also marked nearly the entire CD34
+
 population (Figure 5.3).  
Therefore, our data clearly indicated that day 7 progenitors closely resemble primitive yolk 
sac erythropoiesis. On day 10 of analysis a second wave of definitive-type multipotent 
progenitors was observed. These progenitors could generate significantly increased numbers 
of CFU-M, CFU-GM and CFU-Mix colonies. Additionally, erythroid colonies had 
dramatically reduced in numbers, were of more mature type, BFU-E, large and with a darker 
red colour. CD235a marked a minor cell population, whereas, CD34 and CD43 were co-
expressed in more than 35% of the HPC population.  
In agreement with our data, extensive work by the Slukvin group, using co-culture with OP9 
feeder cells, has demonstrated that hESC-derived multipotent lymphohaemopoietic 






 population of cells (157, 262, 263). 
Transplantation experiments, conducted by Dr Jennifer Easterbrook in our group, have 
shown that day 10 HPCs cannot reconstitute irradiated recipients. It is therefore possible that 
the day 10 HPCs generated in our system more closely resemble definitive erythro-myeloid 
progenitors (EMPs) rather than definitive HSCs. EMPs have broad erythroid and myeloid 
potential, distinct phenotype from primitive progenitors but lack lymphoid and long-term 
engraftment potential (264). Lymphoid in vitro differentiation of day 10 HPCs will clarify 
whether our cells represent EMPs or truly multipotent progenitors that still lack the ability to 
engraft. Nonetheless, considering that long-term engraftment has not been achieved yet, and 
that haemopoietic differentiation efficiency is measured mainly through colony formation 





 CFU-Cs compared to most published human differentiation protocols 
using either feeder cell lines or haemopoietic cytokines (158, 161, 163, 174, 176, 180, 262).  
The differentiation protocol was also tested in hiPSCs, which can potentially serve as an 
embryo-free, patient-specific alternative source for cell therapy of haematologic disorders. 
Consistent with previous published reports, we found that hiPSCs behaved similar to hESCs, 
followed the same maturation stages and could efficiently generate multipotent HPCs (157, 
179, 180, 181, 260). Nonetheless, we did observe differences in the haemopoietic activity of 




 cells which was 
reflected in reduced CFU-Mix colony numbers. Similar to our findings, a number of studies 
have shown that even though hiPSCs are capable of generating haemopoietic cells, they 
exhibit large variability. Feng and co-workers have demonstrated that haemato-endothelial 
progeny of hiPSC lines have increased apoptosis, and dramatically reduced expansion and 
colony forming activity compared to hESCs (265). Additionally, work by Choi and 
colleagues proved that hiPSC lines present intrinsic variability. While some hiPSC lines 
could generate more than 1500 CFUs per 10
5
 cells, colony forming ability could get severely 
limited to less than 400 CFUs per 10
5
 cells in some others (157). Cell line variability has also 
been a major issue in hESC lines, hindering their clinical potential (266, 267). Variability 
may be due to passage number, genetic background, quality of the embryos at derivation in 
the case of hESCs, or tissue of origin and epigenetic memory for hiPSCs. It therefore 
becomes evident that large-scale comparative studies are necessary for hPSCs to be reliably 
used in clinical applications. These studies will help identify and carefully select cell lines 
that stably reproduce and enhance the yield of the desired lineage. Currently more hiPSC 
lines are being tested in our lab to further investigate the reproducibility of our protocol and 
variations between cell lines.  
5.6.2 Intraspecies and interspecies differences in the activity of HOXB4 
It is only reasonable to assume that the cell line variability described above may have 
functional consequences in the testing of exogenous factors. Indeed we observed that hiPSCs 
and hESCs responded quite differently to the addition of secreted proteins encoded by 
HOXB4 target genes. Depending on the secreted protein and the concentration that was used, 
the haemopoietic differentiation of hESCs was affected differently. In contrast, none of the 
tested proteins had any effects on the differentiation output of hiPSCs. There have been 
numerous reports suggesting that there are marked genomic differences between hESCs and 
hiPSCs, which could explain the observed variability. A comprehensive genome-wide 
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analysis conducted by Chin and colleagues, which included gene expression, RNA and 
histone modification profiling, investigated differences between early and late-passage hESC 
and hiPSC lines. They concluded that hiPSCs are more similar to each other than to hESCs 
and that they should be considered a unique subtype of PSCs (268). Interestingly, among the 
differentially expressed genes identified in early-passage cells, was HOXB4 together with a 
large number of genes from the HOXA and HOXB clusters. Expression of genes from the 
HOXB cluster was also found significantly different between late-passage hESCs and 
hiPSCs. Additionally, work by Doi and colleagues demonstrated that hESCs and hiPSCs 
could be distinguished by differential methylation of tissue-specific CpG island shores (269). 
More recently Bock and co-workers showed that there are no clear-cut differences in DNA 
methylation and gene expression among hESC and hiPSC lines. Nonetheless, they cannot be 
considered as one cell population because variation in hiPSC lines is more prevalent 
compared to hESCs (259). Notably epigenetic and transcriptional variation was observed in 
this study as well, for genes of the HOX family. It is thus probable that differences between 
our cell lines in the expression of endogenous HOXB4 and/or genes related to its function 
affect their in vitro behaviour and response to added factors.  
Human iPSCs remained unaffected by all HOXB4 targets tested in this study, clearly 
indicating that their regulatory network is completely different to mouse ESCs. On the other 
hand human ESCs showed not only differences but also similarities to their mouse 
counterparts suggesting some conserved mechanisms between species. FGF17 had an 
enhancing effect on the haemopoietic differentiation of mouse ESCs, but in contrast, human 
ESCs were negatively affected by its presence in culture, where we observed a reduction in 






 cells (Figure 5.5). Our cell expansion data indicated 
that the observed difference was not a secondary effect of FGF17 proliferative activity 
(Figure 5.6) as we would expect, based on the growth effects it has on human haemopoietic 
tumour cell lines (246). Addition of RSPO3 generated the same response in both species. 
HPCs reduced in numbers as RSPO3 concentration increased (Figure 5.7, 5.8). As already 
mentioned RSPO3 is an activator of Wnt signalling (238), and numerous reports have 
demonstrated the important role of Wnt signalling in hESC haemopoietic development (270, 
271). Nonetheless, as described by Gertow and colleagues, correct timing of Wnt signalling 
induction is crucial for the differentiation outcome. In their study, use of WNT3A in the 
early steps of differentiation promoted mesoderm development and generation of 
haemopoietic colonies. However, addition of WNT3A in later stages inhibited haemopoietic 
development, and instead resulted in the formation of mesenchymal colonies (272). It is 
possible that the prolonged use of RSPO3 in our protocol led to the development of non-
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haemopoietic cells, which could account for the observed reduction in haemopoietic activity. 
In the case of Apelin peptides, the haemopoietic activity of neither mouse nor human ESCs 
was altered (Figure 5.10, 5.11). However, Yu and colleagues have reported the enhanced 
growth of hESC-derived haemopoietic and endothelial cells upon addition of Apelin in the 
media (252). It is quite possible that fast degradation of Apelin peptides accounts for our 
negative results, and repetition of our experiments using an effective peptide delivery 
method can clarify the role of Apelin in haemopoiesis.  
It can be concluded from our ESC data that despite being partly conserved, the activity of 
proteins induced by HOXB4 varies between species. Therefore, directly extrapolating data 
will not always be effective. To date species-specific differences in HOXB4 activity have 
only been assessed based on the functional readout of developing HPCs. Our data clearly 
indicate that in order to clarify HOXB4 role and mechanism of action in human HSC in vitro 
differentiation, we need to focus on the subcellular level. An inducible HOXB4-ER
T2
 system 
in hESCs has been developed in our group. It would be interesting to see whether the genes 
found upregulated in response to HOXB4 in our mouse expression analysis also respond to 
HOXB4 induction during human haemopoietic differentiation. Additionally, the possibility 
that different HOX genes are required for the generation of human repopulating HSCs cannot 
be excluded. Molecular profiling by Salvagiotto and co-workers has shown that HOXA 
cluster genes are significantly reduced, whereas, HOXB cluster genes are highly expressed in 
hESC-derived HPCs compared to fetal liver HSCs (273). A similar study by Shojaei and 
Menendez comparing hESC-derived HPCs and fetal blood HSCs supported the above idea. 
They found that HOXB4 was not differentially expressed between the two cell populations, 
confirming their earlier data that ectopic HOXB4 expression fails to enhance the in vitro 
clonogenic and in vivo engraftment activity of hESC-derived HPCs (274, 188). Interestingly, 
they also found the expression of other members of the HOX family, and most significantly 
HOXA13, reduced in the hESC-derived cells suggesting their involvement in HSC 
specification. In conclusion further large-scale comparative studies are required for the 






























Human pluripotent stem cells, hESCs and hiPSCs, are promising sources for the in vitro 
generation of haemopoietic stem cells required in clinical applications. Even though 
progenitors capable of differentiating into multiple lineages in vitro have been successfully 
generated, they still lack the ability to repopulate recipients in vivo. In the mouse, the 
transcription factor HOXB4 has been shown to efficiently confer repopulating ability to 
embryonic and ESC-derived HSCs. Previous work in our group has suggested that this is 
achieved through a paracrine mechanism, where a supportive niche environment induced by 
HOXB4 secretes the necessary factors to promote HSC development. Even though the 
mouse and human haemopoietic systems are highly conserved, HOXB4 has not been 
efficient in conferring repopulating activity in human PSC-derived haemopoietic cells and 
studies looking into the underlying regulators are limited. In this study we investigated the 
suggested HOXB4 paracrine activity and how it differs between species. Particularly we 
assessed the effects that various secreted proteins, which we identified as HOXB4 targets, 
have in the haemopoietic differentiation of mouse and human PSCs. 
We developed a serum-free and feeder-free mouse differentiation protocol that provided a 
clear background in which to monitor any effects induced by the tested proteins. We 
observed that this new protocol could significantly enhance the generation of haemopoietic 
cells compared to our standard serum-based protocol. We noted a 10-fold increase in the 
numbers of colony forming cells which were mainly characterised by the co-expression of 
CD41/CD144 or CD41/c-Kit. We used this protocol to characterise the more recently 
derived mouse EpiSCs. EpiSCs exhibit a more primed developmental state compared to 
mouse ESCs and more similarities to human ESCs, which can possibly render them an 
improved model system. Time-course analysis of the differentiation process revealed that 
EpiSCs generated colony forming cells at earlier time point thus proving they can progress 
faster to the haemopoietic lineage compared to mESCs. Nonetheless, mESC haemopoietic 
output was not exceeded. Surface marker analysis confirmed there were no significant 









 cells. We concluded that our serum-free protocol is 
reproducible between cell lines, and it can efficiently generate HPCs which phenotypically 
resemble embryonic HSCs. Additionally, we demonstrated that although EpiSCs exhibit a 
developmental advantage over mESCs due to their primed state, they generate HPCs with 
the same efficiency.     
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Mouse ESCs were used in the serum-free protocol to test a number of secreted factors 
encoded by HOXB4 target genes, whose role in haemopoiesis had not been studied before. 
We observed that each tested factor had a different effect on the differentiation of the cells 
suggesting a complex regulatory network of HOXB4 activity. High concentrations of FGF17 
increased the portion of cells expressing the surface marker c-Kit, leading to increased 
colony forming activity. In contrast, increasing concentrations of RSPO3 reduced the 
generation of CD41
+
 cells, significantly decreasing the numbers of CFU-Cs. Addition of 
Apelin peptides did not affect either positively or negatively the differentiation of mESCs. 
Finally, the combined use of the secreted proteins did not increase the haemopoietic activity 
of the cells, as did the overexpression of HOXB4. Our data demonstrated that our well-
defined protocol is highly efficient in detecting even slight changes caused by added factors. 
Regarding the paracrine activity of HOXB4 it is suggested that either a larger number of 
secreted factors are needed, or that a better fine-tuning of their timing and concentration is 
required. Given the complexity of in vivo niches it is also possible that direct cell contact 
with the supportive stromal population in combination with the soluble proteins is necessary 
for the full effects of HOXB4 to be seen.  
We followed a similar strategy to assess the effects of the above factors in the haemopoietic 
activity of human PSCs. We established a serum-free and feeder-free protocol for the 
differentiation of human cells, which we used to monitor the differentiation of a hESC and a 
hiPSC line, in order to also examine variation between cell lines. When differentiated the 










multipotent HPCs. However, addition of secreted proteins encoded by HOXB4 revealed that 
there are marked differences between the two cell lines. In the case of hiPSCs none of the 
tested factors had any effect on the differentiation outcome. In contrast hESCs were affected 
variably depending on the added protein. FGF17 resulted in reduced percentage of CD34
+
 




 colony forming cells was noted upon 
RSPO3 addition. We did not observe any changes with the use of Apelin peptides. We 
concluded that mouse and human paracrine HOXB4 activity is only partly conserved, 
therefore attention is needed when extrapolating data. More importantly, even within a 
species cell line variation may lead to different results stressing even more the need for 




The data presented in this thesis not only answer some of our questions regarding HOXB4 
activity, but also raise some new ones worthy of further investigation. Additionally, some 
important conclusions are drawn relating to the current methodologies followed in human 
PSC research and how they need to be adapted in the future. 
6.2.1 Xenogeneic-free generation of human HSCs 
One of the major hurdles to overcome before applying human PSC-based therapy in the 
clinic is the safety of culture conditions (275). With the increasingly tight regulatory 
guidelines on PSC-based therapy, the need for xenogeneic-free culture conditions, which 
avoid the risk of infections and immune reactions by animal products, is heightened. We 
established serum-free and feeder-free conditions, and managed to efficiently generate 
mouse and human haemopoietic cells. More importantly, the use of these well-controlled 
protocols allowed us to reliably reproduce our data between cell lines from both species, and 
examine the effects of additional factors. Therefore, the application of xeno-free conditions 
can provide a reliable and controllable model system for scientific research which will allow 
the generation of clinical grade HSCs in the future. 
As indicated by our data in order to generate human HSCs with long-term multilineage 
repopulating ability addition of soluble factors in the culture media may not be sufficient. It 
will probably be necessary to develop culture systems that closely resemble the human in 
vivo haemopoietic niche environment. This is achievable through the use of supportive 
feeder cell lines. Currently, however, the established feeder cell lines used for human 
differentiation are of mouse origin, introducing animal products in culture. Although some 
efforts have been made to derive human feeder lines, there are no established cell lines 
shown to reproducibly support human haemopoiesis (162, 163). It is therefore essential to 
focus future research on the generation of supportive lines derived from human haemopoietic 
tissues. The use of human feeders in combination with serum-free media will provide the 
necessary cues for specification of clinical grade human HSCs, which will be easily 
collected through cell sorting assays.   
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6.2.2 Combined mouse and human studies 
For decades the mouse has been an indispensable model system for studying in vivo and in 
vitro haemopoiesis. Using mouse ESCs, the cellular and molecular developmental principles 
that control HSC specification have been identified. Due to the high conservation of the 
haemopoietic system between mammals, the information gained in the mouse has helped in 
recognising critical regulatory pathways in human. Nonetheless, species-specific differences 
have also led to conflicting results, which impact clinical translation. We evaluated the 
activity of HOXB4 mediators in ESC haemopoietic differentiation in vitro, and identified 
such interspecies differences.  
HOXB4 is only one example of the many differences in the molecular regulation, lineage 
commitment, phenotype and function between mouse and human haemopoietic cells (276, 
277). Apart from the evolutionary divergence of the two species, mouse strains used in 
research are inbred. Therefore the results gained in these genetically homogeneous strains 
may not apply in precisely the same way in the heterogeneous human population. 
Continuous advances in the field of human PSCs have many times allowed scientists to 
complement the knowledge gained in the mouse. Undoubtedly the mouse system will 
continue being absolutely essential in deciphering haemopoiesis. Nonetheless, in our view, 
parallel studies between the two organisms are absolutely critical in understanding how this 
information can be applied in humans. Research studies need to carefully interpret data and 
to clearly state findings not applicable in the human system. In the future more combined 
mouse and human studies will lead to more efficient therapeutic applications. 
6.2.3 HOXB4 use in HSC differentiation cultures 
We aimed to identify soluble mediators that can substitute HOXB4 overexpression in 
haemopoietic differentiation cultures. We found that even though some of the tested proteins 
could affect the haemopoietic output, they could not enhance HPC generation to the same 
level as HOXB4 overexpression. It is possible that more proteins, and improved fine-tuning 
of the quantity and time they are added in culture is needed. Nonetheless, this approach can 
be proven too complicated and uneconomic. Additionally, it is possible that, if indeed 
HOXB4 promotes the formation of a haemopoiesis-supportive population, direct cell 
interactions are required. The generation of a HOXB4-overexpressing stromal cell line will 
ultimately answer our questions. Since HOXB4 expression levels have been shown to be 
critical for the differentiation outcome (215, 278, 279),  it is possible that multiple cell lines 
with different HOXB4 expression levels will need to be generated to identify the optimal 
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level for HSC development. The fact that human HOXB4-expressing mesenchymal cell lines 
can be derived in vitro (240), is of critical importance as they can ensure clinically safe 
culture conditions free of animal products. Some may argue against the safety of using 
genetically modified cells in clinical applications. An alternative to genetic manipulation 
would be the addition of recombinant HOXB4 proteins in culture. Initial efforts have been 
made towards this direction with promising results (214). Further studies addressing the 
stability and the amount of the administered protein could enhance the generation of 
functional HSCs.  
6.2.4 In vivo functional evaluation of HPCs 
Secreted proteins encoded by HOXB4 target genes were use in differentiation cultures to 
assess whether they can mediate HOXB4 activity. We measured the effects that the tested 
proteins had in HPC generation using haemopoietic colony forming assay and flow 
cytometry analysis. Although valuable assays in measuring haemopoietic potential, they are 
not sufficient to measure the most important aspect of HSC activity: long-term multilineage 
repopulation. As scientific interest has focused on HOXB4 due to the repopulating ability it 
confers to mouse cells, in vivo repopulating assays are important in clarifying its activity in 
human cells. It is possible that the secreted factors we added in culture may have a 
qualitative rather than quantitative effect on differentiating cells. Therefore, even if there are 
no changes in the numbers of generated HPCs, the tested factors may change their 
engraftment potential. It would be interesting to address this possibility by transplanting our 
HPCs to irradiated mice and measuring their long-term engraftment potential.     
6.2.5 Involvement of other factors in human HSC development 
Although the ability of HOXB4 to confer repopulating activity to mouse ESC-derived 
haemopoietic cells has been repeatedly reported, HOXB4 success in human cells remains 
limited. This discrepancy may be due to the fact that the molecular regulators and signalling 
pathways of definitive haemopoiesis differ between mouse and human. Our results support 
this concept as none of the tested factors had enhancing effects in hESC or hiPSC 
differentiation. It is possible that even though HOXB4 plays a central role in human 
haemopoietic development, factors other than HOXB4 are needed for the full maturation of 
human PSCs into definitive HSCs.  
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Gene expression profiling studies comparing ESC-derived and in vivo derived haemopoietic 
progenitors point to that direction. In one study HOXB4 was found overexpressed in ESC-
derived cells compared to HSCs from in vivo sources (274). Additionally, other members of 
the HOXA and HOXB clusters have been found underexpressed in ESC-derived HPCs 
suggesting their involvement in the maturation of HSCs (273, 274). Indeed many members 
of the HOX gene family are expressed in adult HSCs and have been shown to have 
redundant functions. Therefore, the combined activity of HOX genes may be required for 
fully functional human HSCs to develop. Additionally, in the above studies in vivo HSCs 
overexpressed a number of genes associated with HSC self-renewal and survival, such as 
EZH2, MEIS1, MLL, ARHGAP1, ETV6, and HLF, some of which are known upstream HOX 
regulators. In conclusion, while the involvement of HOXB4 in human haemopoiesis needs 
further clarification, future studies will need to address the role of other genes in establishing 
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Table S 1: List of qRT-PCR primers and probes used in this project 
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The population of interest (SSC-A vs FSC-A) was gated for singlets (FSC-H vs FSC-A) and 
live cells with 7-AAD staining (SSC-A vs 7-AAD). The population was further gated on the 
TER119 negative cells (SSC-A vs TER119) to exclude autofluorescence from red cells. 


























































FSC-A FSC-A 7-AAD TER119 
Live Singlets Cells of interest TER119- 




Cells were first gated for the population of interest (SSC-A vs FSC-A) and singlets (FSC-H 
vs FSC-A). The population of interest was further analysed for their uptake of 7-AAD to 
determine live versus dead cells and an unstained control was used to further gate the CD34 









































Antibody Fluorochrome Supplier 
Anti-mouse CD144 eFluor450 eBiosciences 
Anti-mouse CD144 Ef660 eBiosciences 
Anti-mouse CD41 PE eBiosciences 
Anti-mouse CD45 V450 BD Biosciences 
Anti-mouse CD45 FITC eBiosciences 
Anti-mouse Sca-1 V500 BD Biosciences 
Anti-mouse CD117 APC eBiosciences 
Anti-mouse CD117 PerCP-eFlour710 eBiosciences 
Anti-mouse TER-119 FITC eBiosciences 
Anti-human CD43 APC eBiosciences 
Anti-human CD34 PE eBiosciences 
Anti-human CD235a FITC BD Biosciences 
 












Representative flow cytometry scatter plots of haemopoietic differentiation between day 0 to 





























Representative flow cytometry scatter plots of haemopoietic differentiation between day 0 to 






























Representative flow cytometry scatter plots of haemopoietic differentiation between day 0 to 










































Representative flow cytometry scatter plots of haemopoietic differentiation between day 0 to 














































Representative flow cytometry scatter plots of type II pre-HSC markers between day 4, when 


























Representative pictures showing the variation in Bry expression between cell colonies of the 
culture. DAPI used as nuclear staining.  
Oct4 Bry DAPI Merge 
Supplementary Figure S 8: Immunohistochemistry of ESC-derived EpiSCs. 
